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ABSTRACT 
Vanillin (4-hydroxy-3-methoxybenzaldehyde) is a natural occurring phenolic 
compound and it is the main component of the bean and pod of vanilla 
orchids. It is widely used as flavouring agent in food and drinks and as 
preservative in the cosmetic and pharmaceutical industry. In the past 
decades, several studies had reported the antioxidant and protective effects 
of vanillin in several oxidative stress models, both in vitro and in vivo. 
The aim of the project was to synthesise novel vanillin derivatives with 
enhanced antioxidant properties and to study their potential neuroprotective 
activities in in vitro oxidative stress models. To achieve this aim, novel 
vanillin derivatives were synthesised thorough reductive amination reaction, 
by reacting vanillin with a selection of amines, and all the derivatives were 
characterized using 1H and 13C NMR and Mass spectrometry. 
Vanillin derivatives were tested in several antioxidant assays with different 
mechanisms of action in order to identify the functionalities that contributed 
to the antioxidant properties of this novel class of compounds. A structure-
activity relationship (SAR) was therefore determined. The tetramer 4c 
turned out to be the most efficient antioxidant in all the assays. The latter 
compound consists of four vanillin moieties together with a molecular 
structure that facilitates electrons delocalisation for enhanced antioxidant 
activity. A selection of vanillin derivatives, based on their chemical 
structures and antioxidant properties, was therefore tested as potential 
multi-target-directed ligands (MTDLs) for the treatment of Alzheimer’s 
disease (AD), a multifactorial neurodegenerative disease. For this reason, 
the vanillin derivatives were tested for their ability to inhibit both 
acetylcholinesterase (AChE) enzyme and the self-mediated Aβ(1-42) 
aggregation. The monomer 1f displayed the best inhibitory activities toward 
both of the latter targets, with IC50 values at µM concentrations. In silico 
studies were performed to identify the molecular elements involved in the 
AChE inhibitory activities and to predict the ability of selected compounds to 
cross the blood-brain-barrier (BBB), which is of critical importance when 
targeting neurodegenerative diseases. Monomer 1f was predicted cross the 
BBB. 
A selection of vanillin derivatives, based on their antioxidant and AChE and 
amyloid inhibitory activities was then tested in oxidative stress models, by 
applying hydrogen peroxide or a mixture of rotenone/oligomycin A as 
stressors, in neuroblastoma SH-SY5Y cell line. Vanillin derivatives showed 
cellular protective effects, by increasing cell viability and reducing reactive 
oxygen species (ROS) production but they were unable to protect the cells’ 
DNA from oxidative damage. Again, compound 4c displayed the most 
efficient protective effects at micromolar concentrations. 
Finally, in order to study the mechanism behind the protective effects of 4c 
in SH-SY5Y cell line, its ability to activate the Nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) pathway, which is known to be a predominant 
mediator of cellular antioxidant response, was studied. Since no Nrf2 was 
observed in the nucleus confirms an alternative mechanism for the 
antioxidant activity of 4c. Overall, compounds 1f and 4c showed promise 
for their further development, as potential for the treatment of AD. 
Keywords: Vanillin, free radicals, antioxidants, oxidative stress, Nrf2, 
Alzheimer’s disease, multi-target-directed ligands, acetylcholinesterase, 
beta-amyloid, molecular modelling, SH-SY5Y, neurodegeneration. 
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1 
 
Thesis Layout 
 
This thesis has been arranged in 6 chapters. 
 
Each chapter has its own specific introduction, material and methods, 
results, discussion and conclusion sections. 
 
Chapter 1 provides a general introduction on the background to the work 
 
Chapter 2 discuss the chemical synthesis and characterization of novel 
vanillin derivatives. 
 
In chapter 3, the antioxidant properties of this new class of compounds 
were studied using a number of in vitro assays including the  2,2-diphenyl-
1-picrylhydrazyl (DPPH), ferric reducing/antioxidant power (FRAP), oxygen 
radical absorbance capacity (ORAC) and DNA protection assays. 
 
Chapter 4 entails the cellular studies of a selection of the novel compounds 
using neuroblastoma SH-SY5Y cell line. Furthermore the cellular protective 
effects of those compounds against hydrogen peroxide and a mixture of the 
mitochondrial inhibitors (rotenone and oligomycin A) are discussed. 
 
Chapter 5 introduces the concept of multi-targeted therapy for Alzheimer’s 
disease, with particular attention to the antioxidant properties, the 
inhibitory activity towards acetylcholinesterase enzyme and the amyloid 
Aβ(1-42) self-induced aggregation. The blood-brain-barrier permeability using 
in silico studies is also discussed. 
 
Chapter 6 summarizes all the findings from this study and includes 
conclusions and future work sections. 
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Chapter 1: Introduction 
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1. 1 Oxidative Stress 
 
1.1.1 The Theory of Oxidative Stress 
 
Over the past few decades it has been proposed that oxidative stress is 
linked to the imbalance between reactive oxygen and nitrogen species (ROS 
and RNS) production and antioxidant defences, leading to oxidative damage 
to lipids, proteins and genetic material that contributes to the development 
of a range of different pathophysiological conditions (Sies, 1991, 2015). For 
a number of years, there has been strong evidence that linked oxidative 
stress to many different chronic conditions including neurodegenerative 
diseases (Alzheimer, Parkinson, Huntington), cardiovascular pathologies 
(atherosclerosis, heart failure), cancer and inflammation (Madamanchi, 
Vendrov and Runge, 2005; Lin and Beal, 2006; Reuter et al., 2010). 
 
1.1.2 Sources and formation of Oxygen and Nitrogen Reactive 
Species 
 
ROS include both free radical and non-free radical oxygenated molecules. 
They are normally produced in aerobic processes such as respiration, 
immune system activation and physical activity or after exposure to toxins 
and/or pollutants such as alcohol, cigarette smoke, ionizing and UV 
radiations, pesticides and ozone. In contrast, at low concentrations, ROS 
are involved in different and important physiological processes, e.g. as 
signalling molecule in cell proliferation and apoptosis (Poljsak, Šuput and 
Milisav, 2013b). 
 
The most important endogenous source of ROS is the mitochondrial electron 
transport chain that leads to the production of heat and chemical energy in 
the form of adenosine 5-triphosphate (ATP) after the oxidation of carbon 
and hydrogen-containing biomolecules (Gutteridge, 1994). 
 
A detailed scheme of ROS production and regulation in mitochondria is 
illustrated in figure 1.1. 
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Figure 1.1 ROS generation in mitochondria, adapted from Tang et al. (2014), Copyright © 2014 Tang, 
Luo, Chen and Liu.  
 
Mitochondria are the cell’s metabolic site involved in ATP production, as well 
as in the regulation of apoptosis (Kroemer, Galluzzi and Brenner, 2007; 
Zhou et al., 2011). The respiratory chain generates the proton gradient 
over the mitochondrial inner membrane that drives ATP generation by ATP 
synthase (complex V). 
During this process, molecular oxygen is reduced stepwise into a series of 
intermediate and highly reactive species as shown by the following 
equations (Gutteridge, 1994): 
 
O2 + e- + H+ → HO2∙   (1) 
HO2. ↔ H+ +O2.-   (2) 
2O2.- + 2H+ → O2 + H2O2   (3) 
2 H2O2 → H2O + O2   (4) 
H2O2 + 2GSH → GSSG + 2H2O   (5) 
 
Although molecular oxygen (O2) is not a free radical, it is however 
considered as a highly reactive oxygen species in which the spin restriction 
of oxygen (two unpaired electrons with parallel spins) is removed, which 
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enhances its oxidative power (Gutteridge, 1994). In equation (1), molecular 
oxygen is reduced into hydroperoxyl (HO2∙) radical which is in equilibrium, 
in aqueous solution, with the superoxide radical anion (O2.) (2). The latter 
can be converted into hydrogen peroxide (H2O2), a non-radical ROS, by 
enzymes belonging to the superoxide dismutase family (3) (Jomova et al., 
2010). Finally, hydrogen peroxide can be depleted by catalase (4) (Alfonso-
Prieto et al., 2009) or glutathione peroxidase (5) (Day, 2009). 
 
Along with the electron transport chain, it is well established that enzymes 
such oxidases can produce high levels of ROS during normal physiological 
processes (Cadenas and Davies, 2000; Zangar, Davydov and Verma, 2004; 
Valko et al., 2007). 
The oxidase enzymes family includes: 
 
- Cytochrome P450s: insert an oxygen atom into an aliphatic chain 
during the process of metabolism. 
- Monoamine oxidase: removes the amino group from monoamines 
during the deamination process. 
- NADPH oxidases: produce superoxide anion in response to 
pathogens, such as bacteria and fungi.  
- Xanthine oxidase: promotes the oxidation of hypoxanthine to 
xanthine and can further catalyse the oxidation of xanthine to uric 
acid during the catabolism of purines.  
 
ROS production is also linked with eicosanoid synthesis, a physiological 
process that converts free fatty acids into corresponding oxygenated 
derivatives during inflammation and immune response. Eicosanoids are 
produced from three different fatty acids, arachidonic acid (AA), 
eicosapentaenoic acid (EPA) and dihomo-gamma-linoleic acid (DGLA) 
through three different enzymes: cyclooxygenases (COXs), which produce 
prostanoids from AA, lipoxygenases (LOXs), which produce leukotrienes 
from AA and epoxygenases, involved in epoxyeicosatrienoic acids synthesis 
(Wang and DuBois, 2010). This family of compounds are involved in many 
physiological processes; for example, the prostanoids (prostaglandins, 
thromboxanes and prostacyclins) mediate symptoms of inflammation, such 
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as vascular permeability and fever, whereas leukotrienes stimulate immune 
responses (Rothwell, 1992; Dennis and Norris, 2015). 
It has been shown that COX enzymes oxidize AA through a free radical 
mechanism that leads to the generation of prostaglandin after the formation 
of a lipid peroxy radical (see figure 1.2). (Marnett et al., 1999); however, 
AA can be reduced, via non-enzymatic peroxidation into isoprostanes and 
other lipid peroxidation end-products, all are highly reactive and harmful to 
the cellular membranes (Ayala, Muñoz and Argüelles, 2014) 
 
Figure 1.2. Free radical mechanism of the conversion of AA into prostaglandin GG2, adapted from 
Marnett et al. (1999), Copyright © AMERICAN SOC FOR BIOCHEMISTRY & MOLECULAR 
BIOLOGY .  
 
Furthermore, metal-catalysed processes are linked with ROS production. 
Almost one-third of all proteins contain transition metal ions such iron and 
copper: two of the most active and abundant redox-actives metals in the 
human body. It has been shown that divalent metal ions can reduce 
molecular oxygen to superoxide radicals (equation 6): 
 
Fe2+ + O2 → Fe3+ +O2∙-   (6) 
 
Furthermore, these ions can react with hydrogen peroxide, leading to the 
formation of the hydroxyl radical (Jomova, Baros and Valko, 2012) known 
as the Fenton reaction (equation 7). The latter plays a critical role in the 
oxidative stress process, since hydroxyl radical is the most reactive free 
radical. 
 
Fe2+ + H2O2→ Fe3+ + OH- + OH∙   (7) 
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Due to its extreme reactivity, the hydroxyl radical has a short life-span and 
can react with alkyl chains of different molecules, removing the terminal 
hydrogen atom (equation 8) (Pignatello, Oliveros and MacKay, 2006): 
 
OH. + RH→ H2O + R∙   (8) 
 
Finally, the alkyl radical easily reacts with molecular oxygen, leading to the 
formation of peroxyl radical (equation 9): 
 
R∙ + O2 → ROO.   (9) 
 
At the same time, copper ions can be involved in oxidation and reduction 
reactions; for example, cupric ions can be reduced into cuprous ions by 
superoxide radical ions (equation 10) (Gutteridge and Wilkins, 1983): 
 
Cu2+ + O2.- → Cu+ + O2   (10) 
 
Cuprous ions can then lead to the generation of hydroxyl radicals via the 
Fenton reaction (equation 11). 
 
Cu+ + H2O2 → Cu2+ + OH- + OH.   (11) 
 
Along with ROS, reactive nitrogen species (RNS) play a critical role in 
oxidative stress. Nitric oxide (.NO, commonly referred to as “NO”) and 
nitrogen dioxide (.NO2) contain unpaired electrons and are therefore 
considered to be free radicals. NO is biosynthesized by enzymes belonging 
to the nitric oxide synthase (NOS) family from L-arginine, oxygen and 
NADPH or by reduction of inorganic nitrate. This reactive nitrogen species 
exerts the role of signaling molecule, being involved in vasodilation, platelet 
aggregation and neurotransmission (Radomski, Palmer and Moncada, 1990; 
Moncada and Higgs, 1991). NO can react with superoxide radical anion 
leading to the generation of the highly reactive RNS peroxynitrite, a 
powerful oxidant against many biological molecules (equation 12) (Beckman 
and Crow, 1993) 
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O2.- + .NO → ONOO-   (12) 
 
The protonation of the latter can occur, yielding a strong oxidizing agent 
(ONOOH) that is able to oxidize proteins and to cause DNA damage, in 
addition to the nitration of aromatic amino acids such as tyrosine (Sawa, 
Akaike and Maeda, 2000).  
Furthermore, it can decompose to yield hydroxyl radicals (equation 13) 
(Gutteridge, 1994): 
 
ONOOH → OH. + .NO2   (13) 
 
1.1.3 The Role of Oxidative Stress in Diseases 
 
1.1.3.1 Oxidative Stress in Inflammation and Cancer 
 
Over 5000 years ago, the traditional Ayurvedic medical system reported 
that continuous irritation over long period can lead to cancer (Reuter et al., 
2010). 
However, the relationship between inflammation and cancer was only 
confirmed two centuries ago, when Rudolph Virchow noted leukocytes,  cells 
of the immune system, in neoplastic tissue. He suggested that the 
infiltration of white blood cells in tumour tissue reflects the origin of cancer 
at sites of chronic inflammation (Balkwill and Mantovani, 2001). Today, 
although most of the molecular and cellular mechanism for the link between 
inflammation and cancer are still unresolved, the relationship has been 
generally accepted. 
 
Inflammation is the biological response to tissue injury and a detailed 
scheme is reported in figure 1.3. 
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Figure 1.3. Cells and mediators of the inflammatory response Newton and Dixit (2012), with copyright 
agreement © 2012 Cold Spring Harbor Laboratory Press. 
 
The inflammatory process is mediated by a complex network of chemical 
signals, including cytokines (Interleukin-2, known as IL2, Interferon-, IL-
10, tumour necrosis factor alpha; TNF-), eicosanoids, cell adhesion 
molecules (CAMs) and chemokines, that cause the migration of the immune 
system cells (leukocytes) to the site of damage, the immobilization of 
neutrophils on the surface of vascular endothelium and the progression of 
inflammatory process (Balkwill and Mantovani, 2001; Coussens and Werb, 
2002; Newton and Dixit, 2012).  
 
There are two stages of inflammation: acute and chronic. The first one 
reflects the controlled inflammation (innate immunity) mediated by the 
immune system. This first stage of inflammation usually lasts for a short 
time and it is aimed to remove the causes of the inflammation. However, if 
the process lasts for a longer period, chronic inflammation sets in (Reuter et 
al., 2010). 
Free radicals may initiate or amplify inflammation, upregulating several 
genes involved in the inflammatory response (Conner and Grisham, 1996). 
Although the molecular pathway is not completely understood, it has been 
demonstrated that the activation of certain transcription factors, such as 
NFB, can upregulate the production of different cytokines, including IL-2 
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and TNF-  contributing to the chronic nature of inflammation. Several 
antioxidants such as vitamin E, -lipoic acid ((R)-5-(1,2-Dithiolan-3-
yl)pentanoic acid) and N-acetylcysteine, all free radical scavengers, showed 
inhibition of NFB, confirming its activation through a free radical 
mechanism (Conner and Grisham, 1996). 
 
Chronic inflammation is associated with several carcinogenesis stages, such 
as cellular transformation, promotion, proliferation, invasion, angiogenesis 
and metastasis (Mantovani, 2005). It is also well established that oxidative 
stress is strictly linked with cancer during the three stages of initiation, 
promotion and progression (Klaunig et al., 1998). It has been shown that 
high ROS concentrations can lead to DNA strand breaks, point mutations 
and abnormal DNA cross-linking, thus leading to neoplastic transformation 
(Hussain, Hofseth and Harris, 2003). However, the harmful actions of ROS 
are not only based on their ability to react with DNA.  
 
In fact, it has been reported recently that these reactive molecules can 
mediate the cellular signal transduction pathways involved in tumour cell 
survival. These effects can be observed in mitogen-activated protein kinase 
(MAPK)/AP-1 and NFB pathways, both of which are involved in tumour cell 
proliferation. MAPK represents a wide family of proteins involved in gene 
expression through phosphorylation of different transcription factors 
(Pearson et al., 2001). Among these pathways, the MAPK/ERF pathway is 
that which is most commonly linked with the cell proliferation control which 
is overexpressed in response to changes in the cellular redox balance, along 
with JNK and p38 subfamilies. (Xia et al., 1995; McCain, 2013). In addition, 
it has been shown that carcinogens and tumour promoters, such as 
asbestos, ionizing radiation and benzo[a]pyrene are able to activate NFB 
through free radical pathway (Mohan and Meltz, 1994; Janssen et al., 
1995).  
 
It is well established that its activation is linked with an increase in cell 
proliferation and angiogenesis, both crucial for cancer cell survival, due to 
the high energy requirements for cell division. However, the mechanism for 
activation of NFB by ROS and RNS is not completely understood. In fact it 
has been demonstrated that mild oxidative stress can lead to an increase in 
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NFB activation, while extensive oxidative stress can inhibit the latter and 
induce mitochondrial permeability transit pore. This leads to the disruption 
of the electron transfer, resulting in apoptosis or necrosis (Gloire, Legrand-
Poels and Piette, 2006). This pathway is described in figure 1.4. 
 
 
Figure 1.4. Hierarchal oxidative stress model, adapted from Gloire, Legrand-Poels, and Piette (2006), 
with copyright agreement © 2006 Elsevier Inc. 
 
1.1.3.2 Oxidative Stress and Neurodegenerative Diseases 
 
Neurodegenerative diseases are characterized by a slow progressive loss of 
neurons (Lin and Beal, 2006); although their aetiology has not been fully 
understood and can follow different pathways, oxidative stress has been 
suggested as one of the potential common contributing factors (Gandhi and 
Abramov, 2012). It is well established that the latter induces cellular 
damage which are both key factors in the development of 
neurodegenerative disorders. 
 
Parkinson's disease (PD) is a neurodegenerative disorder characterized by 
loss of dopaminergic (DA) neurons in the substantia nigra pars compacta 
(SNc), with the consequential depletion of dopamine levels in the 
nigrostriatal dopaminergic pathway in the brain (Blesa et al., 2015). 
Although the aetiology of PD has not been completely elucidated, oxidative 
stress has been considered as one of the causes behind this 
neurodegenerative illness. 
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In PD, the concentration of polyunsaturated free fatty acids in the 
substantia nigra is lowered, with consequential enrichment in 4-
hydroxynonenal and malondialdehyde, both of which are hallmarks of lipid 
peroxidation (Dexter et al., 1989). Furthermore, in the past few decades, 
several studies have suggested a possible link between the reduced activity 
of complex I of the respiratory chain in SNc, with the consequential 
generation of ROS, and PD.  
 
In fact, several complex I inhibitors (see figure 1.21, page 30), such as 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rotenone 
((2R,6aS,12aS)-8,9-dimethoxy-2-(prop-1-en-2-yl)-1,2,12,12a-
tetrahydrochromeno[3,4-b]furo[2,3-h]chromen-6(6aH)-one)), exert 
cytotoxic effects on dopaminergic neurons (Langston et al., 1983; Li et al., 
2003), resulting in clinical PD phenotype. For these reasons, several studies 
on antioxidant therapy have been conducted to confirm the radical cause of 
PD, but the results have been conflicting: for example, treatment of 800 
patients with early stage of PD with vitamin E, a liposoluble antioxidant, at 
2000 IU/d had no impact in delaying the need of L-DOPA (see figure 5), a 
common PD treatment, after a follow-up of 14 months. In contrast, 
treatment with 10 mg of selegiline ((R)-N-methyl-N-(1-phenylpropan-2-
yl)prop-2-yn-1-amine) (see figure 1.5) per day delayed the need of the L-
DOPA by 9 months (Delanty and Dichter, 2000).  
 
 
Figure 1.5. Chemical structures of L-DOPA (left) and Selegiline (right). 
 
Although selegiline has shown to be able to protect against MPTP (N-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine) toxicity by scavenging the 
highly toxic cation MPP+ (1-methyl-4-phenyl-pyridinium), it is a well-known 
selective inhibitor of monoamine oxidase B (MAO-B), thus increasing 
dopamine levels in the brain. For this reason, the beneficial effects of the 
latter could not be associated to the antioxidant activity of selegiline 
(Mytilineou and Cohen, 1985; Olanow et al., 1995). 
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Alzheimer’s disease (AD) is an age-related neurodegenerative disorder 
characterized by neuronal loss, reduced cholinergic transmission, 
extracellular amyloid beta-peptide ()–rich senile plaques and oxidative 
stress (Mufson et al., 2009; Butterfield, Swomley and Sultana, 2013). 
Oxidative stress has been shown to play a fundamental role during the early 
stage of the disease. For example several studies have shown an increase of 
ROS and RNS mediated injuries in AD brain along with increased levels of 
oxidized biomolecules (proteins, nucleic acids and lipids) and altered 
regulation of antioxidant enzymes (Mecocci and Polidori, 2012; Rosini et al., 
2013).  
 
Several studies have been conducted to evaluate the potential therapeutic 
effects of antioxidants on the onset and delay of AD. Similar to the PD 
studies, the antioxidant therapy for AD produced contrasting results: a 
study conducted on 341 patients with moderate to severe AD showed that a 
daily intake of vitamin E of 2000 UI/d for 2 years showed a slower 
progression of the disease whereas no significant improvements were 
obtained in 769 patient with mild cognitive impairment (MCI) (Sano et al., 
1997; Mecocci and Polidori, 2012). 
 
In addition, other natural antioxidants failed to improve AD patients’ 
symptoms; for example resveratrol ((E)-5-(4-hydroxystyryl)benzene-1,3-
diol) (see figure 1.6), a stilbene compound, has shown no short term 
positive effects on cognitive performance in AD patients in a double blind, 
placebo controlled study (Bass et al., 2007; Kennedy et al., 2010).  
 
 
Figure 1.6. Chemical structure of resveratrol. 
 
Curcumin ((1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-
3,5-dione) (see figure 1.7), a strong antioxidant and a known β-amyloid 
aggregation inhibitor naturally found in turmeric, has shown no significant 
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improvement in cognitive performance on a study involving 34 AD patients 
(Mecocci and Polidori, 2012). 
 
 
Figure 1.7. Chemical structure of curcumin. 
 
However, a supplementation of lipoic acid, the coenzyme of mitochondrial 
pyruvate dehydrogenase and -ketoglutarate dehydrogenase, reduced 
memory loss and stabilized cognitive function in a 48 months study 
involving 43 patients (Hager et al., 2007). 
 
1.1.3.3 Oxidative Stress and Cardiovascular Diseases 
 
Oxidative stress plays a fundamental role in different cardiovascular 
pathologies that include atherosclerosis, heart failure and stroke. It has 
been recently shown that the oxidation of the low density lipoproteins (LDL) 
in the arterial walls is linked with the thickening of the latter (Madamanchi, 
Vendrov and Runge, 2005), the principal hallmark of atherosclerosis. 
Lipoproteins are biomolecular structures containing both lipids and proteins; 
these particles effectively emulsify fatty molecules, facilitating their 
transport in the aqueous environment of the blood.  
These biomolecules are classified, depending on their density, into very low-
density lipoproteins (VLDL), low-density lipoproteins (LDL) and high-density 
lipoproteins (HDL). HDL are involved in the transport of cholesterol and 
other fatty molecules from tissues and artery vessels to the liver whereas 
VLDL and LDL carry their fatty contents to the artery vessels and, after 
oxidation, they can invade endothelium and contribute to the 
atherosclerosis process (Shinkai, 2012) as illustrated in figure 1.8. 
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Figure 1.8. Cholesterol transport in human body, adapted from Shinkai (2012) with copyright agreement 
© 2012 DOVE MEDICAL PRESS LTD.  
 
In addition, free radicals, such as superoxide, can inactivate the signaling 
molecule NO (see equation 12, page 8), involved in the blood vessel muscle 
tone regulation, leading to impairment of vasorelaxation, a condition linked 
with heart failure (Ogita and Liao, 2004). Furthermore, a meta-analysis of 
23 randomized controlled trials published between 2001 and 2013 showed 
that perioperative supplementations with vitamin C (L-ascorbic acid), N-
acetyl cysteine (NAC) and poly-unsaturated fatty acids (PUFA) prevented 
atrial fibrillation after cardiac surgery (Ali-Hassan-Sayegh et al., 2014). 
However, a study conducted on 14641 men showed no significant effects of 
a daily multivitamin intake on major cardiovascular events after 14 years of 
treatment (Sesso et al., 2013). In addition, another study involving 161808 
women treated with multivitamins showed, after 8 and 7.9 years of median 
follow-up, little or no influence on the risk of cardiovascular diseases. 
 
Furthermore, oxidative stress plays a fundamental role in brain ischaemic 
injury, enhancing peroxidation of unsaturated fatty acids of cell membranes 
leading to neuronal death and oedema (Yoshida et al., 2006). Recent 
studies demonstrated the beneficial effects of edaravone (3-methyl-1-
phenyl-2-pyrazolin-5-one), a potent free radical scavenger, in brain 
ischaemia/reperfusion, attenuating vascular and cellular damage. Although 
edaravone does not bear phenolic functionality, it undergoes keto-enol 
tautomerization (see figure 1.9) and generates the aromatic hydroxyl group 
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which exhibits free radical scavenging activities (Watanabe, Tahara and 
Todo, 2008). 
 
 
Figure 1.9. Chemical structure of 3-methyl-1-phenyl-2-pyrazolin-5-one (Edaravone) and its keto-enol 
tautomerization. 
 
The protective effects of edaravone in brain ischaemia/reperfusion injury 
are not based only on its antioxidant properties since the compound had 
shown to increase the expression of NO through activation of endothelial NO 
synthase (eNOS), ameliorating the blood flow and thus reducing post-
ischaemic reperfusion-induced tissue damage. Edaravone is commercially 
available in Japan (since 2015) and USA (since 2017) for patients 
recovering from stroke and for treatment of amyotrophic lateral 
sclerosis (ALS) (Rothstein, 2017).  
 
1.2 Antioxidants 
 
1.2.1  Definition of Antioxidants 
 
Different definitions of antioxidants have been described over the years; 
Halliwell defined antioxidant as “any substance that, when present at low 
concentrations compared with that of an oxidizable substrate, significantly 
delays or inhibits oxidation of that substrate” (Halliwell and Gutteridge, 
1995). Lately, after the increasing knowledge on oxidative stress and its 
role in several diseases, he described antioxidants as “any substance that 
delays, prevents or removes oxidative damage to a target molecule” 
(Halliwell, 2007). In addition, to be considered as an antioxidant, a 
molecule should be able to generate a new stable radical (through 
intramolecular hydrogen bonding) after scavenging a free radical (Halliwell, 
1990). Being more stable, the new free radical will be less reactive towards 
biological structures such as DNA, lipids and proteins. 
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1.2.2 Mechanism of Action of Antioxidants 
 
1.2.2.1 Free Radical Scavengers 
 
The classical mechanism of action from an antioxidant can be shown by 
equation 14: 
 
AH + R∙ → A∙ + RH   (14) 
 
Where AH is the antioxidant and R∙is the free radical. This equation explains 
the ability of antioxidants to inhibit (or delay) many damaging processes 
induced by free radicals on biological structures, such as lipids, proteins or 
DNA and to generate a new stable free radical (A∙) that is less reactive 
compared with the original one (R.) (López-Alarcón and Denicola, 2013). 
However, the ability of the antioxidant to react with the free radical is of 
critical importance and it can be described by equation 15:   
 
r = K1 [AH] [R]ss   (15) 
 
where r is the reactivity, k1 is the kinetic rate constant (the higher this 
value is, the stronger is the antioxidant), [AH] is the concentration of the 
antioxidant and [R] is the concentration of the free radical at the steady 
state. 
 
In addition, the ability of the antioxidant to reach the biological site where 
the free radicals are exerting their damaging activity is another crucial 
limiting factor. For example, an antioxidant that can prevent lipid 
peroxidation should possess relevant chemico-physical properties in order 
to reach the cell membranes and reacts with free radicals (Niki, 1987). 
 
Another important aspect is the stability of the secondary free radicals A∙ 
formed after the reaction with the reactive intermediates. It is well known 
that some secondary free radicals could damage DNA, proteins and other 
biological targets (Kagan and Tyurina, 1998). Furthermore, secondary free 
radicals can react with oxygen, yielding peroxyl and superoxide free 
radicals, as shown by equations (16) and (17): 
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A∙ + O2 → AOO∙   (16) 
A∙ + O2 → Aox + O2∙-   (17) 
 
1.2.2.2 Metal Chelation 
 
As described previously (equations 7 and 11) , Fe2+ and Cu+ are involved in 
the generation of free radicals through the Fenton reaction (see equations 7 
and 11) (Gutteridge and Wilkins, 1983; Jomova, Baros and Valko, 2012). In 
particular, ferrous ion (Fe2+) is the most powerful pro-oxidant among the 
metal ions whereas ferric ion (Fe3+) can produce free radicals from 
peroxides at a rate 10-fold less than Fe2+ (Gülçin, 2006). 
 
Most polyphenol compounds are effective metal chelators; in particular, 
acidic polyphenols such as gallol (benzene-1,2,3-triol) and catechol (1,2-
dihydroxybenzene), are easily deprotonated, and can form stable complexes 
with both ferrous and ferric ions (Perron and Brumaghim, 2009). Once 
complexed, these metals cannot exert their toxic effects on biological 
macromolecules through the Fenton reaction. At the same time, phenolic 
compounds such naringenin and catechin can form complexes with both 
cuprous and cupric ions in stoichiometries 1:1 or 1:2 (Fernandez et al., 
2002).  
 
1.2.2.3 Antioxidant Responsive Element (ARE)-mediated Pathway 
 
The first observations of inducible anti-oxidation were made in 1978 by 
Benson et al. when they noticed that phenolic antioxidants, such as the 
synthetic butylated hydroxyanisole (BHA) (2-tert-Butyl-4-methoxyphenol 
and 3-tert-butyl-4-methoxyphenol), protected animals from 
benzo[a]pyrene-induced tumour formation, inhibiting mutagenic 
metabolites of the latter and inducing the expression of two different drug-
metabolizing enzymes, glutathione S-transferases (GSTs) and NAD(P)H 
dehydrogenase (quinone1) (NQO1) (Benson et al., 1978). 
 
In recent years, the list of the inducers of these enzymes has increased and 
it includes a wide range of natural and synthetic compounds such as 
sulphorapane (1-Isothiocyanato-4-methylsulfinylbutane) and triterpenoids, 
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therapeutics such as dimethyl fumarate, poisons such as paraquat (N,N′-
dimethyl-4,4′-bipyridinium dichloride) and arsenic and even endogenous 
molecules such as prostaglandin J2, hydrogen peroxide and 4-
hydroxynonenal (4-HNE) (see figure 1.10) (Nguyen, Nioi and Pickett, 2009; 
Ma, 2014).  
 
 
Figure 1.10. Chemical structures of sulphorapane (top left), dimethyl fumarate (top right), paraquat 
(bottom left) and 4-HNE (bottom right). 
 
The induction of the cytoprotective enzymes is regulated at transcriptional 
level, mediated  by a cis-acting element termed antioxidant responsive 
element (ARE) (Friling et al., 1990) (see figure 1.11).  
 
 
Figure 1.11. Proposed Nrf2-ARE signaling pathway, adapted from Cabrera et al. (2015), with permission 
from Future Science OA.  
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The main mediator of the ARE activation is the nuclear factor E2-related 
factor 2 (Nrf2), which is regulated by the actin-associated Keap1 protein. 
Nrf2 is an unstable protein with a half-life of about 15 minutes. Due to its 
short lifespan, the activation of this factor is associated with its 
accumulation in the cell (Nguyen, Nioi and Pickett, 2009; Ma, 2014). Under 
normal conditions, Nrf2 is bound to Keap1 and compartmentalized in the 
cytoplasm, where it is degraded after ubiquitination. However, under 
oxidative conditions, the cysteine residues in Keap1, involved in the bond 
with Nrf2, can be oxidized, leading to the translocation of the latter into the 
nucleus, where it can induce the transcription of antioxidant genes. This 
mechanism is supported by the fact that the inducers of ARE pathway are 
electrophiles, suggesting an inducer-cysteine thiol interaction as the early 
stage for Nrf2 activation (Itoh et al., 1999; Kobayashi et al., 2004; Nguyen, 
Nioi and Pickett, 2009; Ma, 2014). 
 
1.2.3 Classification of Antioxidants 
 
Antioxidants can be classified, according to their source, in natural or 
synthetic antioxidants (Carocho and Ferreira, 2013). Although the interest 
in new synthetic antioxidants has dramatically increased in the past 
decades, due to the potential beneficial properties of the latter to human 
health and wellbeing, the natural antioxidant family is still the most popular 
and with high level of diversity. A detailed scheme of this classification is 
shown in figure 1.12. 
21 
 
 
Figure 1.12. Natural and synthetic antioxidants and their chemical structures. 
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1.2.3.1     Natural Antioxidants 
 
1.2.3.1.1 Endogenous Antioxidants 
 
Endogenous antioxidants represent the first line of defense against 
oxidative stress and these include antioxidant enzymes and their cofactors. 
The main antioxidants enzymes are: superoxide dismutase (SOD), 
glutathione peroxidases and catalase. SOD converts the superoxide anion 
radical into hydrogen peroxide. There are three isoforms of the SOD 
enzyme known as (I) the cytosolic, which uses zinc or copper as cofactors, 
(II) mitochondrial, which uses manganese as cofactor, and (III) 
extracellular, which is less involved in oxidative stress, since it is expressed 
through a cytokine-mediated pathway. The antioxidant effects of SOD are 
exerted by successive oxidative and reductive cycles of the transition metal 
ions at its active site (Landis and Tower, 2005; Rahman, 2007). 
 
Glutathione peroxidases catalyse the reduction of hydrogen peroxide into 
water and organic hydroperoxides into the respective alcohols. This enzyme 
bares a selenol moiety (R-Se-OH) in its active site which can be oxidized by 
hydrogen peroxide into seleninic acid (R-SeO2H) (Bhabak and Govindasamy, 
2010). The latter is then reduced to its initial status by two molecules of the 
antioxidant glutathione (GSH). Reduced glutathione is an endogenous 
tripeptide (figure 1.13) which protects the cells against free radicals acting 
either as hydrogen donors or electron donors due to its thiol moiety 
(Carocho and Ferreira, 2013). 
 
 
Figure 1.13. Chemical structure of L-Glutathione. 
 
It is synthesized from precursor amino acids and its concentration in the 
human body ranges from 2 up to 7 mM in the liver (Kaplowitz, 1981). When 
it reacts with hydrogen peroxide, the reduced tripeptide is oxidized into its 
disulphide form (GS-SG) (Bhabak and Govindasamy, 2010), as depicted in 
equation (18). 
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2 GSH + H2O2 → GS–SG + 2H2O   (18) 
 
Catalase is an antioxidant enzyme expressed in the peroxisome of cells and 
it is involved in the conversion of hydrogen peroxide into water and 
molecular oxygen (equation 19).  
 
2 H2O2 → 2 H2O + O2   (19) 
 
This enzyme is selective toward hydrogen peroxide, since it is not able to 
deplete other peroxides (Pisoschi and Pop, 2015). Interestingly, catalase 
has one of the highest turnover rates for all enzymes since one molecule of 
the latter can convert almost 6 million molecules of hydrogen peroxide into 
water and oxygen each minute (Rahman, 2007). 
 
(R)-lipoic acid and its reduced form (R)-dihydrolipoic acid (DHLA) (figure 
1.14) are endogenous antioxidants able to react with reactive oxygen 
species such as superoxide radicals, hydroxyl radicals, hypochlorous acid, 
peroxyl radicals, and singlet oxygen. 
 
 
Figure 1.14. Chemical structures of (R)-DHLA (left) and (R)-lipoic acid (right). 
 
These molecules exert protective effects on cellular membranes, interacting 
with vitamin C and glutathione, promoting the recycling of vitamin E 
(Packer, Witt and Tritschler, 1995; Kagan and Tyurina, 1998). Several 
studies have demonstrated the beneficial effects of DHLA administration in 
rats and guinea pigs; DHLA treated animals showed reduced symptoms of 
vitamin E and C deficiency and reduced lipid peroxidation in the brain and 
liver after treatment with the stressor azobis (2,4-dimethylvaleronitrile) 
(Packer, Witt and Tritschler, 1995). 
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1.2.3.1.2 Exogenous Antioxidants 
 
Exogenous antioxidants are molecules that cannot be biosynthesized by 
cells and are obtained through the diet. These molecules can be found in 
fruits and vegetables and their intake is commonly linked with health and 
wellbeing since the latter work synergistically with endogenous antioxidant 
to maintain the physiological redox homeostasis (Bouayed and Bohn, 2010). 
However, it has been showed that the ingestion of high amount of 
exogenous antioxidants (for example through supplements) may result in 
pro-oxidant effects or in the so called “antioxidant stress” (Poljsak and 
Milisav, 2012). 
 
1.2.3.1.2.1 Vitamins 
 
Vitamins are organic and essential compounds that an organism is not able 
to produce in sufficient amounts and thus must be obtained through the 
diet. Among these wide family of molecules, three vitamins that have strong 
antioxidant properties are vitamin A, C and E. Vitamin A includes several 
antioxidant compounds such as its active form retinoic acid and derivatives, 
for example retinal, retinol and provitamin A carotenoids (Fragoso et al., 
2012). Retinol and retinyl esters such as palmitate are dietary sources 
which are metabolized into the active form retinoic acid (see figure 1.15). 
 
 
Figure 1.15. Chemical structures of functional vitamin A molecules, adapted from Tanumihardjo (2011). 
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In addition to their role in vision, growth and other cellular functions, these 
fat soluble molecules exert strong antioxidant activities due to their 
conjugated double bonds, which stabilize unpaired electrons (Rahman, 
2007). Recent studies have shown that high consumption of carotenoids 
(precursors of vitamin A) in diet is linked with lower risk of age-related 
diseases; however, these molecules can act as pro-oxidant at high 
concentrations or in the presence of high oxygen pressure (Stahl and Sies, 
2003). 
 
Vitamin C (figure 1.16) is the L-enantiomer of ascorbic acid and is one of 
the most ubiquitous, water-soluble antioxidants. It has several roles in 
cells: it is involved in maintaining tissue integrity, in neuroprotection, in iron 
absorption and collagen biosynthesis (Pisoschi and Pop, 2015). Vitamin C 
can scavenge hydroxyl and superoxide radicals, along with NRS, and it can 
even protect lipids from peroxidation in combination with vitamin E. 
Moreover, although vitamin C is water soluble, it can regenerate the 
tocopherol free radical at the lipid-aqueous interface (Kojo, 2004; Du, 
Cullen and Buettner, 2012; Sung et al., 2013). 
 
 
Figure 1.16. L-ascorbic acid (vitamin C). 
  
Vitamin E exists in eight isoforms ( , ,  tocopherols and tocotrienols) 
with the -tocopherol being the most active and abundant. It is a 
liposoluble antioxidant and, for this reason, its main role is the protection of 
lipids from peroxidation, in combination with ascorbic acid. Its synergistic 
effect with vitamin C is shown in figure 1.17. 
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Figure 1.17. Synergistic effects of Vitamin C and E against lipid peroxidation, adapted from Marian 
Valko et al. (2004) with copyright agreement © 2006 Springer Nature. 
 
1.2.3.1.2.2 Phenolic Compounds 
 
Phenolic compounds are characterized by one or more aromatic rings to 
which is linked at least one hydroxyl group. This wide family of antioxidants 
can be further divided into flavonoids and non-flavonoid compounds. 
Flavonoids are the most common phenolic compounds that are introduced 
through the diet; their chemical structure consists of two aromatic carbon 
rings, benzopyran (A and C rings) and benzene (B ring) (Figure 1.18).  
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Figure 1.18. Chemical structures of Flavonoids. 
 
Depending on the degree of oxidation of the C-ring, the substitution at 
 the 3-position and the hydroxylation in the ring, flavonoids can be 
classified in six groups: flavonols (for example kaempferol and quercetin), 
flavones (luteolin and apigenin), isoflavones (genistein), flavanones 
(naringenin), flavanols (catechin) and anthocyanidins (cyanidin) (Manach et 
al., 2004; Spencer, 2008). 
 
These molecules can be found in a wide variety of vegetables and fruits that 
include broccoli, leeks, onions, parsley, berries, tea and citrus fruits. 
Flavonoids have shown strong antioxidant activity in vitro while several 
studies have demonstrated the ability of flavonoids to act as both free 
radical scavengers and to activate Nrf2 pathway in vitro (Hollman and 
Katan, 1997; Gao et al., 1999; Johnson, Maher and Hanneken, 2009; Zhai 
et al., 2013). However, these phenolic compounds showed reduced activity 
in vivo, due to their poor absorption, high metabolism and rapid excretion 
(Manach et al., 2004; Spencer, 2008; Goszcz et al., 2015). 
 
Stilbenes are a small family of plant secondary metabolites biosynthesized 
via the phenylpropanoid pathway; their antimicrobial and antifungal 
activities along with their pathogen-mediated induction suggest their 
importance in plant defense (Chong, Poutaraud and Hugueney, 2009). 
Resveratrol (see figure 1.6, page 13) is probably the most studied member 
of the phenolic family of compounds. Resveratrol is relatively abundant in 
grape skins and red wine and it showed interesting biological properties. In 
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fact, along with its ability to scavenge ROS to form a stable free radical due 
to the conjugation between the two aromatic rings via a double bond, it can 
act as metal chelating agent, NO synthase inducer, Nrf2 pathway inducer 
and COX-2 inhibitor (Harikumar and Aggarwal, 2008; Chong, Poutaraud and 
Hugueney, 2009; Nakata, Takahashi and Inoue, 2012; Pisoschi and Pop, 
2015). Several other studies have shown resveratrol to have interesting 
properties in vivo, reducing oxidation of LDL, inhibiting angiogenesis, 
reducing chronic inflammation and decreasing brain lipid peroxidation, due 
its ability to cross the blood-brain barrier (Baur and Sinclair, 2006). 
 
Phenolic acids are compounds containing a benzoic or cinnamic acid moiety 
and at least one hydroxyl group (figure 1.19). The latter are commonly 
found in the human diet and their daily intake is estimated to be 200 mg 
(Heleno et al., 2015). Among the benzoic acid derivatives, gallic acid is one 
of the most studied, since it is often used as standard for different 
antioxidant assays; it can be found in its free acid form or esterified with 
glucose (to form hydrolysable tannins known as gallotannins), flavanols (to 
form epigallocatechin) or other phenolic structures. 
 
 
Figure 1.19. Benzoic acid derivatives (left) and Cinnamic acid derivatives (right) chemical structures. The 
substituents in the aromatic rings (R) are often hydrogen, hydroxy and methoxy groups. 
 
Among the cinnamic acid derivatives, caffeic acid ((E)-3-(3,4-
dihydroxyphenyl)acrylic acid) is the most abundant, often esterified with 
quinic acid as in chlorogenic acid ((1S,3R,4R,5R)-3-(((E)-3-(3,4-
dihydroxyphenyl)acryloyl)oxy)-1,4,5-trihydroxycyclohexane-1-carboxylic 
acid), the major phenolic compound in coffee (Dai and Mumper, 2010). 
Recently ferulic acid, a cinnamic acid derivative, showed to block rotenone-
induced dopaminergic neurodegeneration in a mice PD model in a 4 weeks 
study. During this study, ferulic acid showed to reduce inflammatory 
mediators such as cyclooxygenase and iNOS and to restore antioxidant 
enzymes and the glutathione levels (Ojha et al., 2015). 
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It is interesting to note that, whereas small phenolic acids such as gallic 
acid can act as pro-oxidants under conditions that favour their autoxidation 
(high pH and high concentrations of transition metal ions), high molecular 
weight phenolics such as gallotannins have little or no prooxidant activity 
(Hagerman et al., 1998). 
 
Vanillin (4-hydroxy-3-methoxybenzaldehyde, figure 1.20) is a phenolic 
compound and is the main component of the bean and pod of tropical 
vanilla orchids (v. planifolia, v. tahitensis and v. pompona).  
 
 
Figure 1.20. Chemical structure of vanillin. 
 
Vanillin is widely used as flavouring agent in food industry and preservative 
in food, cosmetics and drugs industry with an estimated annual 
consumption in the world of more than 2000 tons (Kamat, Ghosh and 
Devasagayam, 2000). In addition to the flavouring properties, vanillin has 
shown promising biological activities in several studies; this included 
antimicrobial activities against a wide spectrum of bacteria (Fitzgerald et al., 
2004), as well as antimutagenic (King et al., 2007) and anticarcinogenic 
properties (Kapoor, 2013). Moreover, it has been reported recently that 
vanillin can decrease angiogenesis in vivo and inhibit cancer cell migration 
and metastasis (Lirdprapamongkol et al., 2009). Interestingly, vanillin 
showed protective effects against oxidative stress in both in vitro and in 
vivo studies. In fact, this phenolic compound also exhibited protection of 
SH-SY5Y neuroblastoma cells in rotenone-induced oxidative stress. 
Rotenone is a lipophilic pesticide that can easily cross cell membranes, 
inhibiting mitochondrial complex I activity, leading to an increase in ROS 
and oxidative stress (Dhanalakshmi et al., 2015) (see figure 21). This 
property makes rotenone a valid compound to model PD phenotype 
(Betarbet et al., 2000); its mechanism of toxicity is shown in figure 1.21. 
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In a study by Dhanalakshmi et al., vanillin was shown to protect SH-SY5Y 
cells at concentration as low as 100 nM, when stressed with rotenone (100 
nM), by increasing the cell viability by 25% compared to the control. 
 
 
Figure 1.21. Mechanism of rotenone toxicity, adapted from Xu, Shang, and Jiang (2016) with copyright 
agreement © 2016 Royal Society of Chemistry. 
 
In addition, two different in vivo experiments from Makni et al. showed the 
protective effects of vanillin in rats. Using carbon tetrachloride (CCl4)  as an 
oxidative stress inducer, the authors measured the protective effects of 
vanillin in brain and liver, showing lower levels of lipid peroxidation, reduced 
pro-inflammatory cytokines release, increase in antioxidant enzymes 
expression and in glutathione levels (Makni et al., 2011, 2012). 
Furthermore, vanillin protected hepatic mitochondria against oxidative 
damage in rats induced by photosensitization at concentrations normally 
found in food preparations (2.5 mM), reducing lipid peroxidation and 
preventing protein oxidation (Kamat, Ghosh and Devasagayam, 2000). 
The free radical scavenging activities of vanillin are well established: it is a 
powerful peroxynitrite inhibitor and a scavenger of hydroxyl and superoxide 
radicals (Kamat, Ghosh and Devasagayam, 2000; Kumar, Priyadarsini and 
Sainis, 2004). However, this natural compound showed weak or no activity 
in scavenging synthetic free radicals such as 2,2-diphenyl-1-picrylhydrazyl 
(DPPH) and galvinoxyl radicals; the latter is a well-established in vitro assay 
to determine free radical scavenging activity of antioxidants. It is worth 
noting that latter assay, involving the use of a synthetic radical, is less 
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relevant to biological system (Brand-Williams, Cuvelier and Berset, 1995; 
Tai et al., 2011). 
In contrast, vanillin is able to scavenge the peroxyl free radical generated in 
the oxygen radical absorbance capacity (ORAC) assay, which mimics the 
lipid peroxyls radicals occurring in the lipid peroxidation process in vivo. For 
this reason, the latter assay is more relevant to biological system (Isa et 
al., 2012). In this assay, vanillin exhibited more effective antioxidant 
properties when compared to ascorbic acid and the synthetic vitamin E-
related antioxidant, Trolox (Tai et al., 2011). 
 
1.2.3.2 Synthetic Antioxidants 
 
Antioxidant research has focused on the search for new compounds with 
improved antioxidant properties due to their important role in human health 
and wellbeing. However, the main use of synthetic antioxidants nowadays is 
in food preservation and cosmetics, in particular for the prevention of fatty 
acid oxidation (Carocho and Ferreira, 2013). Today, almost all processed 
foods have synthetic antioxidants incorporated in them in order to increase 
their shelf-life. For example, BHA and butylated hydroxytoluene (BHT) (2,6-
Di-tert-butyl-4-methylphenol) (figure 1.22) are widely used in the cosmetic 
and food industries. 
 
 
Figure 1.22. BHA (left) and BHT (right) chemical structures. 
 
Several studies have shown contrasting results on the potential for food 
preservatives in chemoprevention and carcinogenesis (Hocman, 1988). For 
example, propyl gallate (PG) is a synthetic gallic acid derivative (figure 
1.23) commonly used as food preservative, obtained by its condensation 
with propanol; its antioxidant properties have been exploited using different 
stable free radicals. It has been showed that PG has free radical scavenging 
activity against ABTS and DPPH comparable to vitamin C (Soares, 
Andreazza and Salvador, 2003). 
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Figure 1.23. Propyl gallate chemical structure 
 
Other modifications of natural antioxidants’ chemical structures to improve 
their antioxidant activity have been made. For example, Trolox (6-hydroxy-
2,5,7,8-tetramethylchroman-2-carboxylic acid, figure 1.24) is one of the 
most common synthetic antioxidants used in research laboratories since it is 
widely used as standard in many antioxidant activity assays (often 
expressed as Trolox Equivalent, TE).  
 
 
Figure 1.24. Chemical structure of Trolox. 
 
Trolox was developed by Scott et al. in the early 1970s at Hoffman-La 
Roche research laboratories during the search for new antioxidants that are 
able to prevent the oxidation of animal fats and vegetable oils. Chemically, 
it is a derivative of -tocopherol in which the isoprenoid chain, which is not 
involved in the antioxidant activity, has been replaced by a carboxylic 
group; this substitution makes the derivative water-soluble (Scott et al., 
1974). 
Several attempts were made to improve the antioxidant activity of Trolox 
and to target specific biological structures. In 1998, Moulin et al. described 
a series of N-(aza)arylcarboxamides derivatives of Trolox with strong anti-
inflammatory activity in rats, using the carrageenin-induced paw oedema 
test. Those compounds were orally administered at 0.4 and 0.1 mmol/kg, 
with the most active showing a 97.1% of oedema inhibition, and turning out 
to be more active than common anti-inflammatory drug such as 
indomethacin (Moulin et al., 1998). In 2001, Koufaki et al. reported a series 
of strong lipid peroxidation inhibitors in rat liver microsomial membranes 
induced by ferrous ions and ascorbate bearing both Trolox and lipoic acid 
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moieties, linked together by different chemical spacers (Koufaki et al., 
2001). That study was based on a previous finding by Coombes et al. where 
the synergistic effect of tocopherol and -lipoic acid in the reduction of lipid 
peroxidation during in vivo ischaemia-reperfusion in young adult rats was 
shown (Coombes et al., 2000). The most active compound, N-(4-(4-(5-
(1,2-dithiolan-3-yl)pentanamido)phenoxy)phenyl)-6-hydroxy-2,5,7,8-
tetramethylchromane-2-carboxamidethe (figure 1.25), reported by Koufaki 
et al., inhibited lipid peroxidation at nanomolar concentrations and totally 
suppressed arrhythmias induced by reoxygenation during reperfusion in an 
in vitro model (Koufaki et al., 2001). 
 
 
Figure 1.25. Trolox-lipoic acid hybrid reported by Koufaki et al. (2001). 
 
Interest around the resveratrol moiety (see figure 1.6, page 13) and its 
apparently powerful antioxidant properties, both in vitro and in vivo, had led 
to a substantial volume of work published during the past 20 years. 
It is well established that the scavenging activity of phenolic compounds 
against DPPH free radical is due to their hydrogen-donating ability. Wang et 
al. tested different stilbene derivatives using the DPPH assay and they 
showed that increasing the number of phenolic moieties resulted in an 
increase of antioxidant activity. In particular, the pentahydroxy stilbene 
derivatives turned out to be more active than tetrahydroxy and trihydroxy 
stilbene derivatives (Wang, Jin and Ho, 1999). In another example, Lee et 
al. confirmed the vital role for antioxidant activity of phenolic group in the 
stilbene chemical moiety by replacing them with a methoxy group, that 
resulted in the complete loss of the free radical scavenging activity (Lee et 
al., 2004). 
 
The role of the hydroxycinnamic acid moiety in antioxidant property has 
been studied by Gaspar et al. and Terpinic et al. for a number of years. 
Gaspar et al. reported a series of 5-bromo derivatives of caffeic acid, ferulic 
acid and their corresponding ethyl esters. These derivatives showed 
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enhanced partition coefficients (logP) compared with the respective starting 
compounds, a fundamental requirement for what concern absorption, 
distribution, metabolism and excretion (ADME), however no significant 
difference was observed for their antioxidant activities in both DPPH and 
ABTS assays (Gaspar et al., 2009).  
Subsequently, 4-vinyl derivatives of hydroxycinnamic acids have been 
described by Terpinc et al. These novel compounds 4-vinylphenol, 4-
vinylguaiacol, 4-vinylsyringol and 4-vinylcatechol were prepared from the 
corresponding acids and their antioxidant activities were tested (see figure 
1.26).  
 
 
Figure 1.26. Chemical structures of 4-vinylphenol (4-VP), 4-vinylguaiacol (4-VG), 4-vinylsyringol (4-
VS), 4-vinylcatechol (4-VC) and their corresponding hydroxycinnamic acids reported by Terpinc et al. 
(2011) 
 
Interestingly, those derivatives showed weaker antioxidant activities 
compared with the starting compounds in DPPH and superoxide anion 
scavenging assays, both using polar media. However they showed better 
performances in the β-carotene bleaching test, which was performed in an 
emulsion system, indicating the enhanced activity of the latter due to the 
improved lipophilicity (Terpinc et al., 2011). 
 
Gallic acid derivatives were described by Khaledi et al. in 2011 and they 
were hydrazone derivatives (figure 1.27) containing an indole moiety. All 
the 8 derivatives reported were more active in the DPPH assay compared 
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with ascorbic acid and -Tocopherol, whereas only two showed similar anti-
lipid peroxidation effects to these natural antioxidants (Khaledi et al., 
2011).  
 
Figure 1.27. Most active gallic acid derivatives reported by (Khaledi et al., 2011); compound 3e (X = Cl) 
and compound 3f (X = Br). 
 
1.2.3.2.1 Multitarget-based Synthetic Antioxidants 
 
Drugs hitting a single biological target could be inadequate for the 
treatment of diseases which involve multiple factors, such as 
neurodegenerative diseases, cancer, cardiovascular diseases and diabetes. 
Recently, the idea of multi-target-directed ligands (MTDLs), able to hit 
multiple target thought to be responsible for the diseases has rapidly gain 
the attention of researchers (Cavalli et al., 2008). A wide number of 
synthetic antioxidants have been recently described for their possible use in 
the treatment of pathologies for which oxidative stress is not the only 
hallmark. 
 
1.2.3.2.1.1 Synthetic Antioxidants in AD 
 
It is well established that Alzheimer’s disease (AD) is characterized by 
neuronal loss, depletion of cholinergic transmission, extracellular amyloid 
beta-peptide (Aβ)–rich senile plaques and oxidative stress (Mufson et al., 
2009; Butterfield, Swomley and Sultana, 2013). For this reason, recent 
research has focused on the synthesis of new antioxidants able to reduce 
oxidative stress as well as prevent amyloid aggregation and improve 
cholinergic transmission by inhibiting acetylcholinesterase enzyme (Leon, 
Garcia and Marco-Contelles, 2013; Benchekroun et al., 2016). Recently, Li, 
Wang and Kong reported the synthesis of several imine resveratrol 
derivatives with strong antioxidant properties (almost 8 times more active 
than resveratrol using the DPPH assay) and furthermore they were able to 
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inhibit the amyloid Aβ(1-42) self-induced aggregation. In addition, these 
derivatives showed improved protective effects on hydrogen peroxide-
stressed SH-SY5Y cells when compared with resveratrol (Li, Wang and 
Kong, 2014). The most active compound of the series, (E)-4-(((2-
hydroxyphenyl)imino)methyl)benzene-1,2-diol, is reported in figure 1.28. 
 
 
Figure 1.28. Synthetic resveratrol analogue reported by Li, Wang, and Kong (2014). 
 
In another example, Yang et al. reported several resveratrol-pyridoxine 
hybrids bearing antioxidant and anticholinesterase properties. These 
compounds prevented the oxidation of the fluorescent probe fluorescein in 
the ORAC assay, showing better free radical scavenging properties 
compared with the synthetic antioxidant Trolox, and good inhibitory activity 
towards cholinesterase enzyme, with an IC50 as low as 1.56 µM ((E)-2-
((diethylamino)methyl)-5-(2-(2,2,8-trimethyl-4H-[1,3]dioxino[4,5-
c]pyridin-5-yl)vinyl)phenol, see figure 1.29) (Yang et al., 2017). 
 
 
Figure 1.29. Resveratrol-pyridoxine hybrid reported by Yang et al. (2017). 
 
Recently, several molecules obtained by the combination of tacrine 
(1,2,3,4-tetrahydroacridin-9-amine), a well-known cholinesterase inhibitor, 
with several antioxidant moieties, have been reported. Benchekroun et al. 
showed tacrine derivatives with a melatonin moiety, have shown to activate 
the Nrf2/ARE pathway, together with a lipoic acid or ferulic acid moiety, 
both of which exhibit antioxidant properties. In particular, compound ((E)-
3-(4-hydroxy-3-methoxyphenyl)-N-(7-((7-methoxy-1,2,3,4-
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tetrahydroacridin-9-yl)amino)heptyl)-N-(2-((2-(5-methoxyindolin-3-
yl)ethyl)amino)-2-oxoethyl)acrylamide, figure 1.30) turned out to be the 
most active of the series, with strong cholinesterase affinity (IC50 of 1.29 
µM), strong antioxidant properties in the ORAC assay (9.11 Trolox 
Equivalents) and an ability to activate the Nrf2/ARE pathway in AREc32 cells 
at concentration as low as 3 µM (Benchekroun et al., 2016).  
 
 
Figure 1.30. Tacrine-melatonin hybrid described by Benchekroun et al. (2016). 
 
Previously, Rodriguez-Franzo et al. reported tacrine-melatonin hybrids with 
higher cholinesterase activities, with IC50 value of 0.5 nM, but with reduced 
antioxidant properties (4 Trolox Equivalents, compared to the 9.11 TE of the 
hybrids reported by Benchekroun et al.) (Rodríguez-Franco et al., 2006). 
In 2012, Chen et al. described a series of tacrine-ferulic acid-NO donors 
with cholinesterase activities at nanomolar levels. These compounds were 
able to improve cognition activities in mice when treated with scopolamine. 
The ability of these compounds to release NO was important because 
increasing evidences showed the beneficial effects of increasing blood 
supply in cerebral circulation in AD treatment. It is worth noting that all the 
derivatives (general structures reported in figure 1.31) showed weak or no 
antioxidant activities, due to the substitution of the phenolic group in the 
ferulic acid moiety (Chen et al., 2012, 2013).  
 
 
Figure 1.31. General structures of tacrine-ferulic acid-NO donors reported by Chen et al. (2012). 
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In the same year, Huang et al. reported a series of benzylideneindanone 
derivatives with significant antioxidant activities (ranging from 2.60 up to 
9.37 TE using the ORAC assay) and able to prevent self-mediated Aβ(1-42) 
amyloid peptide aggregation (up to 80.1%, compared with the positive 
control, curcumin, 52.1%). In addition, the compound (E)-5,6-dihydroxy-2-
(4-(methyl(propyl)amino)benzylidene)-2,3-dihydro-1H-inden-1-one (figure 
1.32) exhibited chelating properties toward Cu2+ ion, which is involved in 
oxidative stress through the Fenton reaction and in Cu(II)-induced Aβ 
aggregation (Huang et al., 2012). 
 
 
Figure 1.32. Chemical structure of (E)-5,6-dihydroxy-2-(4-(methyl(propyl)amino)benzylidene)-2,3-
dihydro-1H-inden-1-one reported by Huang et al. (2012). 
 
More recently, Wang et al. described new cinnamamide-dibenzylamine 
hybrids with modest antioxidant properties (ranging from 0.26 up to 4.24 
TE in ORAC assay) and anti-cholinesterase activity (with IC50 ranging from 
1.05 to 6.63 µM). Furthermore, these compounds showed interesting 
abilities in preventing the self-mediated Aβ(1-42) amyloid peptide aggregation 
(up to 56.8%, compared with the positive control curcumin 42.5%) and in 
chelating metal ions, with derivative (E)-N-(4-
((benzyl(methyl)amino)methyl)phenyl)-3-(3,4-dihydroxyphenyl)acrylamide 
(figure 1.33) was able to chelate Cu2+, Zn2+ and Fe3+ but not Fe2+. 
 
 
Figure 1.33. Chemical structure of (E)-N-(4-((benzyl(methyl)amino)methyl)phenyl)-3-(3,4-
dihydroxyphenyl)acrylamide described by Wang et al. (2017). 
 
The latter compound was then tested in a learning and memory impairment 
model in rats. Beneficial effects were detected at concentration of 10 mg/kg 
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in a scopolamine-induced memory deficit involving the step-down passive 
avoidance test, showing comparable effects to donepezil (5 mg/kg) (Wang 
et al., 2017). 
 
Due to the ability of curcumin to inhibit amyloid aggregation, several 
synthetic derivatives have been synthesized in an attempt to improve its 
antioxidant activities and solubility. In 2014, Fang et al. reported several 
dimethylaminomethyl substituted curcumin derivatives with improved 
antioxidant activities toward DPPH and galvinoxyl radicals; in particular, 
derivative (1E,4Z,6E)-1,7-bis(3-((dimethylamino)methyl)-4-
hydroxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one (figure 1.34) showed an 
IC50 of 1.6 µM in DPPH assay and 4.9 µM in galvinoxyl, compared with 
curcumin (26.5 and >100 µM, respectively).  
 
 
Figure 1.34. Dimethylaminomethyl substituted curcumin derivative reported by Fang et al. (2014) 
 
Moreover, the latter showed similar activity compared with curcumin in the 
inhibition of the self-aggregation of Aβ(1-42) amyloid at concentrations of 50 
and 100 µM, whereas both compounds were not active at concentrations of 
5 µM. Of note, the hydrochloride salt of the curcumin derivative (figure 
1.34) showed a solubility of 16.7 mg/ml, far higher than that of curcumin 
(<0.1mg/ml), making it amenable for possible clinical application (Fang et 
al., 2014). 
 
1.2.3.2.1.2  Synthetic Antioxidants in PD 
 
Parkinson’s disease (PD) is a neurodegenerative disease associated with the 
loss of dopaminergic neurons in the substantia nigra pars compacta (SNc), 
with the consequential depletion of dopamine levels in the nigrostriatal 
dopaminergic pathway in the brain. Although the molecular pathway is not 
completely understood, mitochondrial dysfunction, protein misfolding, 
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protein phosphorylation and oxidative stress play a major role in 
development of the disease (Cavalli et al., 2008; Blesa et al., 2015). 
 
Kaidery et al. described new synthetic triterpenoids (TP-224, TP-319 and 
TP-500) (see figure 1.35) that were able to activate the Nrf2/ARE pathway 
in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of 
PD. 
 
 
Figure 1.35. Synthetic triterpenoids TP-224 (X = -Me), TP-319 (X = -Et) and TP-500 (X = -CH2-CF3) 
described by Kaidery et al. (2013). 
 
Mice were treated with the synthetic triterpenoids (4 µmol) twice a day for 
12 weeks and the levels of ARE-controlled gene expression, such as 
glutamate-cysteine ligase regulatory subunit (GCLM), glutamate-cysteine 
ligase catalytic subunit (GCLc), haem-oxygenase-1 (HO-1), NAD(P)H 
dehydrogenase quinone 1 (NQO1) and glutathione-disulfide reductase 
(GSR) were measured in the liver and striatum. The expression of all these 
genes was significantly increased (between 5 to 25-fold times) in the liver, 
but only NQO1 and HO-1 were upregulated in the striatum. 
 
These synthetic triterpenoids were then tested in the MPTP model of PD, 
where mice were treated with 10 mg MPTP/kg three times a day every 2 
hours, causing 50% dopamine loss in the SNc compared with the saline 
control. The synthetic triterpenoids were found to reduce cell death while 
increasing the levels of dopamine up to 37% compared with the MPTP 
control. In addition, the inflammatory marker, 3-nitrotyrosine, in SNc was 
completely depleted in this area of the brain from the triterpenoid-treated 
mice. Finally, to confirm the Nrf2-dependent pathway in the neuroprotection 
identified, these triterpenoids were tested in Nrf2 KO mice, where they did 
not show significant protection against MPTP toxicity (Kaidery et al., 2013). 
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In 2009, Pinnen et al. reported a series of L-Dopa derivatives with 
antioxidant properties to avoid the pro-oxidative effects of the L-Dopa 
treatment for PD. These compounds were found to release L-Dopa and 
dopamine in the plasma after enzymatic hydrolysis and had a higher 
antioxidant activity compared with N-acetylcysteine. In addition, one of the 
synthetic compounds (methyl ((S)-2-acetamido-3-(3,4-
dihydroxyphenyl)propanoyl)-L-methioninate, see figure 1.36) increased the 
level of dopamine in the rat’s striatum, after intracerebroventricular 
injection, compared with the L-Dopa-treated group, showing a longer half-
life in the brain (Pinnen et al., 2009). 
 
 
Figure 1.36. Methyl ((S)-2-acetamido-3-(3,4-dihydroxyphenyl)propanoyl)-L-methioninate, reported by 
Pinnen et al. (2009). 
 
In 2008, Liu et al. described a synthetic hybrid of cyclohexyl bisphenol A 
(CBA) and curcumin known as CNB-001 (figure 1.37). Previously, CBA had 
shown to protect cells from Aβ(1-42) and glutamate toxicity as well as from 
the loss of trophic factor support, whereas curcumin was protective in a 
transgenic animal model for AD.  
 
 
Figure 1.37. CNB-001 chemical structure. 
 
In that study, the hybrid showed lower antioxidant activity compared with 
curcumin, but similar activity to that of CBA. However, CNB-001 showed 
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neurotrophic factor-like activities several fold better than CBA in rat cortical 
neurons. It is worth noting that these neurotrophic factors play a 
predominant role in the maintenance of cell survival following CNS injury. In 
addition, the synthetic hybrid inhibited amyloid-induced cell death in MC65 
cell line with an IC50 of 300 nM, compared with CBA (>10 µM) and curcumin 
(inactive) (Liu et al., 2008). These findings prompted a great deal of 
interest on CNB-001. Jayaraj et al. reported a protective effect of this 
curcumin derivative in a SK-N-SH cellular model of PD. The cells were 
pretreated with CNB-001 for 2 hours, with concentrations ranging from 0.5 
up to 4 µM before the exposure to rotenone (100 nM). The results showed 
that CNB-001 protected the cells at all the tested concentrations, with 
higher protection at 2 µM concentration. In addition, CNB-001 showed a 
reduction of ROS formation after treatment with rotenone (100 nm), using 
2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) as a fluorescent probe 
for ROS detection. Furthermore, pretreatment with the drug significantly 
attenuated the expression of pro-apoptotic proteins and increased the 
expression of the anti-apoptotic protein Bcl-2, implicating a dual mechanism 
of protection against rotenone toxicity that included both antioxidant and 
anti-apoptotic pathways (Jayaraj et al., 2013). 
 
A year later, another work by Jayaraj et al. reported the protective effect of 
CNB-001 in a different PD model, using MPTP in adult mice. In this work, 
the authors observed an increase in dopamine levels in the mice pretreated 
with concentrations of drug ranging from 6-48 mg/kg, with its maximum 
between 24 and 48 mg/kg. Mice pretreated with 24 mg/kg of CNB-001 
showed attenuation of Parkinsonian impairments, reduced lipid 
peroxidation, activation of antioxidant response and reduced dopaminergic 
neuron loss compared with the MPTP control. In particular, the drug 
increased the levels of reduced glutathione, GPx activity and the expression 
of tyrosine hydroxylase (TH), dopamine transporter (DAT) and vesicular 
monoamine transporter 2 (VMAT2), compared with the MPTP control 
(Jayaraj et al., 2014). 
 
More recently, CNB-001 was found to suppress lipopolysaccharide (LPS)-
induced NO production and the expression of the inducible NO synthase 
(iNOS) in primary cultured rat microglia more effectively than curcumin. In 
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addition, CNB-001 suppressed the LPS-induced nuclear translocation of 
NFB and p38 MAPK phosphorylation, both involved in the inflammatory 
response (Akaishi and Abe, 2018). 
 
1.2.3.2.1.3  Synthetic Antioxidants in Inflammation 
 
Several works have reported that antioxidants also exert anti-inflammatory 
properties. For example, the quinolinone moiety has attracted the interest 
of several research groups due to its antioxidant and anti-inflammatory 
properties and, in 2007, Detsi et al. reported a series of quinolinone-3-
aminoamides and their adducts with -lipoic acid. Almost all these 
derivatives demonstrated interesting scavenging activity toward DPPH and 
hydroxyl free radicals, as well as the ability to inhibit 5-lipoxygenase (5-
LOX), a well-known pro-inflammatory enzyme involved in the conversion of 
arachidonic acid into eicosanoids, in an in vitro assay. Furthermore these 
compounds reduced carrageenin-induced rat paw oedema in vivo, with N-
(2-aminophenyl)-4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-
carboxamide (see figure 1.38) the most active, with an activity almost two 
times fold compared to the reference drug, indomethacin (Detsi et al., 
2007). 
 
 
Figure 1.38. N-(2-aminophenyl)-4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide 
described by Detsi et al. (2007) 
 
In 2014, Matralis and Kourounakis described several phenothiazine 
derivatives with strong antioxidant and anti-inflammatory properties. Their 
work was based on the finding that phenothiazine moiety is able to inhibit 
lipid peroxidation and to exert cytoprotective effects due to their antioxidant 
properties (Yu et al., 1992). Compounds synthesized by Matralis and 
Kourounakis were able to inhibit lipid peroxidation at concentrations as low 
as 0.33 µM, together with the complete inhibition of cyclooxygenase-2 
(COX-2) at concentration of 20 µM in vitro. The latter enzyme is involved in 
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pro-inflammatory prostaglandin biosynthesis and is the target of several 
nonsteroidal anti-inflammatory drugs (NSAIDs). In addition, these 
phenothiazine derivatives turned out to be excellent inhibitors of squalene 
synthase (SQS) - a key enzyme in the biosynthesis of cholesterol - in an in 
vitro model. The derivative, 4-methyl-2-(10H-phenothiazin-2-yl)morpholin-
2-ol (see figure 1.39), exhibited anti-hyperlipidaemic properties in an 
experimentally-induced hyperlipidaemic rat model (reducing total 
cholesterol by 70%, LDL by 80% and triglyceride by 94%) and in mice fed a 
high-fat diet (reducing the total cholesterol by 53% and the LDL by 76%) 
(Matralis and Kourounakis, 2014). 
 
 
Figure 1.39. 4-methyl-2-(10H-phenothiazin-2-yl)morpholin-2-ol reported by Matralis and Kourounakis 
(2014). 
 
More recently, Abd El Razik et al. reported a series of benzodioxole-pyrazole 
hybrids with strong anti-inflammatory properties, both in vitro and in vivo, 
and antioxidant activity comparable with ascorbic acid. The chemical 
structures of these derivatives were based on Celecoxib and Lonazolac, two 
pyrazoles currently used as analgesic and anti-inflammatory agents. 
Interestingly, the compounds synthesized by Abd El Razik et al. turned out 
to be potent COX-2 and 5-LOX inhibitors in vitro, with IC50 ranging from 
0.33-3.56 µM and 3.11-9.94 µM, respectively. These activities are 
comparable with the NSAIDs currently on the market such as celecoxib and 
meclofenamate. Furthermore, two of these derivatives decreased TNF- 
expression in LPS-stimulated cells by 85.19 and 97.71%, with activities 
comparable to hydrocortisone (94.74%). In terms of antioxidant potential, 
the ability of several benzodioxole-pyrazole hybrids compounds to scavenge 
the DPPH free radical and to inhibit the lipid peroxidation was comparable to 
that of ascorbic acid. Finally, in vivo studies confirmed the anti-
inflammatory and analgesic properties of these derivatives; in the rat paw 
oedema test, the compounds showed reduced volume of oedema by up to 
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55.5% compared to the control, whereas, after intra-peritoneal injection of 
acetic acid, rats pretreated with the compounds showed less writhing 
compared to the controls, confirming the analgesic effects of these 
benzodioxole-pyrazole hybrids, with (E)-2-(2-(5-(benzo[d][1,3]dioxol-5-yl)-
1-(4-sulfamoylphenyl)-1H-pyrazole-3-carbonyl)hydrazineylidene)propanoic 
acid (see figure 1.40) the most active (El Razik et al., 2017). 
 
 
Figure 1.40. (E)-2-(2-(5-(benzo[d][1,3]dioxol-5-yl)-1-(4-sulfamoylphenyl)-1H-pyrazole-3-
carbonyl)hydrazineylidene)propanoic acid reported by El Razik et al. (2017) 
 
Due to the central role that oxidative stress plays in neurodegenerative 
diseases, cancer, cardiovascular diseases and inflammation, the synthesis of 
novel synthetic antioxidants, with improved antioxidant activities, that could 
hit different biological target is a promising strategy for the treatment or 
prevention of these illness. 
 
1.3 Aims of Project 
 
The aim of the project was to synthesize novel vanillin derivatives and 
determine their antioxidant activities, their cytoprotective effects on 
neuroblastoma SH-SY5Y cell line and the mechanism that may contribute to 
their protective effects. 
 
Several derivatives were synthesized to predict a structure-activity 
relationship (SAR) for this class of compounds in different antioxidant 
assays, which exploited different antioxidant mechanisms.  
 
46 
 
Furthermore, selected  compounds were tested in the SH-SY5Y 
neuroblastoma cell line and their abilities to protect the cells from oxidative 
insult were evaluated. 
 
In addition, the abilities of the selected compounds to supress ROS and to 
protect the DNA in SH-SY5Y cells after the treatment of the cells with 
hydrogen peroxide were investigated. 
 
Moreover, the ability of the selected compounds to trigger the Nrf2 
antioxidant pathway was investigated through western blot.  
The use of selected compounds in the multi-target-directed strategy for AD 
therapy was assessed by evaluating their inhibitory activities toward the 
acetylcholinesterase enzyme and the amyloid Aβ(1-42) self-induced 
aggregation. Modeling studies were performed to better understand the 
molecular elements contributing to the AChE inhibitory activity of latter 
compounds. 
 
Finally, simulations on the ability of selected compounds to cross the blood-
brain-barrier (BBB) were run. 
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Chapter 2: Synthesis of Novel Vanillin 
Derivatives 
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2.1 Vanillin Derivatives 
 
2.1.1 Overview on Vanillin Derivatives  
 
In the past decade, several vanillin derivatives with different biological 
activities have been reported, indicating the versatility of this moiety. In 
particular, a substantial amount of work has been carried out regarding the 
antifungal and antimicrobial activity of vanillin derivatives.  
 
In 2012 Harini et al. described a novel vanillin derived from piperidin-4-one 
oxime esters that possessed antimicrobial properties and modest 
antioxidant activities. Their synthetic approach (figure 2.1) was first based 
on a Mannich condensation reaction between vanillin, acetone and 
ammonium acetate followed by N-alkylation using iodomethane to yield the 
corresponding 2,6-bis(4-hydroxy-3-methoxyphenyl)-1-methylpiperidin-4-
one. The latter was then converted into the corresponding oxime using 
hydroxylamine hydrochloride and finally esterified with different benzoyl 
chlorides to yield the final products. 
 
 
Figure 2.1. Synthetic approach for the synthesis of vanillin derivatives reported by Harini et al. (2012), 
adapted with copyright agreement © 2012 Elsevier Ltd. 
 
The derivatives reported in this work showed inhibitory activity towards E. 
Coli, S. Aureus and P. Aeruginosa comparable with streptomycin, a common 
antibiotic. Of note, 2,6-bis(4-hydroxy-3-methoxyphenyl)-1-methylpiperidin-
4-one O-(3,4,5-trihydroxybenzoyl) oxime (circled in red) showed similar 
antioxidant activity to BHA in DPPH, ABTS and lipid peroxidation assays. 
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The antioxidant activity of this derivative was found to be due to the 
presence of two vanillin moieties and a gallic acid moiety in its chemical 
structure (Harini et al., 2012).  
 
In the same year, Rangaswami et al. described a series of antimicrobial 
benzofuran based 1,3,5-substituted pyrazole bearing the vanillin moiety in 
its structure to boost their antioxidant properties. The synthetic pathway, 
depicted in figure 2.2, involved a five-step reaction strategy; the starting 
material (2-acetyl benzofuran) was prepared by cyclocondensation between 
salicylic aldehyde and chloroacetone in DCM in the presence of 1,8-diaza 
bicyclo[5.4.0]undec-7-ene (DBU) and molecular sieves. 
 
 
Figure 2.2. Synthetic strategy for the synthesis of vanillin derivatives reported by Rangaswamy et al. 
(2012), adapted with copyright agreement © 2012 Elsevier Ltd. 
 
The latter was then reacted with vanillin to afford benzofuran chalcone (E)-
1- (benzofuran-2-yl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one 
through Claisen-Schmidt condensation, which was subsequently reacted 
with hydrazine hydrate to yield 4-(3-(benzofuran-2-yl)-4,5-dihydro-1H-
pyrazol-5-yl)-2-methoxyphenol. The latter was treated with phosgene in the 
presence of triethylamine to afford 3-(benzofuran-2-yl)-5-(4-hydroxy-3-
methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl chloride which was 
finally reacted with different substituted anilines to yield the desired 
products. 
All the compounds were tested for their antioxidant properties through the 
DPPH and microsomal LPO assays; it is interesting to note that the 
derivative which bears an extra vanillin moiety in the chemical structure (R 
= vanillin) showed antioxidant activities in both DPPH and lipid peroxidation 
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assays, comparable to BHA. On the other hand, almost all the derivatives 
showed modest antimicrobial and antifungal properties when compared with 
therapeutic agents, streptomycin and fluconazole (Rangaswamy et al., 
2012).  
 
In addition, Dangar, Borkhataria and Shah (2014) reported in the same 
year Schiff’s base vanillin derivatives, and corresponding reduced products, 
with modest antimicrobial and antifungal activities. The synthetic approach 
of the work is described in figure 2.3. Schiff’s bases are characterized by 
the -CH=N group, obtained by reacting an aldehyde (or ketone) with an 
amine with the loss of water. The resulting imine was reduced to yield the 
corresponding secondary amine.  
 
 
Figure 2.3. Synthetic approach for the synthesis of vanillin derivatives reported by Dangar, Borkhataria, 
and Shah (2014). 
 
These compounds reported by this group showed modest antimicrobial 
activity when compared with amoxicillin and ampicillin (two common 
antibiotics) against E. Coli and S. Aureus and antifungal activity comparable 
to griseofulvin (a common antifungal agent) (Dangar, Borkhataria and 
Shah, 2014). 
In addition to the antimicrobial vanillin-based agents, several other 
antioxidants vanillin derivatives have been reported in the literature.  
 
The synthetic derivative, ethylvanillin (3-ethoxy-4-hydroxybenzaldehyde), is 
extensively used in the chocolate industry due to its intense flavouring 
capacity (~3 fold compared to vanillin). It is synthetically produced 
following the same procedure as for the synthesis of vanillin, but using 
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guethol (2-ethoxyphenol) instead guaiacol (2-methoxyphenol) as the 
starting compound (Fahlbusch et al., 2012), as depicted in figure 2.4.  
 
 
Figure 2.4. Synthetic process for the synthesis of ethylvanillin. 
 
The antioxidant activity of ethylvanillin is comparable to vanillin in both 
ORAC and ABTS scavenging assays, where it turned out to possess stronger 
antioxidant activity compared to Trolox, but was completely inactive in the 
DPPH assay (Tai, Sawano and Yazama, 2011).  
 
In the last decade, Lee et al. published several works on vanillin-based 
dendrimers. In 2009, the group reported three novel dendrimers which 
possessed strong free radical scavenging properties toward DPPH, with IC50 
ranging from 3.7 to 6.0 µM compared with the standard Trolox (27.6 µM). 
In addition, these compounds showed protection against LDL and fatty acids 
oxidation and an ability to reduce plasmid DNA damage after the incubation 
of pBR322 DNA plasmid with 2,2'-Azobis(2-amidinopropane) (AAPH) at 10 
mM concentration. In particular, dendrimer 4,4',4'',4'''-(((1,4-
phenylenebis(methylene))bis(azanetriyl))tetrakis(methylene))tetrakis(2,6-
dimethoxyphenol) completely protected the DNA at concentration of 11 µM 
with only partial protection at 3 µM. 
 
The dendrimer was generally prepared in a one-step reaction by mixing 
syringaldehyde and 4-aminomethylbenzylamine in 1,2-dichloroethane in the 
presence of sodium triacetoxyborohydride as reducing agent, as described 
in figure 2.5. 
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Figure 2.5. Synthetic strategy for the dendrimer reported by Lee et al. (2009), with copyright agreement 
© 2009 Elsevier Ltd. 
 
In 2015, new dendrimers bearing electron donating groups were reported 
by the same group. Interestingly, they found that the free radical 
scavenging activities in DPPH assay of these dendrimers were proportional 
to the number of methoxy group in the aromatic ring. Indeed, 
syringaldehyde derivatives, bearing two methoxy moieties (see figure 2.6) 
were better scavenger than vanillin derivatives (with only one methoxy 
moiety) and 4-hydroxybenzaldehyde derivatives (with no methoxy group) 
showed no activity in the assay. 
 
In the DNA protection assay, the dendrimers followed the same trend with 
the syringaldehyde derivative being the most active, followed by the vanillin 
derivatives and the 4-hydroxybenzaldehyde derivatives (Lee et al., 2015). 
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Figure 2.6. Synthetic strategy for the synthesis of dendrimer adapted from Lee et al. (2015), with 
copyright agreement © 2015 Elsevier Ltd. 
 
To obtain the final product, the two building blocks 1a and 5a, represented 
in the squares of figure 2.6, were synthesized. 
4,4'-((prop-2-yn-1-ylazanediyl)bis(methylene))bis(2,6-dimethoxyphenol) 
(1a) was obtained through reductive amination between propargylamine 
and syringaldehyde in THF using sodium triacetoxyborohydride as reducing 
agent. 
1,15-diazido-8,8-bis((2-(2-azidoethoxy)ethoxy)methyl)-3,6,10,13-
tetraoxapentadecane (5a) was prepared through a three-step reaction; 
sodium azide was reacted with 2-(2-chloroethoxy)ethanol in DMF/H2O 40:1 
to yield 2-(2-azidoethoxy)ethan-1-ol which was treated with triethylamine 
(TEA) and tosyl chloride in chloroform to afford 2-(2-azidoethoxy)ethyl 
benzenesulfonate. 
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The latter was reacted with pentaerythritol in anhydrous DMF in the 
presence of sodium hydride to yield 5a. Finally, microwave energy-assisted 
reaction between the two building blocks (1a and 5a) afforded the desired 
compound. 
 
Very recently, work from Chigurupati et al. reported several vanillin and 
cinnamaldehyde derivatives bearing an imine group. These compounds 
turned out to be good free radical scavengers in DPPH and ABTS assays, 
with activities comparable to ascorbic acid. The general synthetic approach 
for the synthesis of the vanillin derivatives reported in this work is reported 
in figure 2.7.  
 
 
Figure 2.7. Synthetic strategy for the synthesis of the vanillin derivatives reported by Chigurupati et al. 
(2018). Reproduced with copyright agreement  © 2017, Springer Science Business Media, LLC. 
 
The most active compound (E)-4-((4-hydroxy-3-
methoxybenzylidene)amino)benzoic acid (R=-COOH) yielded an IC50 value 
of 14.07 and 15.06 µM in DPPH and ABTS assays, respectively, compared to 
ascorbic acid (15.73 and 16.79, respectively) (Chigurupati et al., 2018). 
 
Due to the potential role of novel synthetic antioxidants in health and 
wellbeing, and the small amount of work on synthetic vanillin derivatives, 
the aim of the experimental work presented in this chapter was to design, 
synthesize and characterize a series of new vanillin derivatives with the 
potential for enhanced activity, particularly in the neurodegenerative 
disease setting. 
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2.2 Chemical Synthesis of Vanillin Derivatives 
 
2.2.1 Rationale Behind the Synthesis of Novel Vanillin Derivatives 
 
Several vanillin derivatives with different structural features were 
synthesized to allow a SAR study as regard to their antioxidant and 
neuroprotective properties. 
 
All the compounds prepared are represented by the general structures 
shown in figure 2.8: 
 
 
Figure 2.8. General structures of the proposed vanillin derivatives. 
 
The vanillin derivatives presented in this work can be classified into four 
groups: 
 
(i) Monomers (imine): characterized by only one vanillin moiety in 
their chemical structure along with an imine group (-CH=N-). 
(ii) Monomers (amine): characterized by only one vanillin moiety in 
their chemical structure along with a secondary amino group (-
CH2-NH-). 
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(iii) Dimers: characterized by two vanillin moieties in their chemical 
 structure. 
(iv) Tetramers: characterized by four vanillin moieties in their 
chemical structure. 
 
Different substituents (R) linked to the nitrogen atom(s) and other 
modifications were exploited to determine their impact on antioxidant 
activity (see schemes 1, 2, 3 and 4 in the results and discussion section).  
 
For example: 
(i) A selection of alkanolamines (HO-CH2(n)-NH2) and alkylamines (R-
NH2) were employed to generate different vanillin derivatives 
(ii) The role of an extra methoxy substituent in the vanillin ring (X = 
-OCH3, syringaldehyde derivatives) in the antioxidant activities 
was also evaluated. 
(iii) Several modifications in the vanillin rings of the tetramers were 
made to study the impact of hydroxy and methoxy groups in the 
vanillin ring. 
(iv) The impact of the electronic conjugation between the two 
nitrogen atoms in the tetramers was studied by using an aromatic 
ring system, which is able to delocalise nitrogen’s lone pair of 
electrons, and a cyclohexane ring, which is not able to delocalise 
nitrogen’s electrons, as linkers between the latter. 
(v) The impact of the protonation of nitrogen atoms on the 
antioxidant activities was also investigated. 
(vi) Finally, several monomers bearing a tacrine or a napthalimido 
moiety were prepared for the evaluation of their cholinesterase 
inhibitory activities along with their antioxidant activities (this will 
be discussed in chapter 5). 
 
Tacrine is a well-known acetylcholinesterase enzyme inhibitor, a common 
target in the Alzheimer’s Disease therapy (Colovic et al., 2013). 
On the other hand, the lack of studies on the naphtalimido moiety as a 
potential scaffold for the synthesis of novel cholinesterase inhibitors 
prompted further investigation with this moiety (Gao et al., 2016). 
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2.2.2 Nomenclature 
 
The nomenclature used in this thesis is based on the number of vanillin 
moieties in each structure to facilitate the discussion of this work. 
Therefore, all the monomers are labelled as compound 1 followed by a 
letter, all the dimers as 2 and all the tetramers as 4 followed by a letter. 
The intermediates prepared for the final synthesis of the compounds are 
labelled with I followed by a number. 
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2.3  Materials and Methods 
 
2.3.1 Materials 
 
All reagents were purchased from Sigma Aldrich unless otherwise stated 
and were used without any further purification. 
 
Chloroform-d                                      Cambridge Isotopes Laboratories Inc 
Dichloromethane            Fisher Scientific 
Diethyl Ether                  Acros Organics  
Dimethyl Sulfoxide            Fisher Scientific  
DMSO-d6        Cambridge Isotopes Laboratories Inc  
Potassium Iodide             Fisher Scientific 
Silica 60 F254 Gel                          Merck 
Silica 70-230 Mesh                     Alfa Aesar 
Sodium Sulfate Anhydrous           Fisher Scientific 
Zinc Chloride             Fisher Scientific 
 
2.3.2  Techniques for the Identification and Characterization of 
intermediates and new Vanillin Derivatives  
 
Techniques employed for the characterization of the products were thin 
layer chromatography (TLC), nuclear magnetic resonance (NMR) and mass 
spectrometry (MS).  
 
Thin Layer Chromatography (TLC) 
 
TLC is a separation technique used for the identification of several 
components within a solution (Meyers and Meyers, 2008). TLC was used to 
monitor the reactions and to determine the purity of the compounds. A 
small drop of reaction mixture was dispensed on a silica gel aluminium plate 
(stationary phase) using a capillary glass. Once dry, the silica gel plate was 
placed in the vertical position in a TLC development tank containing a 
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mixture of dichloromethane (DCM) and methanol (mobile phase). Due to 
capillary action, the mobile phase travels up the plate and the components, 
which show different affinities for both mobile and stationary phases, travel 
at different rates causing the separation. The spots can be then visualised 
under UV-light (λ=243 nm, see figure 2.9). 
 
 
Figure 2.9. Thin Layer Chromatography plate. 
 
Nuclear Magnetic Resonance (NMR)  
 
Nuclear Magnetic Resonance (NMR) spectroscopy is a common tool used for 
the confirmation of a proposed chemical structure. It relies upon the 
magnetic properties of atomic nuclei (nuclear spin); in particular, proton 
(1H) and carbon (13C) nuclei are useful for the characterization of novel 
compounds. In fact, 1H NMR and 13C NMR detect protons and carbon nuclei, 
respectively, in relation to their environment (Morris, 1986). For their 
structural confirmation, the compounds were dissolved in a convenient 
deuterated solvent, such as chloroform-d (CDCl3) or dimethyl sulfoxide-D6 
(DMSO-d6) and transferred into an NMR tube before the introduction into 
the instrument (Bruker 400 Ultrashield). The experimental conditions were 
set using Bruker Topspin 1.3 software and the sample was analysed. An 
NMR spectrum was obtained and was then interpreted for the structural 
confirmation.  
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Mass Spectrometry (MS) 
 
Mass Spectrometry (MS) was employed for the structural characterization of 
the compounds. It is based on the ionization of molecules and the 
separation of charged fragments according to their mass-to-charge ratio 
(m/z) using an electric and/or magnetic field. Molecules were injected into 
MS instrument and ionized through electrospray ionisation (ESI); the ions 
were the accelerated, amplified and detected (Siuzdak, 1996),  generating a 
mass spectrum. 
 
2.3.3 Instrumentation 
 
Thin Layer Chromatography (TLC) was performed on silica gel 60 F254 
Aluminium plates (2 cm x 5 cm) (Merck, Germany) using 
chloroform:methanol (95:5 or 90:10) mixture as mobile phase. Spots were 
visualised using UV-light (254 nm). 
Nuclear Magnetic Resonance (NMR) spectroscopy was performed on a 
Bruker 400 Ultrashield spectrometer operating at 400.1 MHz for proton (1H) 
and, 100.6 MHz for carbon-13 (13C) NMR.  
High Resolution Mass Spectrometry (HRMS) analysis was performed on the 
final compounds at the Engineering and Physical Sciences Research 
Council’s (EPSRC) National Mass Spectrometry Service Centre at Swansea 
University, Swansea, UK.  
Low Resolution Mass Spectrometry analysis was undertaken on the 
intermediates at Robert Gordon University using an Agilent Technologies 
1200 series. 
 
2.4 Methods 
 
2.4.1 Synthesis of Intermediates 
 
Amines I-1 and I-3 used for the synthesis of vanillin derivatives were not 
commercially available and were synthesized.  
Amine I-1 was prepared through a one-step reaction by reacting naphthalic 
anhydride and 1,3 diaminopropane in ethanol under reflux. 
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Amine I-3 was prepared through a two-step reaction; the precursor 9-
chloro-1,2,3,4-tetrahydroacridine (I-2) was obtained by treating a mixture 
of anthranilic acid and cyclohexanone with POCl3. The latter was then 
reacted with p-phenylenediamine in the presence of a catalytic amount of KI 
in 1-pentanol under reflux. 
All NMR data are reported in the appendix (pages 279-351). 
 
Synthesis of 2-(3-aminopropyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione – 
I-1 
 
Naphthalic anhydride (2.8 g, 10 mmol) was dissolved in ethanol (100 ml), 
followed by the addition of 1,3 diaminopropane (1.48 g, 20 mmol). The 
resulting solution was stirred for 1 hour under reflux. After cooling, the 
precipitate obtained, was filtered off and discarded, whereas the filtrate was 
evaporated to dryness using a rotary evaporator. The resulting solid was 
washed several times with diethyl ether through a Buchner funnel and dried 
to yield the product I-1 as a pale-yellow solid (yield: 56%) (Noro et al., 
2015).  
1HNMR(CDCl3): (solvent peak δ:7.27), 8.63-8.61 (dd, 2H, napht-H, J= 6.4 
Hz, 0.8 Hz), 8.25-8.22 (dd, 2H, napht-H, J= 6.4, 0.8 Hz), 7.80-7.76 (t, 2H, 
napht-H, J= 7.6 Hz), 4.32-4.29 (t, 2H, N-CH2-CH2, J= 6.8 Hz), 2.80-2.77 (t, 
2H, CH2-NH2, J= 6.4 Hz), 1.95-1.89 (m, 2H, CH2-CH2-CH2, J= 6.8 Hz), 1.52 
(b, 2H,  NH2). 13CNMR(CDCl3): (solvent peak δ: 77.4-76.8) 164.4 (C=O), 
134.0-122.65 (napht-C), 39.48 (N-CH2-CH2), 37.77 (CH2-CH2-NH2), 32.19 
(CH2-CH2-CH2). LRMS calcd for C15H15N2O2 [M+H]+, 255.1, m/z found 255.0. 
 
Synthesis of 9-chloro-1,2,3,4-tetrahydroacridine - I-2 
 
Intermediate I-2 was prepared following the procedure reported in 
literature (Szymański, Zurek and Mikiciuk-Olasik, 2006). To a mixture of 
anthranilic acid (1.85 g, 1.3 mmol) and cyclohexanone (2.6 ml, 2.6 mmol) 
in an ice bath, was added POCl3 (15 ml, 0.16 mol). The mixture was heated 
under reflux and stirred for 24 hours, then cooled down and concentrated 
under reduced pressure. The residue was diluted with ethyl acetate (50 ml), 
neutralized with saturated Na2CO3 (30 ml) and washed 3 times with brine 
(30 ml). The organic layer was dried and the product was recrystallized 
from acetone (yield: 67%). 
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1HNMR(CDCl3): (solvent peak δ:7.20), 8.11-8.08 (dd, 2H, Ar-H, J= 7.6, 0.8 
Hz), 7.91-7.89 (d, 2H, Ar-H, J= 8.4 Hz), 7.62-7.57 (m, 2H, Ar-H, J= 5.6, 
1.2 Hz), 7.49-7.45 (m, 2H, Ar-H, J= 5.2, 1.2 Hz), 3.07-3.04 (t, 2H, Ar-CH2-
CH2, J= 6.4 Hz), 2.97- 2.94 (t, 2H, Ar-CH2-CH2, J= 6.4 Hz), 1.92- 1.84 (m, 
4H, CH2-CH2-CH2-CH2, J= 6.4 Hz). 13CNMR(CDCl3): (solvent peak δ: 77.8-
76.7) 159.6 (Ar-C=N), 146.8 (Ar-C-N), 141.5 (C-Cl), 129.3-123.7 (Ar-C), 
34.3 (Ar-CH2-CH2), 27.6 (Ar-CH2-CH2), 22.7 (CH2-CH2-CH2), 22.7 (CH2-CH2-
CH2). LRMS calcd for C13H13ClN [M+H]+ 218.7, m/z found 218.1. 
 
Synthesis of N1-(1,2,3,4-tetrahydroacridin-9-yl)benzene-1,4-diamin - I-3 
 
9-chloro-1,2,3,4-tetrahydroacridine (107 mg, 0.5 mmol) and KI (80 mg) 
were dissolved in 1-pentanol (5 ml) and heated under reflux for 5 minutes. 
Then p-phenylenediamine (135 mg, 1.25 mmol) was added and the mixture 
was stirred under reflux for 24 hours. The solution was concentrated under 
pressure and the solid obtained was dissolved in 50 ml of DCM and 
extracted 3 times with a saturated solution of Na2CO3 (50 ml). The organic 
layer was dried with anhydrous Na2SO4, filtered and evaporated through a 
rotary evaporator and the crude was purified by column chromatography 
(DCM/MeOH 99:1) to afford a brown solid (yield 39%). 
1HNMR(CDCl3): (solvent peak δ:7.30), 8.04-8.02 (d, 1H, Ar-H, J= 8 Hz), 
7.76-7.73 (d, 1H, Ar-H, J= 8.4 Hz), 7.61-7.57 (t, 1H, Ar-H, J= 7.6 Hz), 
7.30-7.27 (t, 1H, Ar-H, J= 8 Hz),  6.75-6.72 (t, 1H, Ar-H, J= 4 Hz),  6.65-
6.61 (t, 1H, Ar-H, J= 8.8 Hz), 5.95 (s, 1H, Ar-NH-Ar), 3.59 (b, 2H, Ar-NH2), 
3.20-3.17 (t, 2H, Ar-CH2-CH2, J= 6.4 Hz), 2.72-2.69 (t, 2H, Ar-CH2-CH2, J= 
6.4 Hz), 1.99-1.95 (m, 2H, -CH2-CH2-, J= 5.6 Hz), 1.95-1.89 (m, 2H, -CH2-
CH2-, J= 5.6 Hz). 13CNMR(CDCl3): solvent peak δ: 77.4-76.7) 141.7 (Ar-
C=N), 135.9-116.1 (Ar-C), 25.2 (Ar-CH2-CH2), 24.9 (Ar-CH2-CH2), 22.8 (Ar-
CH2-CH2), 22.7 (Ar-CH2-CH2). LRMS calcd for C19H20N3 [M+H]+ 290.2, m/z 
found 290.2. 
 
2.3.4.2 General Method for the Synthesis of Monomers 
 
The vanillin monomers (imine) were obtained through condensation reaction 
between vanillin and the corresponding amine using methanol or 2-propanol 
as solvents. The imines were then reduced using sodium borohydride 
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(NaBH4) in methanol or 2-propanol to afford the corresponding vanillin 
monomers (amine).  
 
Synthesis of 4-((benzylimino)methyl)-2-methoxyphenol – 1a 
 
Vanillin (1g, 6.6 mmol) was reacted with benzylamine (1.07 g, 10 mmol) in 
methanol (10 ml) overnight at room temperature. Once the reaction was 
completed, the solvent was evaporated and the obtained solid was dissolved 
in chloroform followed by extraction with saturated NaHCO3 solution. The 
organic phase was collected, dried with anhydrous sodium sulphate and 
evaporated to dryness to afford 1a in 63% yield.  
1HNMR(CDCl3): (solvent peak δ:7.38), 8.33 (s, 1H, Ar-CH=N), 7.54-7.53 (d, 
1H, Ar-H, J= 2 Hz), 7.40-7.37 (dd, 4H, Ar-H, J= 3.2, 2.4 Hz), 7.33-7.31 (m, 
1H, Ar-H, J= 2.4 Hz), 7.18-7.16 (dd, 1H, Ar-H, J= 6.4, 1.6 Hz), 6.97-6.95 
(d, 1H, Ar-H, J= 8 Hz), 4.85 (s, 2H, Ar-CH2-N), 3.93 (s, 3H, -OCH3). 
13CNMR(CDCl3): (solvent peak δ: 77.4-76.7), 161.8 (Ar-CH=N), 148.4 (Ar-
C-OH), 147.0 (Ar-C-OCH3), 139.5-108.3 (Ar-C), 64.9 (Ar-CH2-N), 56.1 (-
OCH3). HRMS calcd for C15H16NO2 [M+H]+ 242.1176, m/z found 242.1170. 
 
Synthesis of 2-(3-((4-hydroxy-3-methoxybenzylidene)amino)propyl)-1H-
benzo[de]isoquinoline-1,3(2H)-dione – 1b 
 
Vanillin (0.5 g, 3.3 mmol) was dissolved in methanol (10 ml), then 2-(3-
aminopropyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione  (I-1) (0.83 g, 3.3 
mmol) was added. The reaction was stirred overnight at room temperature. 
The resulting solution, was concentrated through a rotary evaporator and 
the solid obtained, was dissolved in 25 ml of DCM and extracted 3 times 
with saturated NaHCO3 (20ml). The organic layer was collected and dried 
with anhydrous sodium sulphate and concentrated through rotary 
evaporator to afford an orange solid (yield: 73%). 
1HNMR(CDCl3): (solvent peak δ:7.30), 8.61-8.59 (dd, 2H, napht-H, J= 2 Hz, 
1.2 Hz), 8.22-8.20 (dd, 2H, napht-H, J= 7.6, 0.8 Hz), 8.22 (s, 1H, Ar-
CH=N), 7.77-7.74 (dd, 2H, napth-H, J= 7.6, 0.8 Hz), 7.25-7.25 (d, 1H, Ar-
H, J= 1.6 Hz), 7.01-6.99 (dd, 1H, Ar-H, J= 6.4, 1.6 Hz), 6.87-6.85 (d, 1H, 
Ar-H, J= 8 Hz),  4.39-4.36 (t, 2H, N-CH2-CH2, J= 7.2 Hz), 3.81 (s, 3H, -
OCH3), 3.79-3.77 (t, 2H, CH2-N=CH, J= 7.2 Hz ), 2.26-2.23 (t, 2H, CH2-
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CH2-CH2, J= 7.2 Hz). 13CNMR(CDCl3): (solvent peak δ: 77.4-76.7) 164.3 
(C=N), 161.0 (C=O), 148.0 (Ar-C-OH), 146.7 (Ar-C-OCH3), 133.8-107.8 
(napth-C and Ar-C), 59.47 (-OCH3), 55.87 (CH=N-CH2), 38.95 (N-CH2-CH2), 
29.17 (CH2-CH2-CH2. HRMS calcd for C23H21N2O4 [M+H]+ 389.1497, m/z 
found 389.1497. 
 
Synthesis of 4-((benzylamino)methyl)-2-methoxyphenol – 1c 
 
Compound 1a (0.7 g, 3 mmol) and sodium borohydride (0.11 g, 3 mmol) in 
methanol (10 ml) were stirred for 2 hours. The reaction was monitored by 
TLC until completion. The evaporation of the solvent yielded a solid which 
was washed thoroughly with deionized water and dried under vacuo to 
afford 1c in 68% yield as a pale-yellow solid.  
1HNMR((CD3)2SO): (solvent peak δ:2.42-2.40), (H2O, 3.25), 7.33-6.62 (m, 
5H, Ar-H), 6.84-6.84 (d, 1H, Ar-H, J= 1.2 Hz), 6.63-6.62 (d, 2H, Ar-H, J= 
2.8 Hz), 3.86 (s, 2H, Ar-CH2-N), 3.65 (s, 3H, -OCH3), 3.55 (s, 2H, Ar-CH2-
N). 13CNMR((CD3)2SO): (solvent peak δ: 40.6-39.4), 147.9 (Ar-C-OH), 
145.9 (Ar-C-OCH3), 129.0-112.9 (Ar-C), 56.0 (CH2-NH-CH2), 52.2 (-OCH3). 
HRMS calcd for C15H18NO2 [M+H]+ 244.1332, m/z found 244.1333.  
 
Synthesis of 2-(3-((4-hydroxy-3-methoxybenzyl)amino)propyl)-1H-benzo 
[de]isoquinoline-1,3(2H)-dione – 1d 
 
2-(3-((4-hydroxy-3-methoxybenzylidene)amino)propyl)-1H-benzo[de]iso 
quinoline-1,3(2H)-dione (1b) (0.4g, 1 mmol) was dissolved in methanol (10 
ml), then NaBH4 (0.057 g, 1.5 mmol) was added. The reaction was stirred 
for 2 hour at RT and monitored by TLC. At completion, the solution was 
reduced to dryness using a rotary evaporator. The solid obtained was 
dissolved in DCM (25 ml) and extracted 3 times with NaHCO3 (20 ml). The 
organic layer was collected, dried with anhydrous sodium sulphate and 
concentrated through rotary evaporator to afford a pale-yellow solid (yield: 
86%). 
1HNMR(CDCl3): (solvent peak δ:7.31), 8.65-8.63 (dd, 2H, napht-H, J= 6.4, 
1.2 Hz), 8.27-8.25 (dd, 2H, napht-H, J= 7.2, 1.2 Hz), 7.82-7.78 (dd, 2H, 
napht-H, J= 7.6, 0.4 Hz), 6.93-6.92 (dd, 1H, Ar-H, J= 1.6 Hz), 6.85-6.82 
(dd, 2H, Ar-H, J= 3.2 Hz), 4.34-4.31 (t, 2H, N-CH2-CH2, J= 7.2 Hz), 3.91 
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(s, 3H, -OCH3), 3.76 (s, 2H, Ar-CH2-N), 2.78-2.74 (t, 2H, CH2-CH2-N, J= 6.4 
Hz), 2.05-2.01 (t, 2H, CH2-CH2-CH2, J= 6.4 Hz). 13CNMR(CDCl3): (solvent 
peak δ: 77.4-76.7) 164.3 (C=O), 146.6 (Ar-C-OH), 144.6 (Ar-C-OCH3), 
134.0-110.9 (napth-C and Ar-C), 55.9 (-OCH3), 53.8 (napht-N-CH2), 46.4 
(Ar-CH2-NH), 38.3 (CH2-CH2-NH), 28.3(CH2-CH2-NH). HRMS calcd for 
C23H23N2O4 [M+H]+ 391.1652, m/z found 391.1651. 
 
Synthesis of 2-(3-((4-hydroxy-3,5-dimethoxybenzyl)amino)propyl)-1H-
benzo[de]isoquinoline-1,3(2H)dione – 1e 
 
Syringaldehyde (0.29 g, 1.57 mmol) was mixed with methanol (8 mL) 
followed by the addition of 2-(3-aminopropyl)-1H-benzo[de]isoquinoline-
1,3(2H)dione (0.40g, 1.57 mmol). The solution was refluxed for 2 hours 
and left stirring overnight at RT to form a red solution. The solvent was 
evaporated under pressure to yield a red solid which was re-suspended in 
2-propanol followed by the addition of NaBH4 (3.0 mmol). The solution was 
refluxed for 48 hours. At the completion of the reaction, the solvent was 
removed under vacuo to afford a solid. The latter was collected by filtration, 
washed thoroughly with water and methanol to yield the final product 
(38%). 
1HNMR(CDCl3): (solvent peak δ:7.20), 8.53-8.51 (dd, 2H, napht-H, J= 6.4, 
0.8 Hz), 8.16-8.13 (dd, 2H, napht-H, J= 6.4, 0.8 Hz), (dd, 2H, napht-H, J= 
7.6, 0.4 Hz), 6.50 (s, 2H, Ar-H), 4.23-4.20 (t, 2H, N-CH2-CH2, J= 7.2 Hz), 
3.80 (s, 6H, -OCH3), 3.64 (s, 2H, Ar-CH2-N), 2.68-2.64 (t, 2H, CH2-CH2-N, 
J= 6.8 Hz), 1.95-1.91 (t, 2H, CH2-CH2-CH2, J= 6.8 Hz). 13CNMR(CDCl3): 
(solvent peak δ: 77.4-76.7) 164.3 (C=O), 147.1 (Ar-C-OH), 134.0-133.6 
(Ar-C-OCH3), 131.6-104.9 (napth-C and Ar-C), 56.2 (-OCH3), 54.2 (napht-
N-CH2), 46.5 (Ar-CH2-NH), 38.3 (CH2-CH2-NH), 28.3(CH2-CH2-NH). HRMS 
calcd for C23H25N2O5 [M+H]+ 421.1758, m/z found 421.1756. 
 
Synthesis of 2-methoxy-4-(((4-((1,2,3,4-tetrahydroacridin-9-
yl)amino)phenylamino)methyl)phenol – 1f 
 
N1-(1,2,3,4-tetrahydroacridin-9-yl)benzene-1,4-diamin (I-3) (50 mg, 0.17 
mmol) was dissolved in 2-propanol (10 ml), followed by vanillin (20 mg, 
0.13 mmol). The reaction was stirred under reflux and monitored by TLC. 
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When the vanillin spot had disappeared, the solution was cooled down and 
NaBH4 (25mg, 0.7 mmol) was added. The solvent was removed under 
vacuo and the solid obtained, was purified by column chromatography 
(DCM/MeOH 99:1) to afford an orange solid (yield 46%). 
1HNMR(CDCl3): (solvent peak δ:7.19), 8.05-7.65 (m, 2H, Ar-H), 7.63-7.47 
(m, 2H, Ar-H, J= 8.4, 1.6 Hz), 7.19-7.16 (dd, 2H, Ar-H, J= 7.2, 0.8 Hz), 
6.83-6.78 (m, 2H, Ar-H), 6.73-6.70 (d, 1H, Ar-H, J= 8.8 Hz), 6.52-6.50 (t, 
2H, Ar-H, J= 6.8 Hz), 4.14 (s, 2H, Ar-CH2-N), 3.81 (s, 3H, -OCH3), 3.13-
3.11 (t, 2H, Ar-CH2-CH2, J= 6.4 Hz), 2.95-2.93 (d, 2H, Ar-CH2-CH2, J= 7.2 
Hz), 2.60-2.56 (t, 2H, -CH2-CH2-, J= 6.4 Hz), 1.86-1.80 (m, 2H, -CH2-CH2-, 
J= 5.2 Hz). 13CNMR(CDCl3): (solvent peak δ: 77.4-76.7), 146.8 (Ar-C=N), 
145.0-110.3 (Ar-C), 56.0 (-OCH3), 48.8 (Ar-CH2-NH), 45.82 (Ar-CH2-CH2-
CH2), 25.0 (Ar-CH2-CH2-CH2), 22.7 (CH2-CH2-CH2), 22.3 (CH2-CH2-CH2). 
HRMS calcd for C27H28N3O2 [M+H]+ 426.2176, m/z found 426.2172. 
 
2.3.4.3 General Method for the synthesis of Dimers 
 
The dimers were prepared through reductive amination reaction, by 
reacting vanillin or syringaldehyde with an excess of corresponding amine, 
to enhance purification by DCM: saturated NaHCO3 extraction, in methanol 
in the presence of sodium cyanoborohydride and zinc chloride as reducing 
agents. 
 
Synthesis of 4,4'-(((2-hydroxyethyl)eazanediyl)bis(methylene))bis(2-
methoxyphenol)- 2a 
 
Vanillin (1g, 6.6 mmol) and 2-amino-1-ethanol (0.30 ml, 5 mmol) in 
presence of NaCNBH3 (1.2 equiv.) and ZnCl2 (1.2 equiv.) were stirred in 
methanol for 24 hours. The solvent was removed through a rotary 
evaporator and the residue was dissolved in warm chloroform and extracted 
with saturated NaHCO3. The organic layer was dried to afford 2a as a thick 
orange oil (12% yield).  
1HNMR(CDCl3): (solvent peak δ:7.21), 6.76-6.74 (d, 2H, Ar-H, J= 7.6 Hz), 
6.70-6.67 (dd, 4H, Ar-H, J= 8, 1.6 Hz), 3.75 (s, 6H, -OCH3),  3.51-3.50 (t, 
2H, CH2-CH2-OH, J= 5.6 Hz), 3.45 (s, 4H, Ar-CH2-N), 2.59-2.56 (t, 2H, N-
CH2-CH2, J= 5.6 Hz). 13CNMR(CDCl3): (solvent peak δ: 77.4-76.8), 146.8 
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(Ar-C-OH), 145.2 (Ar-C-OCH3), 133.8-111.2 (Ar-C), 58.5 (N-CH2-Ar), 57.9 
(CH2-CH2-OH), 56.0 (N-CH2-CH2), 54.6 (-OCH3). HRMS calcd for C18H24NO5 
[M+H]+ 334.1649, m/z found 334.1648. 
 
Synthesis of 4,4'-(((3-hydroxypropyl)azanediyl)bis(methylene))bis(2-
methoxyphenol)- 2b 
 
Vanillin (1 g, 6.6 mmol) and 3-amino-1-propanol (0.326 ml, 5 mmol) were 
stirred overnight in presence of NaCNBH3 (1.2 equiv.) and ZnCl2 (1.2 
equiv.) in methanol. The solvent was removed through a rotary evaporator 
and the residue was purified through column chromatography (elution with 
increasing volumes of DCM/MeOH) to afford 2b (70% yield) as a thick 
orange oil.  
1HNMR(CDCl3): (solvent peak δ:7.21), 6.82-6.80 (dd, 4H, Ar-H, J= 8 Hz), 
6.74-6.72 (dd, 2H, Ar-H, J= 5.6, 1.6 Hz), 3.83 (s, 6H, -OCH3), 3.65-3.62 (t, 
2H, CH2-CH2-OH, J= 5.2 Hz), 3.45 (s, 4H, Ar-CH2-N), 2.62-2.59 (t, 2H, N-
CH2-CH2, J= 5.6 Hz), 1.74-1.71 (t, 2H, CH2-CH2-CH2, J= 5.2 Hz). 
13CNMR(CDCl3): (solvent peak δ: 77.6-74.8), 147.0 (Ar-C-OH), 145.7 (Ar-
C-OCH3), 129.8-110.7 (Ar-C), 64.3 (Ar-CH2-N), 58.4 (CH2-CH2-OH), 55.9 
(N-CH2-CH2), 53.3 (-OCH3), 27.4 (CH2-CH2-CH2). HRMS calcd for C19H26NO5 
[M+H]+ 348.1805, m/z found 348.1801.  
 
Synthesis of 4,4'-(((4-hydroxybutyl)azanediyl)bis(methylene))bis(2-
methoxyphenol)- 2c 
 
Vanillin (1 g, 6.6 mmol) and 4-amino-1-butanol (0.461 ml, 5 mmol) were 
stirred overnight in presence of NaCNBH3 (1.2 equiv.) and ZnCl2 (1.2 
equiv.) in methanol. The solvent was removed through rotary evaporator 
and the residue was dissolved in warm chloroform and extracted with 
saturated NaHCO3. The organic layer was dried to afford 2c as a thick 
orange oil (14% yield). 
1HNMR(CDCl3): (solvent peak δ:7.21), 6.81-6.76 (t, 4H, Ar-H, J= 8 Hz), 
6.72-6.70 (m, 2H, Ar-H, J= 2 Hz), 3.80 (s, 6H, -OCH3), 3.65 (s, 4H, Ar-CH2-
N), 3.52-3.49 (t, 2H CH2-CH2-OH, J= 5.6 Hz), 2.65-2.63 (t, 2H, N-CH2-CH2, 
J= 5.6 Hz), 2.39-2.37 (d, 2H, CH2-CH2-CH2, J= 6 Hz), 1.61-1.60 (t, 2H, 
CH2-CH2-CH2, J= 2.4 Hz). 13CNMR(DMSO): (solvent peak δ: 40.6-39.3), 
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147.8 (Ar-C-OH), 145.7 (Ar-C-OCH3), 130.9-112.8 (Ar-C), 60.5 (Ar-CH2-N), 
56.1 (-OCH3), 46.8 (CH2-CH2-OH), 29.9 (N-CH2-CH2-CH2), 23.3 (CH2-CH2-
CH2-OH). HRMS calcd for C20H28NO5 [M+H]+. 362.1962, m/z found 
362.1962. 
 
Synthesis of 4,4'-(((5-hydroxypentyl)azanediyl)bis(methylene))bis(2-
methoxyphenol)- 2d 
 
Vanillin (1 g, 6.6 mmol) and 5-amino-1-pentanol (0.326 ml, 5 mmol) were 
stirred overnight in presence of NaCNBH3 (1.2 equiv.) and ZnCl2 (1.2 
equiv.) in methanol. The solvent was removed through a rotary evaporator 
and the residue was purified through column chromatography (DCM/MeOH) 
to afford 2d as thick orange oil (82% yield).  
1HNMR((CD3)2SO): (solvent peak δ:2.52-2.50), (H2O 3.38), 7.21-7.21 (d, 
2H, Ar-H, J= 1.6 Hz), 6.90-6.88 (m, 2H, Ar-H, J= 2Hz), 6.81-6.79 (d, 2H, 
Ar-H, J= 2 Hz), 3.99 (s, 4H, Ar-CH2-N), 3.75 (s, 6H, -OCH3), 2.83-2.80 (t, 
2H, CH2-CH2-OH, J= 6.4 Hz), 2.52-2.50 (t, 2H, N-CH2-CH2, J= 6.4 Hz), 
1.65-1.62 (t, 2H, CH2-CH2-CH2, J= 6.4 Hz), 1.43-1.40 (t, 2H, CH2-CH2-CH2, 
J= 6.4 Hz), 1.38-1.34 (t, 2H, CH2-CH2-CH2, J= 6.4 Hz). 13CNMR(D2O): 
147.7 (Ar-C-OH), 146.7 (Ar-C-OCH3), 124.2-113.8 (Ar-C), 61.2 (Ar-CH2-N), 
57.2 (N-CH2-CH2), 55.9 (-OCH3), 50.7 (CH2-CH2-OH), 46.5, 30.6, 25.2, 22.2 
(alkyl-C). HRMS calcd for C21H230NO5 [M+H]+ 376.2118, m/z found 
376.2108. 
 
Synthesis of 4,4'-((butylazanediyl)bis(methylene))bis(2-methoxyphenol)- 
2e 
 
Vanillin (1 g, 6.6 mmol) and n-butylamine (0.5 ml, 5 mmol) were stirred in 
presence of NaCNBH3 (1.2 equiv.) and ZnCl2 (1.2 equiv.) in methanol. The 
solvent was removed through a rotary evaporator and the residue was 
dissolved in warm chloroform and extracted with saturated NaHCO3. The 
organic layer was dried to afford 2e as a thick orange oil (23% yield).  
1HNMR(CDCl3): (solvent peak δ:7.20), 6.77-6.76 (d, Ar-H, 2H, J= 1.6 Hz), 
6.67-6.63 (m, 4H, Ar-H, J= 8 Hz), 3.73 (s, 4H, Ar-CH2-N), 3.64 (s, 6H, -
OCH3), 2.59-2.55 (t, 2H, N-CH2-CH2, J= 7.6 Hz), 1.46-1.40 (m, 2H, CH2-
CH2-CH2, J= 5.6, 2.4 Hz), 1.26-1.20 (m, 5H, CH2-CH2-CH3).13CNMR(CDCl3): 
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(solvent peak δ: 77.8-76.7), 146.6 (Ar-C-OH), 144.6 (Ar-C-OCH3), 132.4-
110.8 (Ar-C), 55.8 (Ar-CH2-N), 49.2 (-OCH3), 32.2-20.5 (alkyl-C). HRMS 
calcd for C20H27NO4 [M+H]+ 346.2013, m/z found 346.2013. 
 
Synthesis of 4,4'-((benzylazanediyl)bis(methylene))bis(2-methoxyphenol)- 
2f 
 
Vanillin (1.5 g, 10mmol) and benzylamine (0.55 ml, 5 mmol) in presence of 
NaCNBH3 (1.2 equiv.) and ZnCl2 (1.2 equiv.) in methanol gave a precipitate 
which after filtration, washing with deionized water and methanol, afforded 
2f as a white solid (90% yield). 
1HNMR((CD3)2SO): (solvent peak δ:2.42-2.40), (H2O, 3.26), 7.30-6.59 (m, 
Ar-H, 11H), 3.67 (s, 6H, -OCH3), 3.56 (s, 2H, Ar-CH2-N), 3.47 (s, 4H, Ar-
CH2-N), 13CNMR((CD3)2SO): (solvent peak δ: 40.6-39.3), 141.3 (Ar-C-OH), 
141.1 (Ar-C-OCH3), 128.9-115.5 (Ar-C), 55.9 (Ar-CH2-N), 52.5 (Ar-CH2-N), 
45.6 (-OCH3). HRMS calcd for C23H26NO4 [M+H]+ 380.1856, m/z found 
380.1849. 
 
Synthesis of N1,N1-bis(4-hydroxy-3-methoxybenzyl)propane-1,3-diaminium 
chloride- 2g 
 
Vanillin (1 g, 6.6 mmol) and 1,3-diaminopropane (0.84 ml, 10 mmol) in 
presence of NaCNBH3 (1.2 equiv.) and ZnCl2 (1.2 equiv.) in methanol 
afforded a precipitate which was filtered and washed with deionized water 
and methanol. Suspension of the precipitate in methanol (5 mL) followed by 
the addition of concentrated hydrochloric acid, gave a solid. The solvent was 
removed using a rotary evaporator and the resulting solid washed with 
diethyl ether and dried under vacuo to yield 2g as a white solid (67% 
yield). 
1HNMR((CD3)2SO): (solvent peak δ:2.51) (H2O, 3.64), 7.12 (s, 2H, Ar-H), 
7.12-6.90 (d, 2H, Ar-H, J= 8 Hz), 6.81-6.79 (d, 2H, Ar-H, J= 8 Hz), 4.00 (s, 
4H, Ar-CH2-N), 3.78 (s, 6H, -OCH3), 2.97-2.94 (t, 2H, N-CH2-CH2, J= 3.6 
Hz), 2.89-2.85 (t, 2H, CH2-CH2-NH3+, J= 3.6 Hz), 1.93 (s, CH2-CH2-CH2, 
2H). 13CNMR(D2O): 147.6 (Ar-C-OCH3), 123.3-113.8 (Ar-C), 55.9 (Ar-CH2-
N), 51.0 (-OCH3), 43.6, 36.5, 23.7 (alkyl-C). HRMS calcd for C19H26ClN2O4 
347.1965 [M-H2Cl]+, m/z found 347.1965. 
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Synthesis of 4,4'-(((3-hydroxypropyl)azanediyl)bis(methylene))bis(2,6-di 
methoxyphenol)- 2h 
 
Syringaldehyde (0.5 g, 2.7 mmol) and 3-amino-1-propanol (0.2 ml, 1.7 
mmol) were stirred overnight in presence of NaCNBH3 (1.2 equiv.) and 
ZnCl2 (1.2 equiv.) in methanol. The solvent was removed through a rotary 
evaporator and the residue was purified through column chromatography 
(DCM/MeOH) to afford 2h as a thick colourless oil (65% yield). 
1HNMR(MeOD): (solvent peak δ:3.34), 6.81 (s, 4H, Ar-H), 4.17 (s, 4H, Ar-
CH2-N), 3.84 (s, 12H, -OCH3), 3.75-3.72 (t, 2H, CH2-CH2-OH, J= 5.6 Hz), 
3.24-3.21 (t, 2H, N-CH2-CH2, J= 5.6 Hz), 1.97 (t, 2H, CH2-CH2-CH2, J= 6.4 
Hz), 13CNMR(MeOD) (solvent peak δ: 48.2), 149.0 (Ar-C-OH), 148.0 (Ar-C-
OCH3), 144.9-106.8 (Ar-C), 59.4 (Ar-CH2-N), 55.7 (CH2-CH2-OH), 51.6 (-
OCH3), 45.6-28.2 (alkyl-C). HRMS calcd for C21H30NO7 [M+H]+ 408.2017, 
m/z found 408.2012. 
 
Synthesis of 4,4'-((benzylazanediyl)bis(methylene))bis(2,6-
dimethoxyphenol)- 2i 
 
Syringaldehyde (1 g, 5.4 mmol) and benzylamine (0.2 ml, 1.8 mmol) in 
presence of NaCNBH3 (1.2 equiv.) and ZnCl2 (1.2 equiv.) in methanol, gave 
a precipitate which was filtered and washed  with deionized water and 
methanol and dried to afford 2i (46% yield). 
1HNMR((CD3)2SO): (solvent peak δ:2.40), (H2O, 3.25), 7.28-7.12 (m, 5H, 
Ar-H), 6.49 (s, 4H, Ar-H), 3.64 (s, 12H, -OCH3), 3.56 (s, 4H, Ar-CH2-N), 
3.46 (s, 2H, Ar-CH2-N). 13CNMR((CD3)2SO): (solvent peak δ: 40.6-39.3), 
140.3 (Ar-C-OH), 128.7-127.0 (Ar-C), 56.3 (Ar-CH2-N), 45.4 (-OCH3). 
HRMS calcd for C25H30NO6 [M+H]+ 440.2058, m/z found 440.2058.  
 
2.3.4.4 General Method for the Synthesis of Tetramers 
 
The synthesis of the tetramers was achieved following the same method 
used for the preparation of the dimers; however, an excess of aldehydes 
was used since all the products, except compound 4f, precipitated from the 
methanol solution, enabling the purification of the final products by simple 
filtration.  
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Synthesis of N1,N1,N4,N4-tetrakis(3-methoxybenzyl)benzene-1,4-diamine – 
4a 
 
m-Anisaldehyde (0.82 g, 6 mmol) and p-phenylenediamine (0.1 g, 1 mmol) 
in presence of NaCNBH3 (1.2 equiv.) and ZnCl2 (1.2 equiv.) in methanol 
afforded a precipitate which upon filtration, washed with deionized water 
and methanol and drying gave 4a (54% yield). 
1HNMR(CDCl3): (solvent peak δ: 6.81), 7.38-7.34 (t, 4H, Ar-H, J= 8 Hz), 
7.02-6.97 (t, 8H, Ar-H, J= 8 Hz), 6.93-6.90 (dd, 4H, Ar-H, J= 6, 2 Hz), 
6.81 (s, 4H, Ar-H), 4.62 (s, 8H, Ar-CH2-N), 3.87 (s, 12H, -OCH3). 
13CNMR(CDCl3): (solvent peak δ: 77.6-77.0), 160.0 (Ar-C-OCH3), 141.9-
112.2 (Ar-C), 55.5 (Ar-CH2-N), 55.2 (-OCH3). HRMS calcd for C38H41N2O4 
[M+H]+ 589.3061, m/z found 589.3047. 
 
Synthesis of 4,4',4'',4'''-((((1r,4r)-cyclohexane-1,4-diyl)bis(azanetriyl)) 
tetrakis(methylene))tetrakis(2-methoxyphenol) – 4b 
 
Vanillin (1.82 g, 12 mmol) and trans-1,4-diaminocyclohexane (0.2 g, 2 
mmol) in presence of NaCNBH3 (1.2 equiv.) and ZnCl2 (1.2 equiv.) in 
methanol afforded a precipitate which after filtration and washing with 
methanol gave a solid. The latter was dissolved in water, filtered and 
extracted with chloroform. The water phase was freeze dried, using an EF4 
Edwards Modulyo freeze dryer, to yield 4b (18% yield).  
1HNMR((CD3)2SO): (solvent peak δ:2.40), (H2O, 3.26),  7.10 (s, 4H, Ar-H), 
6.80-6.77 (dd, 4H, Ar-H, J= 6.4, 1.6 Hz), 6.69-6.67 (d, 4H, Ar-H, J= 7.2) 
3.88 (s, 8H, Ar-CH2-N), 3.68 (s, 12H, -OCH3), 2.79 (s, 2H, N-CH-(CH2)2), 
2.10-2.09 (d, 4H, CH-CH2-CH2, J= 6 Hz), 1.33-1.30 (d, 4H, CH-CH2-CH2, J= 
8.8 Hz). 13CNMR((CD3)2SO): (solvent peak δ: 39.9-39.0), 148.0 (Ar-C-OH), 
147.4 (Ar-C-OCH3), 123.0-114.4 (Ar-C), 56.2 (Ar-CH2-N), 55.0 (-OCH3), 
48.2 (N-CH(CH2)2), 27.3 (N-CH(CH2)2). HRMS calcd for C38H47N2O8 [M+H]+ 
659.3327, m/z found 659.3327. 
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Synthesis of 4,4',4'',4'''-((1,4-phenylenebis(azanetriyl))tetrakis(methylene)) 
tetrakis(2-methoxyphenol) – 4c 
 
Vanillin (1 g, 6.6 mmol) and p-phenylenediamine (0.1 g, 1 mmol) in 
presence of NaCNBH3 (1.2 equiv.) and ZnCl2 (1.2 equiv.) in methanol 
afforded a precipitate which was filtered and washed with deionized water 
and methanol. The solid was then dissolved in chloroform and extracted 
with saturated NaHCO3. The organic phase was dried and evaporated to 
dryness to give 4c (74% yield).  
1HNMR(CDCl3): (solvent peak δ: 7.30), 6.88-6.86 (d, 4H, Ar-H, J= 8 Hz), 
6.79-6.76 (m, 12H, Ar-H, J= 2 Hz), 4.39 (s, 8H, Ar-CH2-N), 3.83 (s, 12H, -
OCH3). 13CNMR(CDCl3): (solvent peak δ: 77.4-76.7), 164.5 (Ar-C-OH), 
144.4 (Ar-C-OCH3), 142.3-109.9 (Ar-C), 55.9 (Ar-CH2-N), 55.1 (-OCH3). 
HRMS calcd for C38H41N2O8 [M+H]+ 653.2857, m/z found 653.2851. 
 
Synthesis of N1,N1,N4,N4-tetrabenzylbenzene-1,4-diamine – 4d 
 
Benzaldehyde (1.27 g, 12 mmol) and p-phenylenediamine (0.2 g, 2 mmol) 
in presence of NaCNBH3 (1.2 equiv.) and ZnCl2 (1.2 equiv.) in methanol 
afforded a precipitate which was filtered and washed with deionized water 
and methanol. The solid was then dissolved in chloroform and extracted 
with saturated NaHCO3. The organic phase was dried and evaporated to 
dryness to afford 4d (80% yield).  
1HNMR(CDCl3): (solvent peak δ: 7.25), 7.40-7.25 (m, 20H, Ar-H), 6.68 (s, 
4H, Ar-H linker), 4.55 (s, 8H, Ar-CH2-N). 13CNMR(CDCl3): (solvent peak δ: 
77.4-76.7), 141.7-114.77 (Ar-C), 55.1 (Ar-CH2-N). HRMS calcd for C34H32N2 
[M]+ 468.2560, m/z found 468.2550.  
 
Synthesis of N1,N1,N3,N3-tetrakis(4-hydroxy-3-methoxybenzyl)propane-1,3-
diaminium chloride – 4e 
 
Vanillin (1.8 g, 12 mmol) and 1,3 diaminopropane (0.17 ml, 2 mmol) in 
presence of NaCNBH3 (1.2 equiv.) and ZnCl2 (1.2 equiv.) in methanol 
afforded a  precipitate. The latter was washed with deionized water and 
methanol. The resulting solid was suspended in methanol (5 mL), followed 
by the addition concentrated hydrochloric acid. All the solvent was removed 
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by rotary evaporator and the solid obtained, was washed with diethyl ether 
to yield the pure 4e (38% yield).  
1HNMR((CD3)2SO+D2O): (solvent peak δ:2.51), (H2O, 4.03), 7.06-7.05 (d, 
4H, Ar-H, J= 1.6 Hz), 6.86-6.86 (d, 4H, Ar-H, J= 2 Hz), 6.80-6.78 (d, 4H, 
Ar-H, J= 8 Hz), 3.99 (s, 8H, Ar-CH2-N), 3.76 (s, 12H, -OCH3), 2.96 (s, 4H, 
N-CH2-CH2), 2.51-2.51 (t, 2H, CH2-CH2-CH2, J= 1.6 Hz). 13CNMR((CD3)2SO): 
(solvent peak δ: 39.8-38.6), 149.0 (Ar-C-OH), 147.9 (Ar-C-OCH3), 147.3-
114.2 (Ar-C), 56.1 (Ar-CH2-N), 50.7 (N-CH2-CH2), 43.8 (-OCH3), 22.5 N-
CH2-CH2). HRMS calcd for C35H44ClN2O8 [M-H2Cl]+ 619.3014, m/z found 
619.3002 [M-H2Cl]+. 
 
Synthesis of 4,4',4'',4'''-((1,4-phenylenebis(azanetriyl))tetrakis(methylene)) 
tetraphenol – 4f 
 
The reaction between 4 hydroxybenzaldehyde (1.5 g, 12 mmol) and p-
phenylenediamine (0.2 g, 2 mmol) in methanol was evaporated to dryness. 
The resulting solid was washed thoroughly with water, chloroform and after 
drying, gave 4f (66% yield). 
1HNMR((CD3)2SO): (solvent peak δ:2.52-2.50), (H2O, 3.37), 9.23 (s, 4H, 
Ar-OH), 7.02-7.00 (d, 8H, Ar-H, J= 8 Hz), 6.68-6.55 (d, 8H, Ar-H, J= 8 Hz), 
6.55 (s, 4H, Ar-H), 4.27 (s, 8H, Ar-CH2-N). 13CNMR((CD3)2SO): (solvent 
peak δ: 40.6-39.3), 156.5 (Ar-C-OH), 141.3-128.7 (Ar-C), 115.5 (Ar-C 
linker), 54.8 (Ar-CH2-N). HRMS calcd for C34H33N2O4 [M+H]+ 533.2435, m/z 
found 533.2427. 
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2.5 Results and Discussion 
 
2.5.1 Synthesis of the Intermediates  
 
The synthetic strategy for the synthesis of the intermediates I-1 - I-3 is 
shown in scheme 1. 
 
 
 
 
Scheme 1. Synthetic strategy for the synthesis of non-commercially available amines used for the 
synthesis of vanillin derivatives.  
 
Intermediate I-1 was prepared in a one-step reaction by reacting 1,8 
naphthalic anhydride and 1,3 diaminopropane in ethanol under reflux. After 
the removal of the precipitate by filtration, the solution was dried and the 
solid obtained was washed with diethyl ether to afford the pure compound 
in 56% yield. Intermediate I-2 is commercially available but was instead 
prepared by following the method reported by (Szymański, Zurek and 
Mikiciuk-Olasik, 2006). Anthranilic acid and cyclohexanone were reacted in 
POCl3 under reflux for 24 hours. 
 
The solution was then dried and the product recrystallized from acetone to 
afford the pure compound in 67% yield. Intermediate I-3 was prepared by 
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reacting I-2 with a catalytic amount of potassium iodide (KI) and an excess 
of p-phenylenediamine in 1-pentanol under reflux for 24 hours. The final 
product was obtained after purification through column chromatography 
(DCM:MeOH 95:5) in 39% yield. The compounds were characterized 
through 1H and 13C NMR and finally through LRMS. As an example, the NMR 
and mass spectra of I-1 are shown in figures 2.10-2.12. 
 
 
Figure 2.10. 1H NMR spectrum of Intermediate 1 (I-1). 
 
Three different signals, integrating for two protons each, are present 
between 8.63 and 7.78, due to the de-shielding effect of the aromatic 
moieties in the naphthalimido structure (peaks 5, 6 and 7). The three 
methylene groups (2, 3 and 4) are observed between 4.31 and 1.92 ppm, 
each integrating for two protons. 
 
The signal at 4.31 ppm refers to the methylene linked to the nitrogen of the 
naphthalimide moiety (4); the de-shielding is due to the electronegativity of 
the nitrogen atom and the presence of the two carbonyl groups, both 
electron-withdrawing. The signal at 2.79 ppm represents the methylene (2) 
attached to the terminal amino moiety (-NH2); whereas, the multiplet 
centred at 1.92 ppm is due to the remaining methylene group (3). The 
broad signal at 1.52 ppm integrating for two protons, is assigned to the 
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terminal -NH2 group (1). The broad shape of the peak is due to hydrogen-
bonding.  
 
 
Figure 2.11. 13C NMR spectrum of intermediate 1 (I-1). 
 
In the 13C NMR spectrum, the solvent signals (CDCl3) are observed at 77.1 
ppm. The one at 164.4 ppm refers to the two carbons (4) linked with the 
oxygen (carbonyl groups); the electronegativity of the oxygen atom and the 
double bond cause the high de-shielding and the consequential shift of the 
peak to downfield in the spectrum. The six singals between 134.0 and 122.7 
ppm are due to the remaining 6 different carbons in the naphthalimide 
moiety (5 to 10); although a total of twelve carbon atoms are present in the 
naphthalimide structure, only seven signals are observed due to the 
symmetry of the molecule, creating chemical equivalence. 
The three singnals between 39.5 and 32.2 ppm refer to the three aliphatic 
carbons (1, 2 and 3). Finally, the LMRS confirmed the molecular weight of 
the compound (figure 2.12). 
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Figure 2.12. LRMS spectrum of intermediate 1 (I-1). 
 
2.5.2 Synthesis of the Monomers 
 
The synthetic strategy for the synthesis of the vanillin monomers (1a-1f) is 
shown in scheme 2. 
 
 
Scheme 2. Synthetic strategy for the synthesis of monomers and their nomenclature. 
 
The imines (1a and 1b) were prepared by reacting vanillin or 
syringaldehyde with equimolar amounts of the corresponding amines in 
methanol with yields ranging from 63-70 %. The imines were then reduced 
with an excess of sodium borohydride (NaBH4) in methanol to give the 
corresponding secondary amines with yields ranging from 68-86%. 
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Compounds 1e and 1f were prepared without the isolation of the 
corresponding imine; vanillin or syringaldehyde were reacted with a slight 
excess of the corresponding amine. Once the vanillin or syringaldehyde was 
completely consumed (monitored by TLC), a slight excess of NaBH4 was 
added. Once the reaction was complete, the solution was dried and the 
products were purified through DCM/saturated NaHCO3 or column 
chromatography to afford the pure compounds with yields ranging from 38-
67 %. These compounds were fully characterized via 1H, 13C NMR and HRMS 
spectroscopy.  As an example, the NMR and mass spectra of 1d are 
discussed in the following pages (Figure 2.13-2.15). 
 
 
Figure 2.13. 1H NMR spectrum of 1d. 
 
From figure 2.13, the six aromatic protons of the naphthalimido moiety are 
found between 8.65 and 7.78 ppm (4, 5 and 6). The three aromatic protons 
in the vanillin moiety (8, 9 and 10) are situated between 6.93 and 6.82 
ppm. The three protons of the methoxy group (11) in the vanillin moiety 
appear as a singlet at 3.91 ppm, whereas the two protons of the methylene 
group (7) between the nitrogen and the vanillin moiety are located at 3.76 
ppm. The remaining six protons of the three methylene groups (1, 2 and 3) 
appear at 4.32, 2.76 and 2.03 ppm, respectively. 
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Figure 2.14. 13C NMR spectrum of 1d. 
 
For the 13C NMR spectrum, solvent peaks (CDCl3) are located between 77.4 
and 76.7 ppm. The thirteen different aromatic carbons (4 to 17) are located 
between 164.3 and 110.9 ppm. The carbon of the methoxy group (18) and 
the carbons of the four methylene groups (1, 2, 3 and 11) are located 
between 55.8 and 28.3 ppm. Finally, the HRMS confirmed the molecular 
weight of compound 1d; the spectra is shown in figure 2.15. 
 
 
Figure 2.15. HRMS spectrum of compound 1d. 
 
2.5.3 Synthesis of the Dimers 
 
The dimers were synthesized via a one-step reductive amination reaction, 
which involved the condensation of an aldehyde (or ketone) and an amine, 
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followed by reduction of the imine group. Sodium cyanoborohydride 
(NaCNBH3) was used as the reducing agent, along with zinc chloride, due to 
its selectivity toward the imine group and its inability to reduce the 
aldehyde group of vanillin (Borch, Bernstein and Durst, 1971; Baxter and 
Reitz, 2002). The solvent used in all the reaction was methanol. The 
reaction pathway of reductive amination is reported in figure 2.16. 
 
 
Figure 2.16. Reaction pathway of reductive amination, described by (Baxter and Reitz, 2002). 
 
An excess of amine and reducing agents was used in each reaction to 
enhance the purification of the final product by simple extraction using 
chloroform/saturated NaHCO3, in order to avoid the presence of vanillin in 
the chloroform phase. The strategy for the synthesis of the vanillin dimers 
(2a-2i) is shown in scheme 3. 
 
 
Scheme 3. Synthetic strategy for the synthesis of dimers and their nomenclature. 
 
Vanillin or syringaldehyde were reacted with an excess of the corresponding 
amine in the presence of an excess of ZnCl2 and NaCNBH3 in methanol for 
24 hours. The solution was dried through rotary evaporator and the residue 
was purified through extraction (3x DCM/NaHCO3) or through column 
chromatography (DCM:MeOH 95:5) (see method section). Compounds 2f, 
2g and 2i precipitated out of the solution and were filtered off, then washed 
with deionized water and methanol. In addition, due to insolubility of 2g in 
most common solvents, the latter compound was suspended in methanol 
and concentrated hydrochloric acid was added to afford the dihydrochloride 
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salt. The yields (12 to 23%) were generally poor for the compounds purified 
through DCM/saturated NaHCO3 extraction (for example 2a, 2c and 2e) 
compared to the compounds purified through column chromatography. This 
was due to their apparent slight solubility of the latter in the aqueous phase 
during extraction. 
In contrast, purification through column chromatography (compounds 2b, 
2d and 2h) afforded higher yields, ranging from 46 to 82%. Compounds 
isolated by filtration (2f, 2g and 2i) were obtained in yields ranging from 46 
to 90%. The compounds were characterized through 1H, 13C NMR and 
HRMS. As an example of a dimer where the NMR and mass spectra of 2b 
are shown (figures 2.17-2.18) and discussed in the following pages. 
 
 
Figure 2.17. 1H NMR spectrum of dimer 2b. 
 
In the 1H NMR spectrum of 2b, the six aromatic protons (5, 6 and 7) are 
found between 6.82 and 6.72 ppm. The hydrogens from the two methoxy 
groups (8) occur as singlet at 3.83 ppm, due to the de-shielding caused by 
the oxygens linked to the aromatic moieties. The integration of those 
protons, accounted for a total of 6 atoms, confirms that two vanillin 
moieties are present in the molecule (dimer). The two methylene groups (4) 
between the tertiary nitrogen and the vanillin moiety are shown at 3.45 
ppm, integrating for four protons. Due to the de-shielding effect caused by 
the terminal hydroxy group, the protons of the methylene group (1) linked 
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to it are represented at 3.63 ppm. The protons in the methylene group 
linked to the nitrogen (3) occur at 2.60 ppm, due to the lower de-shielding 
activity of the latter compared to the oxygen. Finally, the protons of the 
remaining methylene (2) experience the lower de-shielding force, occurring 
at 1.72 ppm. 
 
 
Figure 2.18. 13C NMR spectrum of dimer 2b. 
 
In the 13C NMR spectrum of 2b, the six aromatic carbons (5 to 10) lie 
between 147.0 and 110.8 ppm whereas the methylene carbons between the 
nitrogen and the aromatic ring (4) occur at 64.30ppm. The three aliphatic 
carbons (1, 2 and 3) are located at 27.40, 53.34 and 58.40ppm, 
respectively whereas the two carbons of the methoxy groups (1) occur at 
55.9 ppm. Finally, the HRMS confirmed the molecular weight of compound 
2b (figure 2.19). 
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Figure 2.19. HRMS of dimer 2b. 
 
2.5.4 Synthesis of the Tetramers 
 
The synthetic strategy for the synthesis of the vanillin tetramers (4a-4f) is 
depicted in scheme 4.  
 
 
Scheme 4. Synthetic strategy for the synthesis of tetramers and their nomenclature. 
 
An excess of vanillin, syringaldehyde, benzaldehyde or 4-hydroxy 
benzaldehyde was reacted with the corresponding amine in the presence of 
an excess of ZnCl2 and NaCNBH3 in methanol for 24 hours. The precipitates 
obtained were then filtered off, washed thoroughly with fresh solvent, 
affording the pure compounds in yields ranging from 18-80%. In addition, 
due to the insolubility of 4e in most common solvents, 4e was suspended in 
methanol and concentrated hydrochloric acid was added to afford the 
dihydrochloride salt in 38% yield. Compound 4f was obtained, after the 
removal of the methanol and after thorough washing of the residue with 
water and chloroform (66% yield). The compounds were characterized 
through 1H, 13C NMR and LRM spectroscopy. As an example, the NMR and 
mass spectra of compound 4c are discussed in the following pages. 
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Figure 2.20. 1H NMR spectrum of tetramer 4c. 
 
In the 1H NMR spectrum of 4c, the sixteen aromatic protons (at carbons 1, 
3, 4 and 5) occur between 6.88 and 6.76 ppm. The eight protons in the four 
methylene moieties (2) are found at 4.39 ppm whereas the twelve protons 
from the four methoxy groups (6) are centred at 3.84 ppm. 
 
 
Figure 2.21. 13C NMR spectrum of tetramer 4c. 
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In the 13C NMR spectrum of 4c (figure 2.21), the eight different aromatic 
carbons (1, 2 and 4 to 9) are located between 146.5 and 109.9 ppm. The 
four carbons in the methylene groups (3) are located at 55.9 ppm whereas 
the carbons of the methoxy groups (10) are situated at 55.2 ppm. Finally, 
the HRMS confirmed the molecular weight of compound 4c (figure 2.22). 
 
 
Figure 2.22. HRMS spectrum of tetramer 2c. 
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2.6 Conclusions 
 
Twenty-one novel vanillin derivatives were successfully designed, 
synthesized and characterized. Six derivatives consist of only one vanillin 
moiety (monomers), nine derivatives have two vanillin moieties (dimers) 
and six derivatives with four vanillin moieties (tetramers) (see schemes 1, 
2, 3 and 4 in section 2.4).  
 
The rationale for the synthesis of these derivatives was to evaluate: 
 
(v)     The impact of the number of vanillin moieties may have on 
their antioxidant activities; this was carried out by comparing the 
antioxidant activities of dimers, tetramers and monomers (see 
schemes 1, 2, 3 and 4 in the previous pages). 
 
(vi) The impact of methoxy and hydroxy groups in the vanillin 
moieties on the antioxidant activities; this can be exploited by 
comparing derivatives  4a, 4c, 4d and 4f or compounds 2b and 
2h, 2f and 2i or 1d and 1e (see figure 2.23). 
 
 
Figure 2.23. Chemical structures of related vanillin derivatives bearing different hydroxy and methoxy 
groups.  
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(vii) The presence of nitrogen atom(s) on the antioxidant activity; 
the derivatives prepared were imines (compounds 1a and 1b), 
secondary (1c, 1d, 1e and 1f) or tertiary amines (the rest of the 
compounds). In addition, the nitrogen atoms were also protonated 
as two hydrochloric salts were prepared to evaluate their 
antioxidant properties (compound 2g and 4e) (see schemes 1, 2, 
3 and 4 in the previous pages). 
 
(viii) The role of alkyl chains linked to the nitrogen atom and their 
impact on the antioxidant activity; compounds 2a, 2b, 2c and 2d 
differ just for the length of the alkyl chain. In addition, the impact 
on antioxidant activity of heteroatoms on the alkyl chain has been 
evaluated by replacing the methyl group of compound 2e with a 
hydroxy group in compound 2b (see scheme 3).  
 
(ix) The impact of electronic conjugation on the antioxidant 
properties; for example, the electrons of nitrogen atoms in 
compound 4c can be delocalised throughout the linker (the 
aromatic moiety) whereas this is not possible for compound 4b 
which bears a cyclohexane moiety between its nitrogen atoms 
(see figure 2.24). 
 
 
Figure 2.24. Chemical structures of compounds 4c (left) and 4b (right). 
 
(x)    The impact of naphthalimide and tacrine moieties (in 
compounds 1c, 1d, 1e and 1f) on antioxidant properties, 
cholinesterase activity and Aβ(1-42) and amyloid aggregation, which 
will be discussed in chapter 5. 
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The synthetic route for the preparation of the monomers involved a multi-
step strategy, with the isolation of the Schiff base (imine), obtained by 
condensation of vanillin or syringaldehyde with the corresponding amine, 
and followed by the reduction using sodium borohydride. The yields for this 
class of derivatives ranged from 38 to 86%. 
 
The dimers were obtained through reductive amination, by reacting vanillin 
or syringaldehyde with an excess of the corresponding amine in the 
presence of zinc chloride and sodium cyanoborohydride with yields ranging 
from 12 to 90%. 
The tetramers were obtained through reductive amination, by reacting an 
excess of vanillin, syringaldehyde, benzaldehyde or 4-hydroxy 
benzaldehyde with the corresponding amine in the presence of zinc chloride 
and sodium cyanoborohydride with yields ranging from 18 to 80%. 
 
The successful synthetic strategies adopted for the novel vanillin derivatives 
has led to the following evaluation of their antioxidant properties (Chapter 
3), protective effects toward SH-SY5Y neuroblastoma cell line (Chapter 4) 
and their potential use in a multitargeted-based Alzheimer’s Disease 
therapy (Chapter 5). 
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Chapter 3: Antioxidant Properties of 
Vanillin Derivatives 
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3.1 Introduction 
 
As described in chapter 1, numerous studies have linked oxidative stress to 
the pathogenesis of many major age-related diseases such as cancer, 
cardiovascular and neurodegenerative diseases (Firuzi et al., 2011; Poljsak, 
Šuput and Milisav, 2013a). Many studies have reported the possible use of 
natural and synthetic antioxidants for the prevention or treatment of such 
diseases. For example, vitamin E, vitamin C and β-carotene was widely 
employed as antioxidant in both animal and human trials for coronary 
diseases and cancer, although the results are far from conclusive (Creagan 
et al., 1979; van Poppel and van den Berg, 1997; Gilgun-Sherki et al., 
2002; Tinkel, Hassanain and Khouri, 2012; Hu et al., 2015). 
 
At the same time, polyphenols have shown protective effects in both in vitro 
and in vivo neurodegenerative disease models, acting as modulator of 
different biological pathways, such as the signalling cascades and anti-
apoptotic processes; however the beneficial effects are not only conferred 
by antioxidant activity (Ramassamy, 2006; Ajami et al., 2017). 
 
In addition, a wide number of synthetic compounds, often based on natural 
antioxidants, have been reported. For example, synthetic derivatives of 
gallic acid have been recently reported, showing neuroprotective effects in 
Parkinson’s Disease model, at a cellular level (Lu et al., 2006). More 
recently, melatonin-cinnamate hybrids showed neuroprotective effects in 
Alzheimer’s Disease model at cellular level (Buendia et al., 2015). In the 
same year, a curcumin-melatonin hybrid known as Z-CM-I-1  was reported 
to show protective effects against oxidative stress, decreased accumulation 
of Aβ amyloid in the cortex regions of the brain and reduction in 
inflammatory response in a transgenic in vivo APP/PS1 AD mouse model 
(Gerenu et al., 2015). 
 
Although the antioxidant therapy produced contrasting results in the past 
years, natural and synthetic antioxidants represent an interesting and 
promising approach for the treatment of neurodegenerative diseases. Thus, 
the decision of the adequate assays for the determination of the antioxidant 
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activity of a target molecule is of critical importance (Moon and Shibamoto, 
2009). 
 
3.1.1 Assays for the Evaluation of Antioxidant Activity 
 
The scientific literature reports a wide number of in vitro antioxidant assays, 
based on different molecular mechanism, for the determination of the 
antioxidant activity of pure compounds and natural extracts. 
The employment of different antioxidant assays leads to a major 
understanding regarding the capabilities of latter extracts or compounds.  
The most common assays employed are reported in the following pages. 
 
3.1.1.2 2,2-diphenyl-1-picrylhydrazyl (DPPH) Assay 
 
DPPH assay was developed in 1958 by Blois with the aim to determine the 
antioxidant activity using a stable free radical (Blois, 1958). It involves the 
use of 2,2-diphenyl-1-picrylhydrazyl (DPPH), a synthetic free radical with an 
absorption maximum at 517 nm which decreases with reduction by an 
antioxidant (Dudonné et al., 2009). The stability of this free radical lies on 
the delocalisation of the spare electron over the molecule as a whole (see 
figure 3.1) (Kedare and Singh, 2011). 
 
 
Figure 3.1. Electronic delocalisation of the lone electron in DPPH molecule. 
 
The assay is based on both hydrogen atom transfer (HAT) and electron 
transfer (ET) from an antioxidant to the DPPH free radical, depending on the 
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nature of the solvent and the redox potentials of the species involved. In 
fact, the HAT mechanism is predominant in non-polar solvents whereas ET 
mechanism becomes predominant in polar solvents where hydrogen bonds 
can be formed with the antioxidant molecules such as methanol or ethanol 
(Foti, Daquino and Geraci, 2004; Villaño et al., 2007). 
The reduction of DPPH free radical is linked with the loss in absorbance at 
517 nm which can be measured with a uv/vis spectrophotometer (Blois, 
1958). The mechanism of the assay is described in figure 3.2. 
 
 
Figure 3.2. Mechanism of DPPH assay. 
 
The results from the DPPH assay are expressed as IC50, which is defined as 
the concentration of sample able to scavenge 50% of the free radical and 
can be determined by plotting the absorbance obtained at each 
concentration (Villaño et al., 2007). 
The IC50 can then be determined using the equation of the linear portion of 
the curve line. This assay is convenient in its application and it is one of the 
most popular antioxidant assay; however, its application is limited as a non-
physiological free radical is employed (Floegel et al., 2011).  
 
3.1.1.3 Ferric Reducing/Antioxidant Power (FRAP) Assay 
 
The FRAP assay was developed by Benzie and Strain in 1996 at the Hong 
Kong Polytechnic University with the original name of “ferric reducing ability 
of plasma”, since it was used for the measurement of the antioxidant 
activity of plasma (Benzie and Strain, 1996). Subsequently, the assay was 
applied to other substrates such as wine and tea and was then renamed as 
the “ferric reducing/antioxidant power” assay (Pulido, Bravo and Saura-
Calixto, 2000). 
FRAP is based on the reduction of ferric ions (Fe3+) to ferrous ions (Fe2+) 
through electron transfer pathway at low pH with the subsequent formation 
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of a blue-coloured ferrous-trypiridyltriazine complex. The molecular 
mechanism of the assay is described in figure 3.3. 
 
 
Figure 3.3. Mechanism of FRAP assay, adapted from Pérez-Cruz et al. (2018). 
 
The results can be obtained by plotting the absorbance at 593 nm at each 
concentration of the sample tested and comparing the curve obtained with 
the calibration curve obtained for antioxidants such as ascorbic acid or 
Trolox (Benzie and Strain, 1996; Pulido, Bravo and Saura-Calixto, 2000). 
Strictly, this is a measure of the reducing power of a compound, as opposed 
to its ability to scavenge ROS, but there is obviously a close link between 
the two. Nevertheless, associating the ability to reduce iron ions to 
antioxidant capacity is an extrapolation, and should be approached with 
caution. 
  
3.1.1.4 2,2-azino-bis(3-ethylbenz- thiazoline-6-sulfonic acid) (ABTS) 
Assay  
 
The 2,2-azino-bis(3-ethylbenz- thiazoline-6-sulfonic acid) (ABTS) assay has 
been widely used for the evaluation of food and beverage components due 
to its applicability in both aqueous and lipid phases (MacDonald-Wicks, 
Wood and Garg, 2006). ABTS assay was firstly developed by Miller et al. in 
1993 and it involved the activation of metmyoglobin by hydrogen peroxide 
in the presence of ABTS (Miller et al., 1993). In the modern version of the 
assay, the ABTS is oxidised to the blue-green ABTS radical cation using 
potassium persulfate (see figure 3.4). 
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Figure 3.4. Formation of ABTS radical cation from ABTS with potassium persulfate, adapted from Moon 
and Shibamoto (2009) with Copyright agreement © 2009, American Chemical Society. 
 
The addition of the antioxidant causes the decolorization of the ABTS which 
can be measured at 734 nm. 
The absorbance of the reaction mixture of ABTS and the antioxidant is 
compared to the mixture of ABTS and Trolox, and the results are expressed 
as Trolox equivalent antioxidant capacity (TEAC) (Moon and Shibamoto, 
2009). 
Again, this assay measures the ability of a compound to scavenge a stable 
radical that is substantially less reactive than oxygen-centred radicals in 
biology. Extrapolating the results to an in vivo situation should be 
approached with caution. 
 
3.1.1.5 Total Phenol Assay (Folin-Ciocalteu reagent) 
 
This assay was originally introduced as “Folin-Ciocalteu assay” for protein 
analysis, exploiting the phenolic moiety of the amino acid tyrosine (Folin 
and Ciocalteu, 1927). Subsequently, Singleton, Orthofer and Lamuela-
Raventós adapted the assay for the measure of phenols in wine, leading to 
the actual name, total-phenol assay (Singleton, Orthofer and Lamuela-
Raventós, 1999; MacDonald-Wicks, Wood and Garg, 2006). 
It is based on the electron transfer from phenolic molecules to 
phosphomolybdic and phosphotungstic acid complexes, the Folin-Ciocalteu 
reagent (FCR), which are coloured in blue and can be spectroscopically 
measured at 760 nm. 
Although the exact chemical nature of the final product from this assay is 
still unknown, it is believed that the intense blue colouration is given by the 
formation of the (PMoW11O40)4- complex (Ainsworth and Gillespie, 2007). 
It is worth noting that, due to the non-selective chemistry behind this 
assay, the FCR is not specific for phenolic molecules and it can be reduced 
by many non-phenolic compounds such as vitamin C, aromatic amines,  
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sulphites and sugars (when present in high concentrations) (Huang, Boxin 
and Prior, 2005; Ainsworth and Gillespie, 2007). 
 
3.1.1.6 Oxygen Radical Absorbance Capacity (ORAC) Assay 
 
The ORAC assay was developed for the first time by Cao, Alessio and Cutler 
in 1993 at the National Institute on Ageing in Baltimore and at the 
Department of Physical Education of Miami University (Cao, Alessio and 
Cutler, 1993). 
It was based on a previous method developed in Glazer’s laboratories at the 
University of California where phycoerythrin fluorescence emission was used 
to measure the rate of free radical-mediated damage induced by 2,2’-
azobis(2-amidinopropane) (AAPH) after thermal decomposition (DeLange 
and Glazer, 1989). AAPH undergoes thermal decomposition in solution, 
generating two amidinopropane radicals, which can react with oxygen to 
yield peroxyl radicals, as depicted in figure 3.5 (Nimse and Pal, 2015). 
 
 
Figure 3.5. Mechanism of peroxyl radical generation mediated by AAPH, adapted from Nimse and Pal 
(2015) Published by The Royal Society of Chemistry. 
 
The use of the peroxyl free radical, which is commonly found in the body, 
makes this assay more applicable to biological systems (Isa et al., 2012). 
However, the DeLange and Glazer’s method was not able to quantify the 
results obtained and was limited to the screening of the free radical 
scavenging capacity of the sample. 
 
Cao, Alessio and Cutler’s method introduced the ORAC values, which refer 
to the net protection area under the quenching curve of the fluorescent 
probe in the presence of the antioxidant (see figure 3.6) 
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Figure 3.6. Example of NET area under the curve for ORAC assay. The latter can be measured 
calculating the area between the sample curve(s) and the blank. 
 
The ORAC values are obtained by comparison with the synthetic antioxidant 
standard Trolox (Cao, Alessio and Cutler, 1993). 
 
At present, fluorescein is the most employed fluorescent probe since it is 
photostable and does not show photo bleaching property after exposure to 
excitation light for certain time, which was the limitation with phycoerythrin 
(Ou, Hampsch-Woodill and Prior, 2001; Alarcón et al., 2008). The 
fluorescein oxidative pathway follows the HAT mechanism, as depicted in 
figure 3.7. 
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Figure 3.7. Proposed fluorescein oxidation pathway in the presence of AAPH, adapted from Ou, 
Hampsch-Woodill, and Prior (2001) with Copyright agreement © 2001, American Chemical Society. 
 
The first step of this process involves the abstraction of the hydrogen of the 
phenolic moiety in the fluorescein molecule by the peroxyl radical generated 
by AAPH, generating a stable phenoxyl radical that can undergo 
dimerization (FL1). 
However, the same phenoxyl radical can react with carbon dioxide in the 
buffer to yield 2-(6-(carboxyoxy)-3-oxo-3H-xanthen-9-yl)benzoic acid 
(FL2). The latter can react with two peroxyl radicals to afford the 
endoperoxide intermediate which can decompose into FL3. The oxidative 
process can further continue to generate an unknown FL4, with m/z 221.3, 
which does not show fluorescent emission at 495/515 nm (Ou, Hampsch-
Woodill and Prior, 2001). 
 
3.1.1.7 Thiobarbituric Acid Reactive Substances (TBARS) Assay 
 
The thiobarbituric acid test has been employed to measure the lipid 
peroxidation in chemicals, food and biological matrices (Janero, 1990). The 
assay is based on the reactivity of malondialdehyde (MDA), a common end 
product of oxidative lipid degradation, toward thiobarbituric acid (TBA) 
following a  1:2 stoichiometry, leading to the formation of a red 
chromophore with an absorption maximum at 532 nm (Hodges et al., 
1999). The reaction between malondialdehyde and TBA is depicted in figure 
3.8. 
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Figure 3.8. Formation of the MDA-TBA adduct, adapted from Janero (1990) with Copyright agreement © 
1990 Published by Elsevier In. 
 
It consists in an acid-catalysed nucleophilic addition involving the C-5 of 
TBA toward one of the carbonyl group of MDA, followed by dehydration and 
subsequent reaction of the 1:1 adduct with another molecule of TBA. 
 
Linoleic acid (LA) is the common substrate employed for the generation of 
MDA in in vitro assays due its availability at high purity; however, due to 
the variety of conditions reported in a wide number of works, the assay has 
been criticised for its lack of robustness (Buenger et al., 2006; Ghani et al., 
2017).   
 
3.1.1.8 DNA Damage Protection Assay 
 
Agarose gel electrophoresis is an efficient technique for the analysis of DNA 
structure; in fact, the electrophoretic migration rate of the latter moving 
through an agarose gel matrix is dependent on conformation, molecular size 
and net charge (Johnson and Grossman, 1977). 
In the past, different studies reported the ability of several compounds to 
induce DNA damage through the production of oxygen radicals. For 
example, benzene and its metabolites such as hydroquinone and 1,2,4-
benzenetriol can undergo autoxidation and to generate superoxide (Lewis, 
Stewart and Adams, 1988). At the same time, AAPH is known to cause 
oxidative damage to pBR332 plasmid DNA, resulting in the DNA strand 
breaks of the supercoiled form into both the open circular and linear forms 
(Wei et al., 2006). 
 
In untreated pBR332 plasmid DNA, the supercoiled form is predominant, 
representing the intact form (Zhang and Omaye, 2001). The conversion of 
the plasmid supercoiled form to the open-circular and linear forms can be 
used as an index of DNA damage (Jeong et al., 2009). In fact, the circular 
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form is indicative of single-strand breakage whereas the linear form is 
indicative of double-strand breakage. 
 
An example of electrophoretic DNA gel separation is shown in figure 3.9. 
 
 
Figure 3.9. DNA fragments separation using gel electrophoresis. Supercoiled DNA moves faster 
compared to the circular and linear fragments. 
 
The difference between the treatments in this assay can be determined by 
comparing the intensities of the three bands (Zhang and Omaye, 2001). 
 
The aim of the work reported in this chapter was to evaluate the antioxidant 
activities of all the novel vanillin derivatives synthesised and to discuss their 
mechanism of action with respect to the SAR of this new class of 
compounds. 
 
To achieve these aims, several antioxidant assays, based on different 
mechanisms of action, were performed. These include the DPPH, FRAP, 
ORAC and DNA damage protection assays. Furthermore, our data will be 
compared and contrasted with other relevant published work.  
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3.2 Materials and Methods 
 
3.2.1 Materials 
 
All reagents were purchased from Sigma Aldrich, unless otherwise stated, 
without any further purification. 
 
2,4,6-Tri(2-pyridyl)-s-triazine (TPTZ)                                       Fluka 
Agarose                                                                      FisherScientific 
DNA Plasmid pbr332       ThermoFisher Scientific 
GelRed® Nucleic Acid Gel Stain                             Biotium 
Phosphate Buffered Saline (PBS) Tablets                    Oxoid 
  
3.2.2 Instrumentation  
 
Absorbances for DPPH and FRAP assays were measured using a Bio-Rad 
iMark microplate reader. 
 
Fluorescence for ORAC assay was measured using a BioTek Synergy HT 
microplate reader. 
 
The gels prepared for DNA protection assay were electrophoresed using Life 
Technologies Horizon 58 gel tank and Thermo EC 105 power pack and 
analysed with a Peqlab Fusion FX7 system (Fusion 15.11 software) for 
chemiluminescence and fluorescence and pictures were taken through high 
resolution camera system. 
 
3.3 Methods 
 
3.3.1 DPPH Assay 
 
The ability of novel compounds to scavenge DPPH free radicals was 
determined on a 96-well plate platform by following Payet, Sing and 
Smadja’s procedure with minor modifications (Payet, Sing and Smadja, 
2005). A DPPH solution (0.1 mM) was prepared in methanol. A dilution 
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series of antioxidant was made in methanol using Eppendorf® tubes, then 
50 µl of each solution was pipetted in the corresponding well of a 96-well 
plate. 50 µl of methanol was transferred in the control wells. Finally, 100 µl 
of DPPH solution was added to each well and the plate was wrapped with 
aluminium foil and kept in the dark for 30 minutes. The absorbance was 
measured at 517 nm. 
An example of the 96-well plate settings is reported in figure 3.10. 
 
 
Figure 3.10. 96-well plate settings for DPPH assay. Two compounds can be tested at the same time. 
DPPH control is represented in purple, the first antioxidant is represented in blue and the second 
antioxidant is represented in red (different shades represent different concentrations tested). 
 
The results were obtained after plotting the graph of concentration of 
compound (µM) in the x-axis against %ABS in the y-axis (calculated as 
shown in the formula below):  
 
% 𝐴𝐵𝑆 =  
𝐴𝐵𝑆𝑠𝑎𝑚𝑝𝑙𝑒  
𝐴𝐵𝑆𝑛𝑒𝑔.𝑐𝑜𝑛𝑡𝑟𝑜𝑙
∗ 100 
 
The linear portion of the curve was isolated and 50% absorbance was 
determined using the equation of the line obtained. 
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3.3.2 FRAP Assay 
 
The ability of novel compounds to reduce Fe3+ into Fe2+ was determined on 
a 96-well plate platform, following the method of Firuzi et al. with minor 
modifications (Firuzi et al., 2005). A dilution series of antioxidants and 
Trolox in methanol was made in Eppendorf® tubes. A TPTZ solution (10 mM) 
was prepared in 40 mM HCl whereas a FeCl3 solution (20 mM) was prepared 
in deionized water. A 300 mM acetate buffer was prepared and the pH was 
adjusted to 3.6. The FRAP reagent was prepared by mixing 2.5 ml of TPTZ 
solution with 2.5 ml of FeCl3 solution and 25 ml of acetate buffer. 10 µl of 
Trolox or antioxidant solution was pipetted in a 96-well plate, followed by 
190 µl of FRAP reagent in each well. An example of the 96-well plate 
settings is reported in figure 3.11. 
 
 
Figure 3.11. 96-well plate settings for FRAP assay. Two compounds can be tested at once. Different 
concentrations of Trolox are represented in blue colour. The first antioxidant is represented in yellow and 
the second antioxidant is represented in red (different shades represent different concentrations tested). 
 
The plate was wrapped in aluminium foil and stored in the dark for 30 
minutes after which the absorbance was measured at 593 nm. The 
calibration curves for both standard Trolox and antioxidant were obtained 
after plotting the graph of concentration of compound (µM) in the x-axis 
against ABS in the y-axis. The results, expressed as Trolox Equivalent (TE), 
were obtained by comparison of the slope of the calibration curve obtained 
for the Trolox with the compound in analysis. 
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3.3.3 ORAC Assay 
 
The ability of the vanillin derivatives to prevent oxidative degradation of the 
fluorescent probe fluorescein was determined using the ORAC assay 
following the protocols described by Huang et al. and Roy et al. with minor 
modifications using a black-walled 96-well plate (Huang et al., 2002; Roy et 
al., 2010). A phosphate buffer solution (75 mM) was prepared and the pH 
was adjusted to 7.4. Stock AAPH (0.15 M) and sodium fluorescein solutions 
(4 mM) were prepared in phosphate buffer. The sodium fluorescein stock 
solution was further diluted to a working concentration of 25 nM. A series 
dilution of Trolox and antioxidants was made in phosphate buffer in 
Eppendorf® tubes then 25 µl of Trolox standard or antioxidant solutions was 
pipetted in the corresponding well in the 96-well plate whereas 25 µl of 
phosphate buffer was added in the fluorescein and AAPH controls. 150 µl of 
fluorescein solution (25 nM) was pipetted in each well and the plate was 
incubated at 37°C for 30 minutes. Then, 25 µl of AAPH solution was 
pipetted in each well except for the fluorescein control in which 25 µl of 
phosphate buffer was added. 
An example of the 96-well plate settings is shown in figure 3.12. 
 
 
Figure 3.12. 96-well plate settings for ORAC assay. Fluorescein control is represented in purple colour 
and AAPH control is represented in grey colour. Different concentrations of Trolox are represented in 
blue colour whereas different concentrations of the antioxidant are represented in red (different shades 
represent different concentrations tested). 
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The fluorescence was measured every 2 minutes over a period of 2 hours at 
37°C (485/20 nm excitation, 525/20 nm emission). The area under the 
curve at each concentration was calculated applying the following formula: 
 
𝐴𝑈𝐶 = 0.5 +
𝑓2𝑚𝑖𝑛 
𝑓0𝑚𝑖𝑛
+
𝑓4𝑚𝑖𝑛 
𝑓0𝑚𝑖𝑛
+  
𝑓6𝑚𝑖𝑛 
𝑓0𝑚𝑖𝑛
+ ⋯
𝑓118𝑚𝑖𝑛 
𝑓0𝑚𝑖𝑛
+ 0.5(
𝑓120𝑚𝑖𝑛 
𝑓0𝑚𝑖𝑛
) 
𝑛𝑒𝑡 𝐴𝑈𝐶 = 𝐴𝑈𝐶𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐴𝑈𝐶𝑛𝑒𝑔 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
where AUC = area under the curve, fxmin = fluorescence measurement at 
the respective minute.  
The area under the curve obtained for each concentration of antioxidants 
and standards were plotted in a graph against the corresponding 
concentrations and the linear portion was isolated. The final results were 
obtained by comparison of the slope of the calibration curve of the selected 
compounds with the standard Trolox. 
 
3.3.4 DNA Damage Protection Assay 
 
The ability of the novel compounds to prevent oxidative stress-mediated 
strand breakage in supercoiled DNA plasmid was measured following the 
methods previously described by Lee et al. and Pohl et al. with minor 
modifications (Lee et al., 2002; Pohl et al., 2018). Phosphate buffered 
saline (PBS) buffer was prepared from tablets according to the instructions 
reported by the manufacturer. A dilution series of Trolox and antioxidants 
was prepared in phosphate buffer in Eppendorf® tubes. A 10 mM AAPH 
solution was prepared in phosphate buffer. A Tris-Acetic acid-EDTA (TAE) 
buffer (50x), consisting of 40 mM tris acetate and 1mM EDTA, was prepared 
and the pH was adjusted to 8.5. The buffer was diluted 50 times with 
deionized water before use (TAE 1x). The loading dye was obtained by 
dissolving 5 mg of bromophenol blue in 1 ml of water/glycerol (50:50). The 
samples were prepared in Eppendorf® tubes by mixing 6 µl of phosphate 
buffer with 8 µl of antioxidant solution at different concentrations, 8 µl of 
AAPH solution and 1 µl of DNA plasmid solution (0.5 µg/µl). DNA control 
was prepared by mixing 1 µl of DNA plasmid solution with 22 µl of 
phosphate buffer whereas AAPH control was prepared by mixing 1 µl of DNA 
plasmid with 8 µl of AAPH and 14 µl of phosphate buffer. 
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The Eppendorf® tubes were incubated in the dark for 1 hour at 37 °C  then 
2 µl of loading dye were added in each tube. Finally, 10 µl of each sample 
was loaded in a 0.7 % agarose gel prepared in 50 ml of TAE (1x) along with 
5 µl of GelRed® Nucleic Acid Gel Stain. The gel underwent electrophoresis 
for 70 minutes at 80 V before visualization and image capture under UV-
light. The results were obtained after calculation of the intensity of the 
bands in the gel using Image J software and the application of the following 
formula: 
 
𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑜𝑓 𝐷𝑁𝐴 𝑠𝑡𝑟𝑎𝑛𝑑 𝑏𝑟𝑒𝑎𝑘𝑎𝑔𝑒 =
𝑏𝑎𝑛𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐷𝑁𝐴+𝑆𝑇𝑅𝐸𝑆𝑆𝑂𝑅+𝐶𝑂𝑀𝑃𝑂𝑈𝑁𝐷
𝑏𝑎𝑛𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐷𝑁𝐴 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑠𝑡𝑟𝑒𝑠𝑠𝑜𝑟
 * 100 
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3.4 Results and Discussion 
 
3.4.1 DPPH Assay 
 
DPPH is a synthetic nitrogen free radical with a maximum absorption at 517 
nm. Its reduction mediated by antioxidants was measured 
spectrophotometrically (Payet, Sing and Smadja, 2005).  
An example of the plate is reported in figure 3.13. 
 
 
Figure 3.13. 96-well plate for DPPH assay. Two compounds were tested per experiment. The wells in the 
red circle represent the DPPH control. The wells in the green and yellow circles represent two different 
compounds at different concentrations. The compound in the green circle showed higher activity in the 
assay due to the loss of colouration whereas the compound in the yellow circle did not show any activity 
in the assay. 
 
All the novel vanillin derivatives were tested, along with vanillin, 
syringaldehyde, Trolox and tacrine, in the DPPH assay. The results, 
expressed as concentration in µM, are reported as their IC50 values which 
are defined as the concentration of compound able to scavenge the 50% of 
the DPPH free radical. The IC50 was determined by plotting a graph with 
concentrations (in µM) on the x-axis and their corresponding % absorbance 
values on the y-axis to obtain a curve. The linear portion of the curve was 
considered for the determination of the IC50 values using the equation of the 
line as shown in figure 3.14. 
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Figure 3.14. Example of DPPH assay results for derivative 1d. The concentrations of compound were 
plotted in a graph along with the amount of unscavenged DPPH expressed as percentage. The linear 
portion of the curve was isolated and the IC50 was calculated using the equation of the line. 
 
The DPPH results of all the compounds tested, are shown in table 3.1. 
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Table 3.1. Antioxidant properties of vanillin derivatives using the DPPH assay. 
 
Compound DPPH (IC50 µM) 
1a 248.5 ± 24.50 
1b >250 
1c 107 ± 1 
1d 50.7 ± 0.8 
1e 19.5 ± 0.3 
1f 20.5 ± 0.3 
2a 12.8 ± 0.11 
2b 13.7 ± 0.15 
2c 21 ± 0.4 
2d 24 ± 2 
2e 21.9 ± 1.7 
2f 29.7 ± 1.3 
2g INACTIVE a 
2h 12.3 ± 1.2 
2i 15.4 ± 1 
4a >250 
4b 137.5 ± 5.5 
4c 5.8 ± 0.1 
4d >250 
4e INACTIVE a 
4f 98 ± 5.51 
Vanillin 4050 ± 25 b 
Syringaldehyde 1150 ± 22 b 
Trolox 24.4 ± 0.9 
Tacrine INACTIVE a 
Results from each experiment are expressed as mean ± SD of three independent experiments. 
a compounds were tested up to 250 µ 
b compounds were tested up to 10 mM. 
For chemical structures of all the compounds, refer to schemes 2,3 and 4 of the second chapter.  
 
The standard Trolox showed an IC50 of 24.4 µM, which is in close agreement 
to previously reported results (27.6 µM), confirming the reliability of this 
assay (Lee et al., 2009). 
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All the derivatives showed increased activities compared to the parent 
compounds, vanillin and syringaldehyde, except for 2g and 4e (see figure 
3.15) 
 
 
Figure 3.15. Chemical structures of dimer 2g and tetramer 4e. 
 
It is interesting to note that both 2g and 4e are the hydrochloride salts with 
protonated nitrogen atoms, thus are unable to donate their lone electron 
pairs. The latter is a feature that contributes to antioxidant activity in this 
assay. Indeed, the antioxidant activity in this assay was strictly linked to 
the availability of the electrons on the nitrogen(s) atoms together with the 
presence of vanillin moieties in the chemical structure. However, imines 1a 
and 1b, bearing only one vanillin moiety, showed weak antioxidant 
activities (with IC50 248.5 and >250 µM, respectively) in this assay. It is 
worth noting that the electrons of the nitrogen are less available compared 
to the corresponding amines due to the sp2 hybridization of the nitrogen 
with consequent low electron density (see figure 3.16).  
 
 
Figure 3.16. Chemical structures of imines 1a and 1b. 
 
This can be further confirmed when comparing 1a (IC50 248.5 µM) with 1c 
(IC50 107 µM) and 2f (IC50 29.7 µM) (see figure 3.17). 
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Figure 3.17. Chemical structure of compounds 1a, 1c and 2f. 
 
Compound 1c is the secondary amine obtained after the reduction of the 
imine group of compound 1a; the lone pair of electrons on the nitrogen 
atom are more accessible due to the sp3 hybridization of the nitrogen with 
consequent higher electron density and increased nucleophilicity. At the 
same time, compound 2f is the tertiary amine obtained by the addition of 
compound 1a with an extra vanillin moiety; the increased nucleophilicity of 
the nitrogen due to the inductive effect of the extra substituent, along with 
the extra vanillin moiety, can explain its increased antioxidant activity. 
  
Syringaldehyde derivatives turned out to be more active than the 
corresponding vanillin derivatives, following the same pattern of behaviour 
of their parent compounds (vanillin itself is almost four times less active 
than syringaldehyde in the DPPH assay (4050 and 1150 µM, respectively)). 
Accordingly, the syringaldehyde derivatives 1e and 2i (with IC50 19.5 and 
15.4 µM, respectively) showed a two-fold increase in activity compared to 
the corresponding vanillin derivatives 1d and 2f (with IC50 50.7 and 29.7 
µM, respectively), highlighting the importance of the extra methoxy group 
in the syringaldehyde for enhanced antioxidant activity. The chemical 
structures of the latter compounds are shown in figure 3.18. 
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Figure 3.18. Chemical structures of vanillin derivatives 1d and 2f and syringaldehyde derivatives 1e and 
2i. 
 
Dimers 2a, 2b, 2c, 2d and 2e (see figure 3.19) showed similar activities, 
with IC50 ranging from 12.8 to 21.9 µM, confirming that the nature of the 
alkyl chain linked to the nitrogen has little impact on the antioxidant 
activity, while shorter alkyl chains enhance the antioxidant power.  
 
 
Figure 3.19. Chemical structures of derivatives 2a-2e. 
 
In addition, the removal of the terminal –OH functional group in the alkyl 
chain of compound 2c (IC50 21 µM) had no impact on the antioxidant 
activity (compound 2e, IC50 21.9 µM). This could be explained by the fact 
that an hydroxy group has no free radical scavenging effects if the oxygen 
is not able to delocalise the negative charge (as in phenolic moieties). 
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The tetramer 4c turned out to be the most active compound in this assay, 
with an IC50 of 5.8 µM, showing similar activity to the vanillin and 
syringaldehyde dendrimers reported by Lee et al. with IC50 ranging from 
3.7-9 µM (Lee et al., 2009). Tetramer 4c bears four vanillin moieties and 
two nitrogen atoms, linked by an aromatic ring. Several substitutions were 
made to explore the role of the different functional groups on antioxidant 
activity. The hydroxy and methoxy groups of the vanillin moieties were 
removed in order to establish their effect on their antioxidant activity (see 
figure 3.20). The removal of the hydroxy group (compound 4a) or both the 
moieties (compound 4d) caused a dramatic decreased in the activity (IC50 
>250 µM), whereas the removal of the methoxy groups (compound 4f) 
caused only a minor loss in activity (IC50 98 µM). 
 
 
Figure 3.20. Chemical structures of derivatives 4a, 4c, 4d and 4f. 
 
This result could be explained by the ability of the hydroxy groups to donate 
electrons in the HAT antioxidant mechanism; the absence of the methoxy 
group (an electron donor substituent) in compound 4f makes the oxygen in 
the hydroxy group less prone to donate the hydrogen atom thus reducing 
the antioxidant activity of the latter compared to 4c. 
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Interestingly, the substitution of the aromatic linker in compound 4c with a 
cyclohexane moiety (compound 4b) (see figure 3.21) resulted in a dramatic 
loss of activity in DPPH assay with the IC50 falling down to 137.5 µM. 
 
 
Figure 3.21. Chemical structures of compounds 4b and 4c. The strong antioxidant properties of 4c could 
be explained by the critical role of electronic delocalisation in the antioxidant activity. 
 
This phenomenon could be explained by the crucial role of the aromatic 
linker in the antioxidant activity of compound 4c, suggesting the 
importance of the delocalisation of the nitrogen’s electrons for the 
antioxidant activity and the possible electron transfer mechanism.  
The importance of electronic delocalisation can also be appreciated by 
comparing the activity of compound 1f, depicted in figure 3.22, with the 
rest of the monomers; although bearing only one vanillin moiety, it showed 
an IC50 of 20.5 µM, and was therefore the most active vanillin monomer of 
the series, achieving a similar activity to the syringaldehyde monomer 1e 
(IC50 19.5 µM). 
 
 
Figure 3.22. Chemical structures of Tacrine and monomer 1f. 
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It is worth noting that this is the first time the electronic delocalisation of 
the nitrogen lone pair has been linked to antioxidant activity. 
  
Finally, tacrine alone turned out to be completely inactive, suggesting that 
the vanillin moiety, the secondary amino groups and the aromatic linker are 
the only groups contributing to the antioxidant activity of 1f.  
 
3.4.2 FRAP Assay 
 
The reducing capacity of the novel vanillin derivatives toward ferric ion, 
along with controls vanillin, syringaldehyde and tacrine, was determined 
using FRAP assay. The reduction of ferric ion leads to the formation of the 
ferrous-tripyridyltriazine complex exhibiting a maximum absorption at 593 
nm.  
 
 
Figure 3.23. 96-well plate for FRAP assay. Two compounds were tested at once. The wells within the red 
perimeter represent the Trolox control, with the highest concentrations on top. The wells within the green 
and yellow perimeters represent two different compounds at different concentrations. The compound in 
the green perimeter showed no activity in the assay, whereas the compound in the yellow perimeter was 
found  to be active due the increase in blue colouration. 
 
Trolox was used as standard reference and the results are expressed as 
Trolox Equivalent (TE). The concentrations of antioxidant and Trolox were 
plotted with their correspond absorbances, then the results were obtained 
by the comparison of the slope of both curves. An example is depicted in 
figure 3.24. 
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Figure 3.24. Example of results for derivative 1f from the FRAP assay . The concentrations of Trolox and 
compound were plotted graphically, along with their corresponding absorbances. The slope of the line 
obtained were then compared to give the results, expressed in Trolox Equivalents (TE) 
 
The results are shown in table 3.2. 
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Table 3.2. Antioxidant properties of vanillin derivatives using the FRAP assay. 
 
Compound FRAP (TE) 
1a 0.06 ± 0.003 
1b 0.07 ± 0.002 
1c 0.16 ± 0.08 
1d 0.26 ± 0.04 
1e 1.45 ± 0.02 
1f 1.54 ± 0.15 
2a 0.62 ± 0.05 
2b 0.68 ± 0.02 
2c 0.62 ± 0.03 
2d 0.63 ± 0.03 
2e 0.6 ± 0.01 
2f 0.55 ± 0.05 
2g 0.28 ± 0.02 
2h 1.14 ± 0.04 
2i 1.11 ± 0.03 
4a 2.54 ± 0.56 
4b 0.56 ± 0.05 
4c 5.29 ± 0.62 
4d 2.81 ± 0.45 
4e 0.74 ± 0.13 
4f 2.78 ± 0.03 
Vanillin 0.11 ± 0.07 
Syringaldehyde 0.93 ± 0.03 
Trolox 1 
Tacrine INACTIVE a 
Results from each experiment are expressed as mean ± SD of three independent experiments. 
a compounds were tested up to 250 µ 
 
 
All vanillin derivatives showed better activities than the respective parent 
compounds, except for imines 1a and 1b (see figure 3.16), which were 
~15x less active than the standard Trolox (0.06 and 0.07 TE, respectively). 
However, syringaldehyde derivatives showed better activities than the 
117 
 
corresponding vanillin derivatives, following the same pattern of their 
precursors, with syringaldehyde to be nine times more active than vanillin 
(0.93 and 0.11 TE, respectively). In fact, the syringaldehyde derivatives 1e, 
2h and 2i (1.45, 1.14 and 1.11 TE, respectively) showed better activities in 
the FRAP assay compared to their corresponding vanillin derivatives 1d, 2b 
and 2f (0.26, 0.68 and 0.55 TE, respectively) (see figure 3.18 in the 
previous section). This could be explained by the electron donating 
mesomeric effect (+M) of the extra methoxy group in the syringaldehyde 
moiety, causing an increase in the electronic density in the phenolic moiety, 
thus resulting in a greater electron transfer activity. 
 
All the vanillin dimers 2a-2e showed similar activities ranging from 0.55-
0.68 TE, showing weaker antioxidant activities compared to the standard 
Trolox; thus highlighting the lack of impact from the different alkyl chains 
present in the these compounds (see figure 3.19). 
 
Both the hydrochloride salts, the dimer 2g and the tetramer 4e (see figure 
3.15), showed modest activities (0.28 and 0.74 TE, respectively) with the 
dimer three times less active than the tetramer, neither as active as Trolox.  
All the tetramers showed strong antioxidant power in this assay (2.54 - 
5.29 TE), except for the above cited hydrochloric salt 4e and 4b (0.74 and 
0.56 TE, respectively), which bear a cyclohexane moiety as the linker 
between the two nitrogen atoms (see figures 3.20 and 3.21). 
 
It is interesting to note that all the tetramers bearing an aromatic ring as 
the linker between the two nitrogen atoms (as in 4a, 4c, 4d and 4f (2.54, 
5.29, 2.81 and 2.78 TE, respectively) (see figure 3.20)) showed improved 
activities in this assay compared to Trolox, highlighting the predominant 
role of the electronic conjugation in the antioxidant activity for this assay 
(figure 3.21). 
The removal of the hydroxy group, the methoxy group, or both, in the 
vanillin moieties of the tetramers caused a loss of activity, as is clearly 
shown by comparing 4a, 4f and 4d with 4c (2.54, 2.78, 2.81 and 5.29 TE, 
respectively). 
The role of electron delocalisation in the FRAP assay is also evident in the 
strong activity of the vanillin monomer 1f (1.54 TE) (see figure 3.22), which 
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showed similar activities to the syringaldehyde monomer 1e (1.45 TE) and 
higher activities compared to the other vanillin monomers 1c and 1d (0.16 
and 0.26 TE, respectively), which are not able to delocalise the electrons 
associated with the nitrogen atom. 
It is worth noting that tacrine is completely inactive in this assay. 
 
3.4.3 ORAC Assay 
 
The ability of a selection of compounds to prevent AAPH-mediated oxidative 
degradation of the fluorescent probe, fluorescein, was tested, along with 
vanillin and syringaldehyde, using the ORAC assay (Huang et al., 2002; Roy 
et al., 2010). The selection of compounds was based on the different 
nitrogen nucleophilicity and number of vanillin moieties in their chemical 
structures. 
Trolox was used as standard reference and the results, shown in table 3.3, 
are expressed as Trolox Equivalent (TE). 
 
The areas under the curve (AUC) for each concentration of standard and 
antioxidant were calculated. Then the area under the curve of the blank was 
subtracted from each AUC to obtain the net AUC. The standard curve for 
both Trolox and antioxidant were obtained by plotting the Net AUC at 
different concentrations of both against their concentrations. The ORAC 
values were finally calculated by comparison of the slopes of the antioxidant 
and Trolox standard curves. An example is shown in figure 3.24. 
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Figure 3.25. Example of results for derivative 1f using the ORAC assay. The areas under the curve (AUC) obtained were plotted against the corresponding 
concentrations of Trolox and antioxidant. The net AUCs were obtained by subtracting the curve from the blank. The linear portion of the calibration curve obtained for 
the antioxidant was isolated and its slope was compared with the Trolox calibration curve to obtain the results, expressed as Trolox Equivalents (TE). 
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Table 3.3. Antioxidant properties of vanillin derivatives in ORAC assay. 
 
Compound ORAC (TE) 
1a 1.9 ± 0.9 
1b 2.1 ± 0.5 
1c 3.2 ± 1.2 
1d 3.9 ± 1.3 
1e 2.0 ± 0.5 
1f 6.4 ± 1.6 
2b 6.0 ± 0.6 
2f 5.3 ± 1.5 
2g 4.1 ± 0.8 
4a INSOLUBLE 
4c 20.4 ± 1.3 
4e 7.5 ± 1.3 
Vanillin 2.2 ± 0.3 
Syringaldehyde 1.5 ± 0.1 
Tacrine <0.01 a 
Results from each experiment are expressed as mean ± SD of three independent experiments. 
a reported by (Rodríguez-Franco et al., 2006). 
 
All the derivatives showed better activities than the corresponding starting 
compounds vanillin or syringaldehyde. In accordance with previous studies, 
vanillin had shown higher antioxidant activities (2.2 TE) than standard 
Trolox in this assay (Tai, Sawano and Yazama, 2011). Contrary to the 
results obtained in the previous assays, vanillin turned out to be more 
active compared to its methoxy derivative syringaldehyde (2.2 and 1.5 TE, 
respectively). 
At the same time, the vanillin derivative, 1d, was found to be more active 
than its corresponding syringaldehyde derivative, 1e (3.9 and 2.0 TE, 
respectively) (see figure 3.18) following the same pattern of their 
precursors. 
The vanillin dimer, 2f, showed higher antioxidant activity when compared to 
its corresponding reduced (1c) and imine (1a) monomers (5.3, 3.2 and 1.9 
TE, respectively) confirming the role of the number of vanillin moieties and 
hence contribution to antioxidant property in this assay (see figure 3.17). 
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As in the previous assays, the nucleophilicity of the nitrogen generated 
significant impact on the antioxidant activity in this assay, since the imines 
1a and 1b (1.9 and 2.1 TE, respectively) showed weaker activities 
compared to their corresponding reduced amine 1c  and 1d (3.2 and 3.9 
TE, respectively) (figure 3.16-3.18). However, both hydrochloride salts 2g 
and 4e (figure 3.15) showed strong antioxidant properties (4.1 and 7.5 TE, 
respectively), although the nitrogen atoms are not nucleophilic, since they 
are involved in the saline bond. This could be explained by the fact that the 
assay is performed at pH 7.4, thus free amines can be formed from the 
original hydrochloric salts. 
Electronic delocalization played a major role in the antioxidant activity in 
this assay, with tetramer 4c to be the most active compound (20.4 TE) and 
monomer 1f (6.4 TE) with similar activity compared to the dimers 2b and 
2f (6.0 and 5.3 TE, respectively) (see figures 3.18, 3.19, 3.21 and 3.22).  
Interestingly the new tacrine-vanillin hybrid 1f showed higher ORAC values 
compared to a series of tacrine-melatonin hybrids reported by Rodriguez-
Franco et al. whose activities ranged from 1.7-4.0 TE (Rodríguez-Franco et 
al., 2006). It is worth noting that tacrine has previously been found to be 
virtually inactive in this assay, being almost one hundred times less active 
than Trolox (Rodríguez-Franco et al., 2006). 
 
3.4.4 DNA Damage Protection Assay 
 
The ability of a selection of vanillin derivatives, vanillin and syringaldehyde 
to prevent oxidative stress-mediated strand breakage in supercoiled DNA 
plasmid was determined using the DNA damage protection assay (Lee et 
al., 2002; Pohl et al., 2018). 
The selection of compounds was based on the presence of different nitrogen 
nucleophilicity and the number of vanillin moieties in their chemical 
structures. 
In this assay the results are expressed as their IC50 values, which are 
defined by the concentration (µM) of compound that is able to protect 50% 
of supercoiled DNA from its conversion to open circular or linear DNA 
mediated by AAPH. 
The determination of the IC50 was made by measuring the band intensities 
of the supercoiled DNA in the gel at each concentration of compound used 
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and compared the intensities obtained with the DNA control. The linear part 
of the curve was used in the equation of the line to obtain the IC50 of each 
compound. 
An example is reported in figure 3.25 for compound 4c. 
 
 
Figure 3.26. Example of DNA protection assay’s results for tetramer 4c. The intensity of each band was 
measured using Image J software and the amount of supercoiled DNA (%) was calculated by comparison 
with the DNA control. The linear portion of the curve was isolated and the IC50 was determined using the 
equation of the line.  
 
The results are reported in table 3.4. 
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Table 3.4. Protective effects of vanillin derivatives against AAPH-mediated DNA damage. 
 
Compound DNA Protection  
(IC50 µM) 
1a 3.8 ± 1.2 
1c 4.1 ± 1.9 
2b 3.6 ± 0.9 
2f 3.8 ± 1.4 
2g 61.5 ± 5.2 
4a 13.6 ± 1.2 
4c 0.6 ± 0.1 
4e 13.9 ± 4.2 
Vanillin 5.6 ± 0.6 
Syringaldehyde 9.5 ± 0.3 
Results from each experiment are expressed as mean ± SD of three independent experiments. 
 
Similar to the ORAC assay, vanillin exhibited a better activity compared to 
its methoxy derivative syringaldehyde, being almost two times more active 
(5.6 and 9.5 µM, respectively). 
Dimer 2f showed similar activity to the corresponding imine (1a) and 
reduced (1c) monomers (3.8, 3.8 and 4.1 µM, respectively) (see figure 
3.17), showing a lack of impact from the nucleophilicity of the nitrogen on 
the activity in this assay. However, protonation of the nitrogen caused a 
dramatic loss of activity, as shown in the hydrochloride salts of dimer 2g 
and tetramer 4e (61.5 and 13.9 µM, respectively), the chemical structures 
of which are shown in figure 3.15. 
Tetramer 4c was the most active compound, with an IC50 of 0.6 µM, being 
almost ten times more active than the starting compound vanillin 
demonstrating the role of electronic delocalisation in the DNA protective 
activity. 
It is interesting to note that a structurally related tetramer reported by Lee 
et al., lacks the ability to delocalise the electrons in the aromatic linker (see 
figure 3.26), showing only detectable DNA protection at concentrations 
above 45 µM, highlighting the role of the electronic delocalisation (see 
figure 3.21) in the activity (Lee et al., 2009). 
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Figure 3.27. Tetramer reported by (Lee et al., 2009). 
 
In addition, compound 4c showed 15% DNA protection at concentrations as 
low as 0.11 µM whereas vanillin showed no protection at concentration of 
2.2 µM. Finally, the removal of the hydroxyl groups from the vanillin 
moieties of tetramer 4c (see figure 3.20) caused a dramatic loss of activity 
(tetramer 4a, IC50 13.6 µM), highlighting the important role of the hydroxyl 
group in DNA protection activity. 
 
3.4.5 Structure Activity Relationship (SAR) 
 
In this chapter, novel vanillin derivatives were tested in different antioxidant 
assays to determine a structure activity relationship (SAR) for this class of 
compounds. 
 
 
Figure 3.28. SAR for this class of vanillin derivatives. The number of vanillin moieties (blue), the 
phenolic and methoxy functionalities of the vanillin core (yellow and green, respectively), the nitrogen 
nucleophilicity (red) and electronic delocalisation (purple) are the key features for the antioxidant 
activity. 
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Syringaldehyde derivatives (1e, 2h and 2i) showed better activities 
compared to their corresponding vanillin derivatives (1d, 2b and 2g) in 
both DPPH and FRAP assays. 
However, in the ORAC assay, a more relevant method to biological systems 
since it is based on peroxyl free radicals and is performed at physiological 
pH, vanillin derivative 1d showed higher scavenging activities compared to 
its corresponding syringaldehyde derivative 1e. 
At the same time, vanillin showed better activities in the same assay 
compared to syringaldehyde. 
In addition, the number of vanillin moieties is strictly linked to the activities 
in DPPH, FRAP and ORAC assays, where tetramers exhibited better results 
when compared to the respective dimers and the monomers. 
However, the number of vanillin moieties in the derivatives had lower 
impact in the activity on DNA protection assay, where the monomer 1c 
showed similar activities compared to its related dimer 2f. The removal of 
one of the substituents in the vanillin moiety, for example the hydroxy or 
methoxy group, caused a dramatic fall in all the antioxidant assays, 
suggesting the major role of the hydroxy group in the scavenging activity 
and the auxiliary contribution of the methoxy group as an electron donor 
group. 
 
For the first time, the nucleophilicity of the nitrogen in all the derivatives, 
has been linked with antioxidant activity; in fact, secondary amines (1c and 
1d) showed better activities in DPPH, FRAP and ORAC compared to their 
corresponding imines (1a and 1b), while tertiary amines (2f) showed better 
activities compared to the secondary amines (1c). Furthermore, the 
presence of electronic delocalisation of electrons associatedc with the 
nitrogen caused a dramatic increase in the antioxidant activities in all the 
assays. For example, both tetramer 4c and monomer 1f showed enhanced 
antioxidant activities in all the assays. In addition, tetramers 4a, 4d and 4f, 
although devoid of the methoxy and hydroxy functionalities of their vanillin 
moieties, achieved strong antioxidant properties in the FRAP assay, 
suggesting the predominant role of the electronic delocalisation in the 
electron transfer antioxidant mechanism of the assay. 
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3.5 Conclusions 
 
Novel vanillin derivatives were tested in a number antioxidant assays based 
on different mechanisms of action:  
 
(i) DPPH assay was performed to investigate the ability of the 
novel compounds to scavenge the synthetic 2,2-diphenyl-1-
picrylhydrazyl free radical. 
 
(ii) FRAP assay was employed to measure the electron transfer 
capacity of the vanillin derivatives acting as reducing agent 
toward Fe3+ ion. 
 
(iii) ORAC assay was applied to determine the hydrogen transfer 
ability of the vanillin derivatives in the scavenging of the 
peroxyl free radical generated by AAPH at physiological pH. 
 
(iv) DNA damage protection assay was employed to determine the 
protective effects of those novel compounds against oxidative 
stress-mediated DNA strand breakage in supercoiled DNA 
plasmid.  
 
In all the assays, most of the novel derivatives showed improved 
antioxidant activities when compared to the starting compound, vanillin.  
Based on the results obtained in the different assays discussed in this 
chapter, a SAR can be presented: the key features responsible for the 
antioxidant activity in this class of novel compounds are: the number of the 
vanillin moieties in the chemical structures, the presence of hydroxy and 
methoxy functionalities in the vanillin core structure, the nucleophilicity of 
the nitrogen atom(s) and the electronic delocalisation of the nitrogen(s) 
lone pair(s). 
Therefore, compound 4c has all the above key features, and was found to 
be the most active compound in this series, showing 700-times fold 
increased activity in DPPH assay, a 50-times fold increase in FRAP assay 
and almost 10-times fold increase in ORAC and DNA damage protection 
assays, when compared to vanillin. 
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Based on the results obtained in the different assays, a monomer (1f), a 
dimer (2b) and a tetramer (4c) were chosen for further testing of their 
ability to protect against oxidative stress in a cellular model. This will be 
discussed in chapter 4. 
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Chapter 4: Protective Effects of 
Vanillin Derivatives in neuroblastoma 
SH-SY5Y Cell Line 
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4.1. Introduction 
 
4.1.1 The Use of SH-SY5Y Cell Line in Neurodegenerative Disease 
Research 
 
The choice of the right cell line for undertaking research on 
neurodegenerative diseases is of critical importance. The molecular and 
biological basis behind neurodegeneration, with particular attention to 
Alzheimer’s disease (AD), will be described in chapter 5. A literature review 
on this topic highlighted that research work in neurosciences use both 
primary neurons and secondary cell lines derived from neuronal cancers. 
The use of primary cultures is desirable because of their non-cancerous 
origins, hence they are more likely to show similar properties to neuronal 
cells in vivo. However, primary cell cultures are not immortal, thus the 
number of cells available for the experiments is limited (Gordon, Amini and 
White, 2013). To deal with this issue, the use of secondary cell lines, which 
are derived from tumours and are immortalized, is a valid option for 
obtaining an unlimited number of cells for experiments. 
 
Neuroblastoma SH-SY5Y cell line used in this work, deposited to the 
American Type Culture Collection (ATCC) in 1970, is a human 
catecholaminergic neuroblastoma derived from SK-N-SH, which resembles 
immature sympathetic neuroblasts in culture (Lopes et al., 2010; 
Kovalevich and Langford, 2013). Despite its cancerous origin and the 
related genetic aberrations, this cell line preserves most genes and 
pathways that are usually dysregulated in Parkinson’s Disease (PD) (Xicoy, 
Wieringa and Martens, 2017), thus making this cell line a good model for 
this particular neurodegenerative disease. However, the use of SH-SY5Y is 
not restricted to PD-related research; in fact, several works reported its use 
in other neurodegenerative disease models, including Alzheimer’s Disease, 
amyotrophic lateral sclerosis (ALS) and neurotoxicity studies (Agholme et 
al., 2010; Ma et al., 2015; Shipley, Mangold and Szpara, 2016; Xicoy, 
Wieringa and Martens, 2017). 
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When undifferentiated (see figure 4.1), SH-SY5Y cells rapidly proliferate, 
growing in clumps and show low dopamine-β-hydroxylase activity which 
converts dopamine into noradrenaline.  
 
 
Figure 4.1. Undifferentiated SH-SY5Y cells (20x magnification, picture size adjusted to fit page). 
 
Furthermore, in the undifferentiated state, the cells are linked to low levels 
of acetylcholinesterase/butyrylcholinesterase and tyrosine hydroxylase 
activities. The latter enzyme is involved in the conversion of tyrosine into L-
dopa, the precursor of dopamine (Xicoy, Wieringa and Martens, 2017). 
Once differentiated, SH-SY5Y cells experience a decrease in proliferation, 
due to cell population growth inhibition, and show markers of mature 
neurons including neuron specific enolase, synaptophysin and a stellate 
shape abundant in neurites (Lopes et al., 2010; Kovalevich and Langford, 
2013; Teppola et al., 2016). The cells can undergo differentiation once 
treated with retinoic acid (RA), phorbol esters, such as 12-O-tetradecanoyl-
phorbol-13 acetate (TPA), dibutyryl cyclic AMP, or cholesterol (Teppola et 
al., 2016). 
 
Differentiated cells showed increased resistance to oxidative stress in recent 
works, displaying higher tolerance to treatment with 6-hydroxydopamine 
(6-OHDA), 1-methyl-4-phenylpyridinium (MPP) (Cheung et al., 2009) and 
2,3-dimethoxy-1,4-naphtoquinone (DMNQ) (Schneider et al., 2011) 
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compared to undifferentiated cells. In addition, differentiation with retinoic 
acid promotes the up-regulation of survival signalling pathways such as Akt 
and ERK1/2, and increases the neuroprotection of differentiated cells in 
response to 6-OHDA insult (Cheung et al., 2009). 
 
For the evaluation of the neuroprotective effects of the novel vanillin 
derivatives, undifferentiated SH-SY5Y cells were chosen due to the easy 
maintenance, the relative weak resistance to oxidative stress and the 
amount of works reported in the scientific literature, facilitating the 
comparison of the results with the latter.  
 
4.1.2 Oxidative Stress Models in SH-SY5Y Cells 
 
Considering the link between oxidative stress and neurodegenerative 
diseases, the development of oxidative stress models is of critical 
importance for the evaluation of protective effects of drugs in 
neurodegenerative research. In the literature, several oxidative stress 
models, based on the use of pesticides, metals and other chemicals, have 
been exploited and optimized in neuroblastoma cell lines. These will be 
further discussed below. 
 
Hydrogen peroxide is enzymatically produced in the mitochondria from 
superoxide free radical and can be converted into hydroxyl free radical 
through Fenton reactions (see equations 3 and 7 in the first chapter, pages 
4-6). The homeostatic concentration of hydrogen peroxide ranges from 1 – 
700 nM and it is hypothesized that at concentration above 1 µM, this can 
induce oxidative stress (Gülden et al., 2010). Whittemore et al. reported 
nuclear changes in cultured cortical neurons cells, for example chromatin 
condensation and fragmentation characteristics of apoptosis after treatment 
with hydrogen peroxide (30 µM) (Whittemore et al., 1995). More recently, 
hydrogen peroxide toxicity has been studied in other neuronal cell lines, 
such as SH-SY5Y and PC-12, with results showing great variability (Othman 
and Yabe, 2015). In particular, SH-SY5Y cells showed different responses 
with respect to hydrogen peroxide toxicity; for example, Ruffels and co-
workers reported a LC50 higher that 750 µM (Ruffels, Griffin and Dickenson, 
2004) whereas Suematsu and co-workers obtained an LC50 lower than 100 
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µM (Suematsu, Hosoda and Fujimori, 2011). The toxicity of hydrogen 
peroxide is believed to lie in its capacity to cause lipid peroxidation, DNA 
oxidative damage and protein oxidation along with its ability to increase 
ERK 1/2, JNK and PKB phosphorylation (Ruffels, Griffin and Dickenson, 
2004; Othman and Yabe, 2015). 
 
Tert-butyl hydroperoxide (tBHP) is a membrane-permeable oxidant 
compound which can generate tert-butoxyl free radicals in an iron-
dependent pathway similar to the Fenton reaction (see figure 4.2), leading 
to lipid peroxidation, depletion of glutathione levels, oxidation of thiols in 
the proteins and reduced cell viability (Zhao et al., 2005), all the hallmarks 
of oxidative stress. 
 
 
Figure 4.2. Mechanism of decomposition of tBHP by Fe2+ adapted from (Hix and Augusto, 1999), with 
copyright agreement © 1999 Elsevier Science Ireland Ltd. 
 
The pesticide rotenone is another well-established oxidative stress model in 
SH-SY5Y cell line (see figure 1.21, page 30, chapter 1), which is able to 
evoke PD symptoms, causing the degeneration of the substantia nigra 
neurons with the induction of cytoplasmic inclusions similar to Lewy bodies 
in vivo, both are hallmarks of PD (Betarbet et al., 2000). Rotenone is a 
well-known complex I inhibitor of respiratory chain in the mitochondria (see 
figure 1.21, page 30 of the first chapter) which forms ROS and 
consequently leads to cell death (Dhanalakshmi et al., 2015). The treatment 
of SH-SY5Y cells with rotenone (250 nM) has been reported to cause 
cellular apoptosis due to the presence of nuclear fragmentation and 
chromatin condensation. However, at higher pesticide concentrations, both 
apoptotic and non-apoptotic morphological changes were observed. 
Similarly to the hydrogen peroxide model, rotenone toxicity is linked with 
activation of JNK and p38 pathways although being not associated to ERK 
1/2 activation (Newhouse et al., 2004). 
 
Rotenone is also used in a more complex oxidative stress model, in 
association with the macrolide antibiotic oligomycin A (see figure 4.3).  
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Figure 4.3. Chemical structure of the macrolide oligomycin A. 
 
Its mechanism of action is based on the inhibition of the subunit Fo (which 
derives its name from being the binding fraction of the oligomycin A) in the 
complex V of the respiratory chain, which is critical for the oxidative 
phosphorylation of ADP to ATP (Lardy, Connelly and Johnson, 1964; 
McCarty, 1992; Kim, Moon and Hwang, 1999) (see figure 4.4). 
 
 
Figure 4.4. Mechanisms of rotenone and oligomycin A cocktail toxicity, adapted from (Kim, Moon and 
Hwang, 1999; Xu, Shang and Jiang, 2016).  
 
Thus, the combination of rotenone and oligomycin A leads to a dual 
mitochondrial disruption; that is the cells are not able to synthesize ATP, 
and ROS are generated beyond the capacity of the cell to buffer them, 
leading to cell death (Canas et al., 2007). 
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6-OHDA (figure 4.5) is a dopamine chemical-related neurotoxin which is 
used in PD models, due to its selective toxicity against dopaminergic 
neurons (Rodriguez-Pallares et al., 2007). 
 
 
Figure 4.5. Chemical structures of dopamine and its related 6-OHDA. 
 
Although the exact mechanism of 6-OHDA-induced toxicity is not completely 
elucidated, it has however been shown that it uses the same catecholamine 
transport system as DA and accumulates in the cytosol of dopaminergic 
neurons. Then, it is rapidly oxidized by molecular oxygen to form H2O2 and 
the corresponding p-quinone, increasing the amount of ROS leading to 
subsequent cell death (Soto-Otero et al., 2000; Rodriguez-Pallares et al., 
2007).  
 
Amyloid peptides Aβ(1-40) and Aβ(1-42) have been recently evaluated for their 
use in oxidative stress models. These proteins, derived from the 110-130 
kDa amyloid precursor protein (APP), represent the major constituents of 
senile plaques, a common hallmark for AD. Recently, it has been shown that 
amyloid-associated free radical generation is linked to the aggregational 
state of the peptides (Monji et al., 2001; Butterfield, Swomley and Sultana, 
2013). Although the mechanism is not completely understood, it has been 
hypothesized that increased β-sheet conformation that occurs during 
protein aggregation causes homolytic bond scission and radical production 
through mechanically activated thermal decomposition. The free radicals 
produced in this process can further react with oxygen to yield peroxyl free 
radicals (Monji et al., 2001). 
 
Finally, transition and heavy metals are known to induce oxidative stress 
through Fenton reaction-like pathways. For example, iron has been reported 
to induce oxidative stress in SH-SY5Y at a concentration of 200 M, 
increasing the levels of lactate dehydrogenase (LDH) and oxidized 
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glutathione and depleting the levels of glutathione peroxidase (GPx) 
(Bermejo-Bescós, Piñero-Estrada and Villar del Fresno, 2008). 
Copper is an essential element that represent the prosthetic group of 
several enzymes and is involved in the transfer of electrons in key reactions 
of metabolism. However, when copper is not bound to proteins, it can cause 
oxidative modifications to proteins, DNA and lipids by leading to the 
formation of ROS (Halliwell and Gutteridge, 1990). In 2005, a study 
revealed the ability of copper sulphate (150 M) to induce ROS in SH-SY5Y 
after 30 minutes exposure. In addition, the cells accumulated this metal in 
the mitochondria, where it caused the depletion of complex I and the α-
subunit of complex V (both reported in neurodegenerative diseases) after 
24 hours exposure with copper sulphate (150 M) (Arciello, Rotilio and 
Rossi, 2005). 
Cobalt is another essential element since it is the metal cofactor of vitamin 
B12 and several enzymes, including dehydrogenases, dehydratases and 
transferases (Kubrak et al., 2011). However, high concentrations of the 
latter can be toxic for humans, animals and plants. Its toxicity is reliant on 
the ability of cobalt to trigger the production of ROS in a Fenton-like 
pathway, leading to oxidative damage to lipids, DNA and proteins (Valko, 
Morris and Cronin, 2005). Recently, cobalt toxicity has been evaluated in 
SH-SY5Y cells and the LC50 was found to be ~50 M (Fedorova et al., 2016).  
 
4.1.2 Neuroprotective Effects of Natural and Synthetic Antioxidants 
 
The strong link between oxidative stress and neurodegenerative diseases 
(Smith et al., 2000; Jenner, 2003; Rosini et al., 2013; Blesa et al., 2015) 
has led to the proposal for the use of antioxidants for the prevention or 
treatment of PD and AD. For several years, a large number of natural and 
synthetic antioxidants have been reported to protect SH-SY5Y cell line in 
different models of oxidative stress. 
 
For example, naturally occurring curcumin (see figure 1.7, page 14 of the 
first chapter), the principal curcuminoid in turmeric, showed protective 
effects on SH-SY5Y cells in two different models, involving Aβ aggregation 
(Thapa, Jett and Chi, 2016) and 6-hydroxydopamine (6-OHDA)-induced 
toxicity (Jaisin et al., 2011). In these studies, curcumin showed protective 
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effects on SH-SY5Y cells by increasing the cell viability by almost 35% at 
concentrations as low as 5 M, compared to the amyloid control, modifying 
the amyloid aggregation pathway and protecting cell membranes against 
amyloid-induced membrane disruption (Thapa, Jett and Chi, 2016). In 
addition, curcumin (20 M) protected the same cell line against 6-OHDA (25 
M), almost completely preventing its toxicity; even concentrations as low 
as 5 M showed significant protection. Furthermore, in the same study, 
curcumin significantly reduced the 6-OHDA-induced ROS generation in SH-
SY5Y cells at concentrations as low as 5 M and reduced the 
phosphorylation of p53, which plays a critical role in cellular apoptosis by 
translocating to the nucleus and increasing the expression of pro-apoptotic 
genes (Jaisin et al., 2011). 
 
Resveratrol (see figure 1.6, page 13, chapter 1), a natural polyphenol 
present in red wine, showed protective effects toward SH-SY5Y cells in both 
amyloid Aβ (10 M) and H2O2 (50 M) oxidative stress models at 
concentrations of 15 M. In addition, resveratrol completely restored the 
levels of the antioxidant glutathione (GSH, see figure 1.13, page 22, 
chapter 1) after treatment with the amyloid Aβ stressor, but was unable to 
restore the level of GSH in the hydrogen peroxide model, suggesting 
different mechanisms of action for the cellular protective effects (Savaskan 
et al., 2003).  
 
Salidroside ((2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(4-
hydroxyphenethoxy)tetrahydro-2H-pyran-3,4,5-triol) (figure 4.6), a 
phenylpropanoid glycoside isolated from Rhodiola rosea, showed significant 
protection against hydrogen peroxide (150 M)-induced oxidative insult in 
SH-SY5Y cells, reducing the H2O2-induced cytotoxicity by almost 20% at 
concentrations ranging from 10-100 M, showing similar activity to vitamin 
E (50 M) (Zhang et al., 2007). 
 
 
Figure 4.6. Chemical structure of salidroside. 
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The protective effects of salidroside in this oxidative stress model included 
the induction of several antioxidant enzymes such, as haeme-oxygenase 1, 
the upregulation of anti-apoptotic genes, such as Bcl-2, and the 
downregulation of the pro-apoptotic gene, Bax (Zhang et al., 2007). 
In another study, salidroside showed protective effects in a different 
oxidative stress model based on β-amyloid-induced cytotoxicity. Pre-
treatment (50 and 100 M) with the glycoside increased cell viability by 
almost 30% compared to the positive control amyloid (25 µM). In addition, 
salidroside reduced the amount of intracellular ROS generated when treated 
with β-amyloid protein compared to the positive control, and inhibited the 
amyloid-induced phosphorylation of JNK and p38 MAP kinase (Zhang et al., 
2010). 
 
As reported in chapter 1, Dhanalakshmi et al. recently reported the 
protective effect of vanillin (see figure 1.20, page 29, chapter 1) toward SH-
SY5Y cells in a PD model employing the pesticide rotenone (Dhanalakshmi 
et al., 2015). In that study, the cells that were treated with vanillin, showed 
a concentration-dependent increase in viability after treatment with 
rotenone (100 nM) compared to the control, with maximum protection at 
100 nM. In addition, vanillin (100 nM) showed a decrease in ROS production 
by almost one third compared to the rotenone control, with decreased 
expression of pro-apoptotic proteins such as p38, p-JNK and p-ERK 
(Dhanalakshmi et al., 2015). 
 
Olivieri et al. reported the protective effects of the endogenous antioxidant, 
melatonin (figure 4.7) an indoleamine hormone produced by the pineal 
gland against oxidative stress induced by cobalt is SH-SY5Y cells (Olivieri et 
al., 2001). 
 
 
Figure 4.7. Chemical structure of the pineal hormone melatonin. 
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Pre-treatment with melatonin (1  M) for 12 hours significantly increased 
the cell viability and GSH levels compared to the cobalt control (330 M. In 
addition, treatment with cobalt was linked with increased Aβ release from 
SH-SY5Y, which was significantly reduced after treatment with melatonin 
(1 M) (Olivieri et al., 2001). 
 
A series of synthetic derivatives of melatonin has been recently reported by 
Benchekroun et al. to protect SH-SY5Y cells in a rotenone/oligomycin A 
model of oxidative stress (Benchekroun et al., 2016). These derivatives 
were obtained by the fusion of melatonin with a ferulic acid and a tacrine 
moiety (see figure 1.30, page 37, chapter 1). They showed an increase in 
cell viability up to 60% when the cells were pre-treated with these 
compounds at concentrations of 1 or 3 µM, before incubating with a stressor 
cocktail (rotenone/oligomycin; 30 and 10 µM, respectively) for 24 hours 
(Benchekroun et al., 2016). In addition, the authors reported the protective 
effects of these compounds in other oxidative stress models, such as H2O2 
(300 µM) and the amyloid proteins Aβ(1-40) and Aβ(1-42) (30 µM), with 
increases in cell viability ranging from 5-85 % compared to the 
corresponding control. Finally, the compounds turned out to be strong 
antioxidants, with ORAC values up to 9 Trolox Equivalents, as well as 
exhibiting Nrf2 activation effects. Taken together, this could explain the 
highly protective properties of those derivatives in the cellular models 
(Benchekroun et al., 2016). 
 
Synthetic derivatives of naturally occurring lipoic acid (see figure 1.14, page 
23, chapter 1), have been reported by Rosini et al. to exert neuroprotective 
effects in SH-SY5Y cellular models of oxidative stress. In particular, 
lipocrine (figure 4.8) showed, along with its strong anti-cholinesterase 
activity (at nanomolar concentrations), a decrease by almost 50% of ROS 
detected in SH-SY5Y cells (at concentrations ranging from 0.1-50 µM), after 
exposure to stressor tert-butyl hydroperoxide, when compared to the 
control (Rosini et al., 2005). 
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Figure 4.8. Chemical structure of the synthetic lipoic acid derivative lipocrine, reported by (Rosini et al., 
2005). 
 
4.1.3 Aims and Objectives   
 
The critical role of oxidative stress in neurodegenerative diseases has led to 
the search for novel molecules that provide antioxidant protection and 
assist prevention or treatment of such diseases. 
 
The aim of the experiments described in this chapter was to evaluate the 
protective effects of selected novel vanillin derivatives using two different 
oxidative stress models: hydrogen peroxide and a mixture of 
rotenone/oligomycin A. 
 
In order to achieve the above aim, the following objectives were completed: 
 
- Assessment of cytotoxic effects of selected vanillin derivatives in SH-
SY5Y cell line. 
- Evaluation of protective effects of selected vanillin derivatives from 
hydrogen peroxide and rotenone/oligomycin A induced toxicity in the 
same cell line. 
- Determination of the ability of selected vanillin derivatives to prevent 
hydrogen-peroxide induced ROS formation in SH-SY5Y cells. 
- Evaluation of protective effects of selected vanillin derivatives from 
hydrogen peroxide-induced DNA damage. 
- Determination of the ability of selected vanillin derivative to trigger 
Nrf2 pathway. 
 
For clarity, a summary of the work described in this chapter is described in 
Figure 4.9. 
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Figure 4.9. Summary of the experimental work described in this chapter. 
 
4.1.4 Introduction to the Analytical Techniques used in this chapter  
 
4.1.4.1 Cell Viability Measurement-MTT assay 
 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) assay 
was employed for the measurement of the cell viability in the cytotoxicity 
experiments and in the protection studies against hydrogen peroxide and 
the rotenone/oligomycin A cocktail. The latter assay is a colorimetric 
method that measures their metabolic activity, which is often extrapolated 
to indicate cell viability. It was first introduced by Pearse in 1957 for the 
evaluation of dehydrogenase activity (Pearse, 1957) and it is currently 
widely used for the assessment of cell viability along with other techniques 
such as resazurin assay (Borra et al., 2009), or the trypan blue exclusion 
assay (Tennant, 1964). The MTT assay relies on the ability of viable and 
metabolically active cells to reduce this salt into its insoluble formazan 
form; the latter is characterized by the purple crystal structure, which can 
be dissolved with an appropriate organic solvent (for example, DMSO). The 
absorbance of the resulting solution can be measured with a 
spectrophotometer (λ=560 nm). The mechanism of MTT assay is depicted in 
figure 4.10. 
 
141 
 
 
Figure 4.10. MTT conversion in metabolic active cells.  
 
4.1.4.2 ROS determination using 2',7'–dichlorodihydrofluorescin 
diacetate (H2DCFDA) dye 
 
For the measurement of ROS, different techniques, such as 
chemiluminescence of luminol, lucigenin, cytochrome C reduction, xylenol 
and 2',7'–dichlorodihydrofluorescin diacetate (H2DCFDA) can be employed 
(Dahlgren and Karlsson, 1999; Eruslanov and Kusmartsev, 2010). H2DCFDA 
is one of the most widely used dye used for ROS measurement since it is 
easy to use, sensitive to changes in the redox state of the cells and 
inexpensive. For these reasons, this dye was employed for the evaluation of 
the alleviating properties of vanillin derivatives against the ROS production 
induced by hydrogen peroxide. H2DCFDA is resistant to oxidation, since the 
phenolic moieties are protected by the acetate groups but, once taken up by 
the cells, it is deacetylated by intracellular esterases and converted into 
2’,7’–dichlorodihydrofluorescein (DCFH) as depicted in figure 4.11.  
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Figure 4.11. Mechanism of fluorescence enhancement of the H2DCFDA induced by ROS, adapted from 
Eruslanov and Kusmartsev (2010), with copyright agreement © 2010, Humana Press, a part of Springer 
Science Business Media, LLC. 
 
The loss of the acetate groups makes the DCFH more hydrophilic and 
unable to cross the cell membranes again, and for this reason the dye is 
retained within the cells. Finally, the dye can be then be oxidized by ROS, 
yielding the fluorescent dichlorofluorescein (DCF). The resulting 
fluorescence can be measured, with appropriate excitation sources and 
emission filters (ex: 490/20, em: 525/20) (Wojtala et al., 2014), with multi-
well plate reader, fluorescence microscope, fluorimeter or flow cytometer. 
 
Although the use of a multi-well plate reader offers the advantage of 
measuring the fluorescence in situ, avoiding the use of trypsin to detach the 
cells, it is only able to measure the total fluorescence, without 
discriminating between extracellular and intracellular fluorescence. For this 
reason, flow cytometry was employed to detect the fluorescence within the 
cells. In addition, this technique can produce quantitative data on the 
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number of cells emitting fluorescence instead providing the arbitrary 
fluorescence units. On the other hand, cells must be in suspension, 
requiring the use of trypsin, which is known to induce oxidative stress, and 
controlled conditions are needed (Eruslanov and Kusmartsev, 2010). 
A schematic representation of flow cytometry is depicted in figure 4.12. 
 
 
Figure 4.12. Schematic of a flow cytometer. 
 
Cells are loaded into the instrument and are aligned in single file; where 
they pass through the excitation laser, also known as the interrogation 
point. Detectors can collect data regarding the forward scatter (FSC), the 
side scatter (SSC) and fluorescent emissions. Scattered light can be used to 
measure volume (FSC) and morphological complexity (SSC) of the cells, 
whereas the fluorescence emission is proportional to the amount of 
fluorescent probe within a cell. Hence, the ROS amounts of different 
samples can be compared depending on the counts of fluorescent cells. 
 
4.1.4.3 DNA Damage Evaluation using the COMET assay 
 
For the evaluation of protective effects of vanillin derivatives against 
oxidative stress-induced DNA damage, the comet assay was employed. The 
latter, also known as single cell gel electrophoresis, was firstly introduced 
by Ostling and Johanson in 1984 for the detection of DNA damage in 
mammalian cells after exposure to radiation (Ostling and Johanson, 1984). 
In the past decades, the DNA comet assay has been employed in a wide 
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number of human clinical studies, with several variants of the assay having 
been optimized. The alkaline comet assay was employed in this study. The 
latter is useful to detect double and single DNA strand breaks and it is 
based on the use of high pH solution (>13) after cell lysis to unwind the 
supercoiled DNA. If strand breaks are present, the DNA supercoils, which 
are negatively charged, will relax and migrate toward the anode during the 
electrophoretic process, forming a shape similar to a comet, hence the 
name of the assay (Pu, Wang and Klaunig, 2015). 
 
For the evaluation of the protective effects of selected vanillin derivatives 
against oxidative stress-induced DNA damage, the cells were pre-treated 
with selected compounds before the addition of hydrogen peroxide (300 
µM). Cells were then harvested with trypsin, centrifuged and suspended in 
low melting point agarose gel on top of frosted microscope slides. The latter 
were suspended in lysis buffer containing high salt and detergent to remove 
membranes, cytoplasm and nucleoplasm, leaving only the nucleoid, 
consisting of the nuclear matrix composed of RNA, proteins and DNA. For 
the survival of the supercoiled DNA, the inability of the latter to freely rotate 
is of critical importance and the presence of agarose gel, which embeds the 
cells causes DNA immobilization (Collins, 2004). After lysis, the alkali 
treatment caused the unwinding of the double DNA strand and the DNA is 
ready for electrophoresis. DNA containing strand breaks loses its 
supercoiling and become free to extend toward the anode leading to the 
typical “comet” shape. On the other hand, undamaged DNA lacks free ends 
and its large size prevents the migration toward the cathode leading to the 
absence of the “comet” shape. For DNA visualization, a fluorescent dye such 
as 4′,6-diamidino-2-phenylindole (DAPI) is needed along with a 
fluorescence microscope. DAPI is a DNA intercalating agent which binds to 
adenine-thymine rich regions of double stranded DNA. The comets are 
finally scored according to their shape with arbitrary numbers ranging from 
0 (no DNA damage, circular comets) to 4 (maximum damage, small head 
and big tail). The scoring criteria is reported in figure 4.14 in the methods 
section. 
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4.1.4.4 Western Blotting for the Detection of Nuclear Nrf2 protein 
 
As described in chapter 1, (pages 18-20), the nuclear factor E2-related 
factor 2 (Nrf2) is the main mediator of ARE activation. Under physiological 
conditions, Nrf2 is bound to actin-associated keap1 protein and 
compartmentalized in the cytoplasm. Under oxidative conditions, Nrf2 
translocates into the nucleus, inducing the transcription of antioxidant 
genes (Itoh et al., 1999; Kobayashi et al., 2004; Nguyen, Nioi and Pickett, 
2009; Ma, 2014). 
 
In order to evaluate the ability of the selected compound to activate the 
Nrf2 antioxidant pathway, Western Blot analysis was employed. The latter is 
a technique developed by Towbin, Staehelint and Gordon in 1977, aimed to 
separate and transfer ribosomal proteins from gel containing urea (Towbin, 
Staehelint and Gordon, 1979). Two years later, Burnette introduced the 
name “western blotting”, playing with the name of two previously reported 
techniques, southern and northern blotting, for the separation of DNA and 
RNA, respectively (Burnette, 1981). 
 
This technique is based on the separation of the proteins according to their 
molecular weight in a sample (for example a cell lysate), through 
electrophoresis and consequent transfer of the latter into a polyvinylidene 
fluoride (PVDF) or nitrocellulose membrane. The membrane is then blocked 
with 5% milk or bovine serum albumin (BSA) for a usual period of one hour, 
and then incubated with an appropriate dilution of primary antibody 
(specific for the protein of interest) overnight at 4°C (Kaur and Bachhawat, 
2009; Mahmood and Yang, 2015). The membrane is washed with TBST, 
which is composed of Tris-buffered-saline + polysorbate 20 (known as 
Tween 20) and incubated with an optimized dilution of the secondary 
antibody for one hour at room temperature. After washing the membrane 
with TBST, protein detection is carried out employing different techniques 
using chemiluminescent reagents, organic dyes, fluorescent labels, silver 
staining, colloidal particles or autoradiography (Kurien and Scofield, 2006).  
 
For this study, the cells were incubated with the selected vanillin derivative 
for different periods, then harvested, washed with PBS and centrifuged. 
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Cells were lysed and the nuclear extract was collected. The protein content 
for each lysate was quantified through Bradford assay and 20 µg of protein 
from each sample was loaded for the electrophoresis run. The proteins were 
then transferred into a PVDF membrane and the procedure above was 
followed. For the detection of the protein of interest, a mouse primary 
antibody for Nrf2 was employed and an anti-mouse secondary antibody was 
added after a careful washing procedure (figure 4.13). 
 
 
Figure 4.13. Principle of protein detection through Western Blotting. 
 
The secondary antibody is conjugated with Horseradish peroxidase (HRP), a 
haeme-containing enzyme found in the horseradish plant that utilises 
hydrogen peroxide to oxidise organic and inorganic compounds (Veitch, 
2004). This enzyme catalyses the oxidation of luminol induced by hydrogen 
peroxide (the components of the chemiluminescent detection kit) as 
depicted in figure 4.14.  
 
 
Figure 4.14. Reaction mechanism of luminol-based chemiluminescence, adapted from Alegria-Schaffer, 
Lodge, and Vattem (2009). 
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The HRP-catalysed reaction of luminol yields the excited state of the 
oxidized product, which decays to the ground state emitting light at 425 
nm. The chemiluminescent signal is finally acquired using dark room with a 
development technique. 
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4.2 Materials and Methods 
 
4.2.1 Materials 
 
All reagents were purchased from Sigma Aldrich, unless otherwise stated, 
without any further purification. 
 
30% Acrylamide/Bis solution 19:1            Bio-Rad 
Agarose gel (high melting point)         Fisher Scientific 
Antibody Nrf2 A-10         Santa Cruz 
Bradford Protein Assay              Bio-Rad 
Developer and Fixer (RP X-OMAT LO)            Kodak, carestream 
DMEM (1x) high glucose, pyruvate         Fisher Scientific 
FBS               Fisher Scientific 
Goat Anti-Mouse IgG H&L (HRP)                             Abcam 
H2DCFDA              Invitrogen 
HALTTM Protease Inhibitor Cocktail (100x)        Fisher Scientific 
Milk powder            Asda 
MTT               Acros Organics 
NE-PER Nuclear and Cytoplasmic Extraction Reagents          Fisher Scientific 
Phosphate Buffered Saline (PBS) Tablets                      Oxoid 
Precision Plus Protein Dual Colours Standards                  Bio-Rad 
Sheath Buffer (flow cytometry)          Beckman Coulter Inc 
SuperSignal™ West Pico PLUS Chemiluminescent Substrate  Fisher Scientific 
Tris Base              Fisher Scientific 
Triton X-100             Acros Organics 
 
4.2.2 Instrumentation  
 
A Leica DMIL microscope was used for cell culture. 
Absorbances for MTT assay were measured using a Bio-Rad iMark 
microplate reader. 
Flow cytometry analysis was carried out using Coulter Epics XL-MCL flow 
cytometer. 
DNA comet assay was performed using Anachem 3003 electrophoretic tank 
and a Leica DMRB fluorescence microscope was used for the comet scoring. 
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4.3 Methods 
 
4.3.1 Cell Culturing 
 
SH-SY5Y cells were maintained as previously reported with minor 
modifications (Smith et al., 2005). DMEM media supplemented with 10% 
FBS, 1% non-essential amino acids (NEAA) and 1% penicillin (100 U/ml), 
streptomycin (100 µg/ml) was employed. Cell plates and flask were 
maintained in a 5 % CO2 humidified incubator at 37°C. Cells were passaged, 
once 80% confluence levels were reached, by discarding the old media, 
washing with PBS and trypsinizing for 5 minutes. Trypsin was deactivated 
with fresh media and the cells were centrifuged for 5 minutes at 1500 rpm, 
414 g. The supernatant was then discarded and the cells were suspended in 
fresh media. Finally, the cells were counted using a haemocytometer and 
seeded in plates or flasks for further experiments.  
 
4.3.2 Cellular Toxicity of Selected Vanillin Derivatives 
 
For the evaluation of cytotoxicity, the selected vanillin derivatives were 
tested at different concentrations and the MTT assay was employed for the 
evaluation of cell viability. The assay was carried out according to Barron et 
al. with minor changes (Barron et al., 2010). Briefly, 7000 cells (100 µl) 
were seeded in a 96-well plate and allowed to attach for 24 hours. Then, 50 
µl containing different concentrations of drug was added in the 
corresponding wells, whereas 50 µl of media was added to the control wells. 
The plate was incubated for 24 hours. On the following day, cell morphology 
at each condition was observed under a light microscope before culture 
media was removed from each well and 100 µl of sterile-filtered (0.22 µm) 
MTT solution (1 mg/ml) was added. After 4 hours of incubation, the MTT 
solution was pipetted off from each well and 100 µl of DMSO was added in 
each well. The plate was wrapped in foil and gently shaken for 20 minutes, 
then the absorbance was measured at 560 nm. Three independent 
experiments were performed for each compound tested. 
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4.3.3 Protective Effects of Selected Vanillin Derivatives in presence of 
H2O2 or Rotenone/Oligomycin A Cocktail stressor 
 
The same vanillin derivatives tested for their toxicity with SH-SY5Y cells 
were studied, along with vanillin, for their protective effects against H2O2 
(400 µM) and rotenone/oligomycin A cocktail (3 and 1 µM, respectively) 
toxicity. The use of these specific concentrations of stressor is linked to their 
toxicity on the SH-SY5Y cell line and represent approximately the LC50 (data 
not shown). The experiments were run using a 96-well platform; briefly, 
7000 cells (100 µl) were seeded in each well and allowed to attach for 24 
hours. 50 µl containing different concentrations of drug was added in the 
corresponding wells, whereas 50 µl of media was added to the control wells. 
The plate was incubated for 24 hours. Then, 50 µl of H2O2 (1.6 mM, to yield 
a 400 µM final concentration in the well) or 50 µl of rotenone/oligomycin 
(12 and 4 µM, to yield a final concentration of 3 and 1 µM in the well, 
respectively) were added in the corresponding wells. After 24 hours (for 
hydrogen peroxide) or 48 hours (for the rotenone/oligomycin mixture) 
incubation, the culture media was removed from each well and the cell 
viability was measured through MTT assay, following the procedure 
mentioned above. Three independent experiments were performed for each 
compound tested. The 96-well plate set-up is shown in figure 4.15. 
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Figure 4.15. 96-well plate settings for MTT assay. Media control is coloured in purple whereas the 
hydrogen peroxide or the rotenone/oligomycin mixture controls are rendered in pink. The different shades 
of blue represent different concentrations of the vanillin derivative tested (1f, 2b or 4c). 
 
4.3.4 Protective Effects of Vanillin Derivatives from ROS Induced by 
H2O2 
 
The ability of the selected vanillin derivatives to alleviate the ROS 
production induced by hydrogen peroxide was evaluated. For the detection 
of ROS in SH-SY5Y cells, 2,7’-dichlorodihydrofluorescein diacetate 
(H2DCFDA) was employed. Cells were cultured in T25 culture flasks (1 
million in 3 ml of media) in duplicate and allowed to attach for 24 hours. 
Then, cells were treated with compound 2b (1ml, 800 µM, for a final 
concentration of 200 µM) or compound 4c (1 ml, 40 µM, for a final 
concentration of 10 µM) for an additional 24 hours, whereas the controls 
were treated with media. After 24 hours, H2O2 (1ml, 5 mM, for a final 
concentration of 1 mM) was added and the cells were incubated for 30 
minutes. The media was then removed and 5 ml of H2DCFDA (1.2 µM) in 
fresh media was added. The cells were incubated for 4 hours, washed twice 
with PBS, trypsinized and collected using PBS. The cells were then 
centrifuged (5 mins, 1500 rpm, 414 g), the supernatant discarded and 
resuspended in 1 ml of PBS for flow-cytometry analysis. Three independent 
experiments were performed.  
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4.3.5 DNA Damage Determination by Comet Assay 
 
Comet assay was performed in a 12-well plate platform following the 
method reported by Duthie et al. with minor modifications (Duthie et al., 
2009). Cells (105 in 800 µl of media) were seeded in each well and allowed 
to attach for 24 hours. Then, 200 µl of compound 2b (1 mM, for a final 
concentration of 200 µM) or 200 µl of compound 4c (50 µM, for a final 
concentration of 10 µM) was added to the corresponding wells, whereas 200 
µl of fresh media was added to the control wells. After 24 hours incubation, 
H2O2 (1 ml, 600 µM, for a final concentration of 300 µM) was added to the 
corresponding wells and the plate was incubated for 30 minutes. The 
concentration of hydrogen peroxide employed in this experiment was based 
on previous studies reported by Dr. Pohl in her PhD thesis “The potential 
application of rapeseed pomace extracts in the prevention and treatment of 
neurodegenerative diseases” (Pohl, 2019) which reported a significant 
amount of damage without detrimental DNA damage or cell death. Cells 
were then washed with PBS and harvested using trypsin (100 µl); the latter 
was inactivated with 900 µl of fresh media and the cells were transferred 
into Eppendorf® tubes. Cells were counted using a haemocytometer, 
centrifuged for 5 minutes (4°C, 2000 rpm, 370 g) and the supernatant 
carefully removed using a pipette. The pellets obtained were kept on ice. 
The bottom gel (1% w/v standard melting point agarose) was prepared and 
kept at 40°C to avoid solidification, in a water bath, then 80 µl of the latter 
was pipetted on frosted microscopy slides (Richardson Supply Ltd) and 
covered with 18x18 mm coverslips (Fisher Scientific). The gels were left to 
solidify at 4°C for 10 minutes. A 1% (w/v) low melting point agarose gel 
was prepared and a certain amount, depending on the number of cells 
counted for each condition, was pipetted into the Eppendorf® tube 
containing the cell pellet to achieve a concentration of around 3x104 cells in 
85 µl of gel. The coverslips were removed from the top of the previous gel 
and a second layer of gel, containing the desired number of cells, was 
added on top. New coverslips (18x18 mm) were added and the gel were left 
to solidify for 10 minutes. The coverslips were then removed and the 
microscopy slides were soaked in lysis buffer (2.5 M NaCl, 0.1 M EDTA, 10 
mM Tris and 4% Triton X-100, pH 10) for one hour at 4 °C. At that point, 
the slides were placed in the electrophoresis tank, containing the 
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electrophoresis buffer (0.3 M NaOH, 1 mM EDTA, pH 13), for the alkaline 
treatment (40 minutes at 4 °C). Finally, the electrophoresis was run at 25 V 
for additional 40 minutes at 4°C. After the electrophoresis, the slides were 
washed three times with neutralising buffer (0.4 M Tris, pH 7.5) and the 
gels were covered using 22x22 mm microscope coverslips (Fisher Scientific) 
and stored in the fridge. For the scoring, coverslips were removed and 20 μl 
of DAPI staining solution (1 μg/ml in distilled water) was added to the gels. 
Comets were scored manually according to Heuser et al. (Heuser et al., 
2007) using a Leica DMRB fluorescence microscope (excitation 340-380 nm, 
emission 425 nm). 100 comets were scored (with scores ranging from 0 to 
4 for each comet, depending on the intensity of DNA damage, see figure 
4.16) and the values were summed to obtain arbitrary numbers between 0-
400 for each scored gel.  
 
 
Figure 4.16. DNA Comet scoring criteria. 
 
 
154 
 
For each experimental condition three gels were scored, and their mean 
value calculated. Statistical analysis was done on three independent 
experiments. 
 
4.3.6 Evaluation of Nrf2 Pathway Activation 
 
Nrf2 activation studies were performed in T25 flasks. Cells (1.5x106) were 
seeded in a total volume of 2.997 ml and allowed to attach for 24 hours. 
The next day, compound 4c was added (3 µl, 10 mM in pure DMSO, to yield 
a final compound concentration of 10 µM) whereas 3 µl of DMSO was added 
in the control flask. The cells were incubated for different periods (3, 6 and 
24 hours), then washed with PBS, trypsinized, centrifuged, washed twice 
with PBS and suspended in PBS in pre-cooled Eppendorf® tubes. Cells were 
centrifuged at 1500 rpm, 414 g, for 5 minutes and the supernatant was 
discarded. Nuclear extraction was performed following the instructions 
reported on the kit employed for the experiment (NE-PER nuclear and 
cytoplasmic extraction reagents, Fisher Scientific). Briefly, the cell pellets 
were suspended in ice-cold Cytoplasmic Extraction Reagent I (CER I) (200 
µl) containing 2 µl of protease inhibitor cocktail, vortexed for 15 seconds 
and incubated on ice for 10 minutes. Then, 11 µl of Cytoplasmic Extraction 
Reagent II (CER II) was added and the Eppendorf® tubes were vortexed for 
5 seconds before the incubation on ice for 1 minute. The tubes were 
vortexed again for 5 seconds and centrifuged at 16000 g for 5 minutes at 
4°C. the supernatants (cytoplasmic extracts) were collected and stored at -
80°C and the insoluble pellets obtained were suspended in 100 µl of ice-cold 
Nuclear Extraction Reagent (NER) containing 1 µl of protease inhibitor 
cocktail. The tubes were vortexed for 15 seconds and incubated on ice for 
40 minutes, vortexing for 15 seconds every 10 minutes. The tubes were 
finally centrifuged at 16000 g for 10 minutes at 4°C and the supernatant 
(nuclear extract) was transferred into a pre-chilled microtube and stored at 
-80°C until further use. 
 
The protein content of each sample was determined using the Bradford 
assay; the latter is a quick and common method for the quantification of 
proteins based on the absorption shift of the Coomassie Brilliant Blue G-250 
dye, from 465 to 595 nm, once bound to protein (Bradford, 1976). Briefly, 
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BSA standards ranging from 0.2 to 2 mg/ml were prepared in PBS. 5 µl of 
each sample or standard was pipetted along with 250 µl of Bradford reagent 
in the corresponding well of a 96-well plate and incubated for 5 minutes. 
The absorbances were measured at 595 nm and the protein content of each 
sample was measured by comparison with the standard curve obtained for 
the BSA. 
 
Once the protein content of each sample had been determined, the volume 
corresponding to 20 µg of protein from each sample was loaded in the 
corresponding well of a 13% polyacrylamide gel along with the protein 
ladder control (Precision plus protein dual Color standards, Bio-Rad).  
 
The latter was prepared in two steps; firstly, the separating gel was 
prepared by mixing 2.4 ml of deionized water with 3.47 ml of 
acrylamide/bis solution, 2ml of Tris solution (1.5 M, pH 8.8), 80 µl of 
sodium dodecyl sulfate (SDS) solution (10% w/v), 80 µl of ammonium 
persulfate (APS) solution (10% w/v) and 8 µl of tetramethylethylenediamine 
(TEMED). The solution obtained was pipetted (4 ml) between two glass 
plates (casting frames) on the casting stands previously set up. Propan-2-ol 
(400 µl) was added on top of the gel to remove air bubbles and the gel was 
left to solidify for 30 minutes. The stacking gel was then prepared, by 
mixing 2.6 ml of deionized water with 1 ml of acrylamide/bis solution, 1.25 
ml of Tris solution (0.5 M, pH 6.8), 50 µl of SDS solution (10% w/v), 50 µl 
of APS solution (10% w/v) and 5 µl of TEMED. The solution obtained (2 ml) 
was added on top of the separating gel after the removal of the propan-2-ol 
lying above the latter. The well-forming comb was inserted and the gel was 
allowed to solidify for 20 minutes. The glass plates were taken out the 
casting frames, placed in the cell buffer dam and covered with running 
buffer (25 mM Tris-HCl, 200 mM glycine, 0.1% w/v SDS) in the 
electrophoresis tank. The electrophoresis was run for 1.5 hours at 120 V 
and the gel was separated from the glass plates. A PVDF membrane was 
activated by soaking it in methanol and was placed on top of the gel, then 
both were placed between two filter papers. A sponge was placed at the top 
and the bottom of the equipment and placed in the specific cassette for the 
protein transfer. The cassette was positioned in the electrophoresis tank 
and covered with transfer buffer (20% methanol, 80% of the previous 
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running buffer) before the electrophoretic process (100 V for 1 hour). The 
presence of the colored protein ladder in the PVDF membrane confirmed the 
successful transfer of the proteins from the gel. The membrane was blocked 
with milk (5% w/v) for 1 hour before the addition of the Nrf2 antibody 
(1:5000 dilution, 4 µl of antibody in 20 ml of 5% milk). The membrane was 
incubated overnight at 4°C. The next day, the membrane was washed with 
TBST solution (3x15 ml) and incubated with the HRP-conjugated secondary 
antibody (1:10000 dilution, 2 µl of secondary antibody in 20 ml of 5% milk) 
for 1 hour at room temperature. After washing with TBST solution (3x15 
ml), the membrane was placed over cling film and 2 ml of the 
chemiluminescent reagent (SuperSignal™ West Pico PLUS 
Chemiluminescent Substrate, Fisher Scientific) was pipetted on top. The 
membrane was incubated for 5 minutes in the dark and the excess reagent 
was removed. The membrane was placed in a film cassette, transferred into 
a dark room and placed close to an x-ray film. The cassette was sealed and 
soaked in the developer solution for 2 minutes, washed with water for 1 
minute, soaked again in the fixer solution and washed again with water for 
a minute (RP X-OMAT LO Kodak, Carestream). Finally, the cassette was 
opened and the x-ray film was left to dry. 
 
4.3.7 Statistical Analysis  
 
Statistical analysis was carried out using GraphPad Prism 6. The statistical 
methods used for each experiment are described in the results section. At 
least 3 replicates were performed for each experiment and the results are 
shown as mean ± standard deviation.  
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4.4 Results and Discussion 
 
4.4.1 Cellular Toxicity of Selected Vanillin Derivatives 
 
The monomer 1f, the dimer 2b and the tetramer 4c were selected for the 
evaluation of their protective effects towards SH-SY5Y in different models of 
oxidative stress. This selection was based on their antioxidant properties 
(described in chapter 3) and their cholinesterase and amyloid inhibitory 
properties, which will be described and discussed in chapter 5. However, to 
achieve this objective, a preliminary screening regarding their toxicity 
towards the same cell line needed to be assessed in order to determine 
their safe working concentrations.  
MTT assay was employed to measure cell viability; the latter is a widely 
employed assay based on the conversion of the water soluble MTT into its 
reduced insoluble reduced form (formazan) which can be dissolved in DMSO 
to yield a deep purple colouration with a maximum absorbance at 560 nm. 
The LC50, corresponding to the concentration needed to kill the 50% of the 
cells, was determined using the following formula: 
 
% 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠 =
𝐴𝐵𝑆(𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)
𝐴𝐵𝑆(𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
∗ 100 
 
Three independent experiments were performed for each compound tested. 
MTT performed on the three vanillin derivatives (1f, 2b and 4c) showed low 
toxicity for the dimer 2b and modest toxicity for both monomer 1f and 
tetramer 4c. 
 
Compound 2b was tested at concentrations ranging between 25 and 1000 
µM and showed the lowest toxicity toward SH-SY5Y cell line with LC50 value 
higher than 1 mM and significant toxic effects only observed at 
concentrations of 800 µM or above (see figure 4.17). 
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Figure 4.17. MTT cell viability assay using compound 2b (25 - 1000 µM, for 24 hrs). One-way ANOVA 
analysis was used for the comparison between the media control and each condition. ***p ≤ 0.001, ns = 
not significant, n=3. 
 
 
Monomer 1f and tetramer 4c (figure 4.18) were tested at lower 
concentrations compared to 2b. The presence of the p-phenylene diamine 
moiety in both the compounds and the tacrine structure in compound 1f 
appear to contribute to the toxic effect in SH-SY5Y cells.  
 
 
Figure 4.18. The p-phenylene diamine moiety (in red) in both compounds 1f and 4c. In addition, the 
tacrine moiety of compound 1f is highlighted in blue. 
 
For those reasons, 4c and 1f were tested at concentrations up to 50 and 
100 µM, respectively. Tetramer 4c did not show significant toxic effects at 
concentration of 25 µM, displaying a LC50 of 45.1 ± 3.5 µM (figure 4.19). 
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Figure 4.19. MTT cell viability assay using compound 4c (0.1 - 50 µM, for 24 hrs). One-way ANOVA 
analysis was used for the comparison between the media control and each condition. ***p ≤ 0.001, ns = 
not significant, n=3. 
 
On the other hand, monomer 1f showed increased toxicity, displaying 
significant cytotoxic effects at concentration as low as 25 µM and a LC50 of 
43.7 ± 1.9 µM (figure 4.20). 
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Figure 4.20. MTT cell viability assay using compound 1f (3.125 - 100 µM, for 24 hrs). One-way ANOVA 
analysis was used for the comparison between the media control and each condition. ***p ≤ 0.001, ns = 
not significant, n=3. 
 
The higher toxicity showed by monomer 1f compared to its related tetramer 
4c could be explained by the presence of the tacrine moiety, which 
contributes to the extra toxic effect of the monomer, since the vanillin 
moiety had a little impact on the toxicity as dimer 2b showed very low 
effects on SH-SY5Y. 
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Similar toxicities were recently reported by Zha et al., who tested tacrine 
and one of its dihydrobenzofuran derivative (figure 4.21) in SH-SY5Y cell 
line showing no toxicity at concentrations up to 10 µM but significant toxic 
effects at concentration of 30 µM (Zha et al., 2016). 
 
 
Figure 4.21. Tacrine-dihydrobenzofuran hybrid reported by Zha et al. (2016) 
 
4.4.2 Protective Effects of Vanillin Derivatives from H2O2-Induced 
Toxicity  
 
Once the relative toxicity of the three selected vanillin derivatives was 
established, they were then evaluated, along with vanillin, for their 
protective effects in a hydrogen peroxide oxidative stress model. The 
concentrations used for the three vanillin derivatives (1f, 2b and 4c) were 
5, 200 and 10 µM, respectively. Oxidative stress was induced by incubating 
SH-SY5Y cells with hydrogen peroxide (400 µM) for 24 hours. At this H2O2 
concentration ~50% of cells death was observed. Cells were pre-treated 
with vanillin or the selected vanillin derivatives for 24 hours before the 
addition of the stressor. 
Vanillin (0.1-800 µM) itself did not show any increase in cell viability when 
compared to H2O2 control at concentrations up to 800 µM; thus confirming 
no protective effects toward the cells at any of the concentrations tested 
(see figure 4.22). 
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Figure 4.22. Protective effects of vanillin in hydrogen peroxide (400 M)-stressed cells. One-way 
ANOVA analysis was used for the comparison between the peroxide control and each condition. ns = not 
significant, n=3. 
 
On the other hand, all of the vanillin derivatives (1f, 2b and 4c) tested in 
this assay exhibited cellular protection against the oxidative insult induced 
by hydrogen peroxide in a concentration-dependent manner. Monomer 1f 
showed significant cellular protection at concentrations as low as 1 µM (with 
an increase of 15% of cell viability) and a maximum at 5 µM, by increasing 
the cell viability by 30% (figure 4.23). 
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Figure 4.23. Protective effects of 1f in hydrogen peroxide (400 M)-stressed cells. One-way ANOVA 
analysis was used for the comparison between the peroxide control and each condition. ***p ≤ 0.001, *p 
≤ 0.05, ns = not significant, n=3. 
   
Similar protective effects were recently reported by Benchekroun and co-
workers who described ferulic and lipoic acid-tacrine hybrids bearing a 
melatonin moiety (see figure 4.24) able to protect SH-SY5Y cells against 
hydrogen peroxide-induced oxidative damage at concentration as low as 1 
µM (Benchekroun et al., 2016). 
 
 
Figure 4.24. Neuroprotective agent against hydrogen peroxide-induced oxidative insult reported by 
Benchekroun et al. (2016). The tacrine moiety is highlighted in red. 
 
Dimer 2b displayed the weakest protective properties among the three 
vanillin derivatives, showing significant protection at concentrations as low 
as 5 µM (with an increase in cell viability of only 6%) and an increase of cell 
viability by almost 20% at concentration of 200 µM (see figure 4.25).  
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Figure 4.25. Protective effects of 2b in hydrogen peroxide (400M)-stressed cells. One-way ANOVA 
analysis was used for the comparison between the peroxide control and each condition. ***p ≤ 0.001, **p 
≤ 0.01, ns = not significant, n=3. 
 
Finally, tetramer 4c turned out to be the most efficient protective agent in 
this assay, displaying significant cellular protection at concentrations as low 
as 0.1 µM, increasing the cell viability by almost 10% and a maximum at 10 
µM, with an increase of cell viability of almost 30% (see figures 4.26). 
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Figure 4.26. Protective effects of 4c in hydrogen peroxide (400M)-stressed cells. One-way ANOVA 
analysis was used for the comparison between the peroxide control and each condition. ***p ≤ 0.001, **p 
≤ 0.01, *p ≤ 0.05, ns = not significant, n=3. 
 
The protective effects of the latter can be appreciated as shown in Figure 
4.27, showing the cells morphology of the different groups (media control, 
peroxide control and after 4c pre-treatment) and the 96-well plate after one 
of the MTT assay (figure 4.28) performed on the vanillin derivative 4c. 
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Figure 4.27. Morphology of untreated (a), hydrogen peroxide-stressed (400 µM) (b) or pre-treated with 4c 
(10 µM) (c) cells during MTT assay (20x magnification, picture size adjusted to fit page). 
 
Untreated cells showed the characteristic elongated shape of healthy SH-
SY5Y cells. Once stressed with hydrogen peroxide (400 µM) for 24 hours, 
the morphology of the cells changed to rounded conformation with the loss 
of their original elongated shape. Pre-treatment with compound 4c (10 µM) 
partially prevented the oxidative damage induced by hydrogen peroxide; 
the cells looked healthier maintaining their original shape while showing 
only fewer rounded shape cells when compared to the peroxide control. 
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Figure 4.28. An example of MTT assay for the evaluation of the protective effects of compound 4c in the 
hydrogen peroxide oxidative stress model. The wells circled in green correspond to the media control, 
whereas the wells circled in red correspond to the hydrogen peroxide control. Decreasing concentrations 
of compound 4c (from left to right) are circled in orange. 
 
The loss of colouration in the wells circled in red (hydrogen peroxide 
control) compared to the strong purple colour in the wells circled in green 
(media control) suggests the decrease in cell viability in the peroxide 
control. In contrast, the increased in purple colouration in the wells circled 
in orange (4c pre-treatment) compared to the stressor control highlights 
the increased cell viability compared to the latter. 
 
It is interesting to note that monomer 1f and tetramer 4c showed similar 
protective effects, although these compounds displayed different antioxidant 
properties (see chapter 3). In addition, the dimer 2b showed modest 
protection toward SH-SY5Y cells even at higher concentrations (up to 200 
µM), suggesting the minor role of the vanillin moieties on the protective 
effects (vanillin itself showed no protective effects at concentrations up to 
800 µM). It is worth to note that, working with cellular models; different 
defensive mechanisms could also be triggered. 
 
4.4.3 Protective Effects of Vanillin Derivatives from 
Rotenone/Oligomycin A Cocktail-Induced Toxicity  
 
The same vanillin derivatives as above were tested, along with vanillin, for 
their protective effects in a rotenone/oligomycin A cocktail (3 and 1 µM, 
167 
 
respectively) oxidative stress model. The cells were pre-treated with vanillin 
or the selected vanillin derivative for 24 hours before the addition of the 
stressor cocktail and then incubated for additional 48 hours. Again, vanillin 
did not show significant protective effects at any concentration tested (see 
figure 4.29). 
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Figure 4.29. Protective effects of vanillin in rotenone/oligomycin (3 and 1 M, respectively)-stressed 
cells. One-way ANOVA analysis was used for the rotenone/oligomycin A control and each condition. 
***p ≤ 0.001, ns = not significant, n=3. 
 
It is worth noting that vanillin was previoulsy reported to protect SH-SY5Y 
cells from oxidative damage induced by rotenone (Dhanalakshmi et al., 
2015); the presence of oligomycin A, which is an inhibitor of the complex V 
the respiratory chain, could nullify the protective effects of this natural 
product. 
Both monomer 1f and dimer 2b did not show significant protection at the 
concentrations tested, as depicted in figure 4.30. 
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Figure 4.30. Protective effects of 1f and 2b in rotenone/oligomycin (3 and 1 M, respectively)-stressed 
cells. One-way ANOVA analysis was used for the rotenone/oligomycin A control and each condition. 
***p ≤ 0.001, ns = not significant, n=3. 
 
An interesting work from Benchekroun et al. reported ferulic and lipoic acid-
tacrine hybrids bearing a melatonin moiety with protective effects toward 
the same cell line against rotenone/oligomycin A induced oxidative damage. 
In particular, the most active compound (see figure 4.24) showed 
neuroprotection at concentrations as low as 1 µM (Benchekroun et al., 
2016). 
 
However, tetramer 4c showed significant protective effects at 
concentrations of 5 and 10 µM, increasing the cell viability by almost 20 and 
25%, respectively. No significant protection was observed at lower 
concentrations (see figure 4.31). 
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Figure 4.31. Protective effects of 4c in rotenone/oligomycin (3 and 1 M, respectively)-stressed cells. 
One-way ANOVA analysis was used for the rotenone/oligomycin A control and each condition. ***p ≤ 
0.001, ns = not significant, n=3. 
 
The lack of protection displayed by compounds 1f and 2b and the modest 
activity of tetramer 4c could rely on the fact that the rotenone/oligomycin A 
cocktail toxicity is manifested in the mitochondria, thus the tested 
compounds might not be able to reach this site of action.  
 
4.4.4 Protective Effects of Vanillin Derivatives from ROS Induced by 
H2O2 
 
Following the protection studies against oxidative insult by hydrogen 
peroxide or rotenone/oligomycin, the ability of selected vanillin derivatives 
to alleviate the production of ROS after treatment with H2O2 (1 mM, 30 
minutes) in SH-SY5Y cells was evaluated. At that concentration of hydrogen 
peroxide significantly increased the levels of ROS while maintaining non-
significant levels of cytotoxicity. H2DCFDA was employed to detect the ROS 
generated within the cells and the fluorescence was measured by flow 
cytometry. An example of the data obtained in this experiment is depicted 
in figure 4.32. 
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Figure 4.32. Raw data obtained from flow cytometry, showing the number of cells (events) and their 
associated fluorescence intensity on a logarithmic scale (FL1 LOG). 
 
Due to instrumental issues at the time those experiments were carried out, 
only dimer 2b and tetramer 4c were tested in this assay. The 
concentrations used for each compound were the highest used in the 
cellular protection studies against hydrogen peroxide and 
rotenone/oligomycin A cocktail i.e. 200 and 10 µM respectively. The relative 
fluorescence of each group (media control, compound control and sample) 
was compared with fluorescence from the peroxide control group, which 
was set as 100% of relative fluorescence. 
Both compounds tested, did not show significant increase in ROS production 
compared to the media control, suggesting their inability to act as pro-
oxidant at the concentrations tested (see figures 4.33 and 4.34).  
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Figure 4.33. Protective effects of dimer 2b against ROS production induced by hydrogen peroxide (1 
mM, 30 mins). Statistically significant difference determined using One-way ANOVA. ***p ≤ 0.001, ns 
= not significant n = 3. 
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Figure 4.34. Protective effects of tetramer 4c against ROS production induced by hydrogen peroxide (1 
mM, 30 mins). Statistically significant difference determined using One-way ANOVA. ***p ≤ 0.001, ns 
= not significant n = 3. 
 
As expected, dimer 2b showed a modest ability to reduce the amount of 
ROS after hydrogen peroxide treatment with a decrease of fluorescence by 
40% (see figure 4.34). In fact, the latter showed the weakest activity 
regarding the protective effects against hydrogen peroxide-induced insult. 
In contrast, tetramer 4c remarkably reduced ROS formation by 76%, 
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confirming its strong protective properties in SH-SY5Y cells against 
oxidative insult induced by hydrogen peroxide (see figure 4.35). 
 
Similar results were described by Kwon and co-workers when they studied 
the protective effects of loganin methyl ((1S,4aS,6S,7R,7aS)-6-hydroxy-7-
methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,4a,5,6,7,7a-
hexahydrocyclopenta[c]pyran-4-carboxylate) (figure 4.35), an iridoid 
glycoside found in Flos lonicerae, Fruit cornus and Strychonos nux vomica, 
which turned out to alleviate ROS formation by 63% compared to the 
control at concentrations of 12.5 µM (Kwon et al., 2011). 
 
 
Figure 4.35. Chemical structure of glycoside loganin. 
 
4.4.5 DNA Comet Assay 
 
The protective effects of selected vanillin derivatives toward pBR332 DNA 
plasmid against oxidative damage were described in the previous chapter. 
In particular, compounds 2b and 4c showed remarkable protective effects, 
with IC50 of 3.6 and 0.6 µM, respectively (see table 3.4, page 123, chapter 
3). To evaluate the ability of the latter to protect the nuclear DNA in SH-
SY5Y cells against hydrogen peroxide-induced oxidative damage, the comet 
assay was employed. 
 
The cells were incubated for 24 hours with the two vanillin derivatives at the 
same concentrations as before (200 µM for 2b and 10 µM for 4c) before the 
addition of hydrogen peroxide (300 µM) for 30 minutes.  
The scoring was performed according to Collins (Collins, 2004) on 100 
comets in each of the three gels for each group (media control, compound 
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control, peroxide control and peroxide + compound group). An example of 
the comet classes obtained in the experiments is figure 4.36. 
 
 
Figure 4.36. Comet classes (0-4) obtained in the comet assay. Leica DMRB microscope (100x) with 
Leica DFC 300FX camera (0.63x). 
 
Both compounds tested did not show to have any impact on the DNA of SH-
SY5Y cells as measured by the comet assay, since the arbitrary scores for 
media control, 2b control and 4c control were 11.4, 11.7 and 11.8 
respectively (figure 4.37). 
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Figure 4.37. Cellular DNA protection from H2O2-induced (300 µM) DNA strand breaks after pre-
treatment with 2b (200 µM) or 4c (10 µM) for 24 hours. Statistically significant difference using One-
way ANOVA compared with peroxide control. ***p ≤ 0.001, ns = not significant, n = 3. 
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Treatment of cells with hydrogen peroxide (300 µM for 30 minutes) caused 
a dramatic increase in DNA strand breaks, leading to an average arbitrary 
score of 287.9. Pre-treatment with dimer 2b (200 µM) or tetramer 4c (10 
µM) did not cause a significant decrease in comet scoring (290.0 and 283.8 
arbitrary units, respectively), highlighting the inability of the latter to 
protect nuclear DNA from the hydrogen peroxide-induced oxidative strand 
breakage.  
 
The results obtained in the comet assay contrasts with the results obtained 
from the protection studies against hydrogen peroxide toxicity and the 
protective effects from ROS as described above, where both compounds 
showed significant protective effects. However, it is worth noting that the 
conditions employed to induce DNA damage did not show signs of 
cytotoxicity, when the cells were observed under the microscope after 
peroxide treatment. The lack of positive effects against DNA damage in this 
assay could depend on the fact that the DNA is located in the nucleus of the 
cells and the vanillin derivatives were unable to reach the relevant site of 
action. This could be further explained by the fact that both compounds 
showed remarkable protective effects on pBR332 plasmid DNA in a cell free 
system (table 3.4, page 123, chapter 3,). 
 
4.4.6 Evaluation of Nrf2 Pathway Activation 
 
Although vanillin derivatives showed strong antioxidant properties (see 
chapter 3), acting as free radical scavenger as well as reducing agents, their 
protective effects in cellular models could rely on more complex 
mechanisms. When working with antioxidants, the evaluation of the 
activation of the antioxidant responsive element (ARE) pathway (see pages 
18-20, chapter 1) is a good starting point for studying the mechanism of 
the protective effects of synthetic and natural products. In order to explain 
the remarkable protective effects against oxidative stress in SH-SY5Y 
cellular model, the ability of tetramer 4c to induce nuclear translocation of 
Nrf2 was evaluated using western blotting. The latter is a widely employed 
technique for the separation of proteins, based on their molecular weight, 
which consists of different steps (electrophoretic run, protein transfer into 
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membrane and protein detection with appropriate antibodies) (Kaur and 
Bachhawat, 2009; Mahmood and Yang, 2015). 
 
Due to its relatively short half-life (approximately 20 minutes), the 
determination of nuclear Nrf2 is challenging and several attempts with 
different incubation times were made. The cells were incubated with the 
usual concentration of compound 4c (10 µM), which turned out to evoke the 
best protective effects against oxidative stress shown above.  
 
The incubation times varied from 3 to 24 hours and the cells were collected, 
washed and the nuclear extraction was performed. 20 µg of protein 
(quantified by Bradford assay) from each sample were loaded for the 
electrophoresis, then transferred into a PDVF membrane for the detection 
with the Nrf2 antibody (A-10, Santa Cruz Biotechnology). 
  
The autoradiograph (figure 4.38) showed strong bands in the nuclear 
extracts (circled in red) at approximately 60 kDa, with minor intensity in the 
media control (0 hours) and increasing intensities moving from 3 to 6 and 
24 hours incubation.  
 
 
Figure 4.38. Western Blot for cytoplasmic (green) and nuclear (red) extracts after different time exposure 
of the cells to tetramer 4c. 
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This may be related to the fact that longer exposure (from 3 to 24 hours) to 
4c increases the translocation of Nrf2 into the nucleus. However, no Nrf2 
was detected in the cytoplasmic extracts (circled in green), which should 
show an inverted scenario in the case of pathway activation. In fact, a 
maximum amount of target protein should be detected in the media control 
and decreasing concentrations in the other cytoplasmic samples, due to the 
translocation into the nucleus. This could be due to ineffective inhibition of 
proteases during the extract preparation or the application of incorrect 
extraction process. In addition, although the molecular weight detected by 
the antibody (~60 kDa) has been reported as the molecular weight of the 
Nrf2 protein, this could be a misconception. In fact, Lau et al. reported the 
correct molecular weight for Nrf2 to be 95-110 kDa, claiming that antibody 
detecting molecular weight of approximately 60 kDa could not be specific 
for this protein and the manufacturing companies could even discard 
specific antibody detecting the correct molecular weight (Lau et al., 2013). 
 
Compound 4c was then sent to Prof. Francesco Galli at university of 
Perugia, which I met at the 19TH SFRRI conference in Lisbon (June 2018).  
Professor Galli and his co-worker Dr. Desiree Bartolini published several 
works on Nrf2 and its role in the antioxidant response to oxidative stress. In 
addition, they worked with the same cell line (SH-SY5Y) in the past. 
 
The immunoblot performed by the Italian researchers involved protein 
quantification using BCA protein assay kit (Pierce, Thermo Scientific.) 
followed by denaturation of the proteins, electrophoresis thorough 10% 
SDS-PAGE and transfer into nitrocellulose membrane. The membrane was 
blocked in phosphate-buffered saline (PBS) containing 5% non-fat milk for 1 
h at room temperature. It was subsequently incubated with anti-Nrf2 
antibody (dilution 1:1,000; Cell Signaling) at 4°C overnight, followed by 
washing and treatment with HRP-labeled secondary antibody (1:2000; Cell 
Signaling) for 2 h at room temperature. The blots were incubated with ECL 
reagent for 5 min, and the signals were then detected with a 
chemiluminescence detection system (Bio-Rad). After stripping, the 
membrane was re-probed with human anti-α-Tubulin (1:1000; Cell 
Signaling) or Histone H3 (1:2000; Cell Signaling) antibodies as a control for 
equal protein loading and protein integrity. 
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Figure 4.39. A) Representative western blot analysis performed by Prof. Galli and co-workers at the 
University of Perugia showing Nrf2 expression in SH-SY5Y cells after treatment with compound 4c (10 
µM). B) Densitometry for the WB analysis. Data represent the means ± SD of 3 experiments (*p<0.05, 
compared with the control group). 
 
The results obtained by the colleagues in Perugia showed a significant 
increase in the cytosolic Nrf2 expression after treatment of the cells with 
compound 4c (10 µM) for 6 hours (see figure 4.39 A). However, no 
significant increase of the latter protein was detected in the nucleus, 
highlighting the inability of the vanillin derivative to induce Nrf2 nuclear 
translocation (see figure 4.39 B).  
 
Bryan et al. recently reported the major classes of Nrf2 inducers. Among 
them, molecules bearing oxidizable diphenols, such as tert-
Butylhydroquinone (tBHQ) or resveratrol, Michael reaction acceptors, such 
as curcumin, thiocarbamates, isothiocyanates, such as sulforaphane, 
dithiolethiones, hydroperoxides, heavy metals and arsenic turned out to be 
potent Nrf2 activators (see figure 4.40) (Bryan et al., 2013). 
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Figure 4.40. Examples of known Nrf2 activator. 
 
It is evident that tetramer 4c does not bear any ressemblance of the latter 
structures; this could explain the inability of this vanillin derivative to 
activate Nrf2 pathway. 
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4.5 Conclusions 
 
A selection of vanillin derivatives, based on their antioxidant properties 
(described in chapter 3) and their cholinesterase and amyloid aggregation 
inhibitory properties (which will be described in the next chapter), were 
tested for their neuroprotective effects in two different oxidative stress 
models, i.e. hydrogen peroxide or a mixture of rotenone/oligomycin A as 
stressors. 
Before testing the selected compounds (1f, 2b and 4c) for their protective 
effects in these oxidative stress models, preliminary tests for the 
determination of cytotoxic effects towards SH-SY5Y cells were performed. 
Dimer 2b turned out to be the least toxic vanillin derivative, with a LC50 
above 1 mM. On the other hand, both 1f and 4c showed much higher 
toxicity, with LC50s of 43.7 and 45.1 µM, respectively. Although the latter 
compounds showed similar LC50s, monomer 1f displayed significant 
cytotoxic effects at concentrations of 25 µM, decreasing the cell viability by 
almost 40% compared to the control, whereas tetramer 4c turned out to be 
safe at that concentration. Hence, the decision to work with lower maximum 
concentration of 1f compared to 4c.  All the compounds tested showed 
concentration-dependent protective effects against hydrogen peroxide (400 
µM) toxicity in SH-SY5Y cells, with the highest protection detected at the 
highest concentrations tested (5 µM for 1f, 200 µM for 2b and 10 µM for 
4c). In addition, the latter showed significant protection at concentration of 
1, 5 and 0.1 µM, respectively. It is worth noting that vanillin did not show 
protective effects in this experiment at concentration as high as 800 µM. 
However, only tetramer 4c displayed protective effects on SH-SY5Y cells 
from rotenone/oligomycin cocktail-induced toxicity, increasing the cell 
viability at concentration as low as 5 µM. Monomer 1f, dimer 2b and vanillin 
did not show significant protective effects at any concentration tested. 
Furthermore, both the vanillin derivatives tested (2b and 4c) showed a 
reduction in ROS within the cells, compared to the control, after treatment 
with hydrogen peroxide (1 mM for 30 minutes). As expected, tetramer 4c 
displayed the best alleviating properties in this assay, reducing the ROS by 
76% compared to the control, whereas the dimer 2b exerted more modest 
activity, decreasing the ROS production by 40%. Unfortunately, due to 
180 
 
instrumental issues, it was not possible to test the monomer 1f for its 
protective effects against hydrogen peroxide-induced ROS formation. 
 
On the other hand, no positive effects against hydrogen peroxide-induced 
DNA damage were determined in the comet assay, where both the vanillin 
derivatives tested (2b and 4c) did not show significant reduction of DNA 
strand breaks compared to the peroxide control. It is worth noting that the 
compounds showed no increase in DNA damage compared to the media 
control, displaying no toxicity toward the nuclear DNA within the cells. 
 
Finally, in order to explain the interesting protective effects of tetramer 4c 
in the two oxidative stress models, the latter was tested for its ability to 
trigger the Nrf2 nuclear translocation, inducing the expression of critical 
antioxidant enzymes. The results obtained through western blotting 
experiment were contrasting. A time-dependent exposure increase of 
nuclear Nrf2 (with a maximum concentration after 24 hours of pre-
treatment with the compound) compared to the untreated control was 
detected; however, the molecular weight of the protein detected by the 
antibody (approximately 60 kDa) was not associated with the correct 
molecular weight of the biological relevant protein (95-110 kDa), showing 
non-specific binding properties of the antibody employed for the western 
blotting.  
The studies performed by Prof. Galli and co-workers at University of Perugia 
showed a significant increase of Nrf2 expression in the cytosol following 
exposure of the cells with compound 4c (10 µM). However, no nuclear 
translocation was detected at this time point. 
These results highlight the inability of compound 4c to trigger the Nrf2 
pathway. 
 
At this stage, no conclusions can be drawn regarding the mechanism of the 
cellular benefits of compound 4c. The increased expression of Nrf2 in the 
cytosol could be counterbalanced by an increased expression of Keap1, 
which is involved in Nrf2 ubiquination and degradation, thus avoiding the 
nuclear translocation of the latter protein (Tonelli, Chio and Tuveson, 2017).  
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Further studies are needed in order to establish the molecular pathways 
behind the protective effects of these vanillin derivatives. 
 
The interesting neuroprotective effects of selected compounds in the cellular 
model described in this chapter can represent a valid starting point for their 
potential use in the treatment of neurodegenerative diseases such as 
Parkinson’s and Alzheimer’s Diseases, where oxidative stress and neuronal 
death is one of the hallmarks.  
 
The potential application of vanillin derivatives in AD will be described in 
chapter 5. 
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Chapter 5: Vanillin Derivatives as 
Multi-Target-Directed Ligands for 
Alzheimer’s Disease 
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5.1. Introduction 
 
5.1.1 An Overview on Neurodegeneration 
 
As described in the previous chapters, oxidative stress is strongly linked 
with cellular damage, due to the ability of ROS and RNS to react with 
biological structures such as lipids, proteins and DNA (Sies, 1991, 2015). 
Neuronal cells are very susceptible to oxidative damage due to low levels of 
enzymatic and non-enzymatic antioxidants (superoxide dismutase, catalase, 
glutathione), high metabolic activity and high levels of lipids susceptible to 
oxidation such as polyunsaturated fatty acids (Ahmed et al., 2015). 
 
Oxidative stress in neurons can lead to the gradual and progressive loss of 
neuronal cells which is known as neurodegenerative process (Brown, 
Lockwood and Sonawane, 2005). 
In addition, specific regions in the nervous system have been reported to be 
vulnerable to oxidative damage; for example, the dopaminergic neurons of 
the substantia nigra are involved in the neurodegeneration that underpins 
Parkinson’s disease, whereas the neurodegeneration of cholinergic neurons 
in the basal forebrain is involved in Alzheimer’s disease (Ahmed et al., 
2015). 
 
For the purpose of this chapter, only the neurodegenerative process 
involved in AD will be further discussed. 
 
5.1.2 Alzheimer’s Disease as a Multifactorial Disorder 
 
AD is the most common cause of dementia among the elderly people and it 
is characterized by progressive neurodegenerative alterations with 
consequent reductions in cognitive and functional abilities, including aphasia 
(language disturbance), agnosia (failure in people recognition), apraxia 
(movement impairment) and executive functions (e.g. planning and 
organization) (Brown, Lockwood and Sonawane, 2005; Mecocci and Polidori, 
2012). 
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The symptoms of AD vary among individuals. It usually starts with a 
gradual worsening ability to remember new information and it proceeds with 
memory loss, confusion with space and time, communication issues and 
changes in mood. With disease advancement, cognitive and functional 
abilities tend to decline, causing an inability to move and to recognize family 
members (Alzheimer's Association, 2015). 
 
In the UK, the number of people suffering for dementia was estimated to be 
slightly more than 800000 in 2013, of whom almost 775000 were aged 65 
years or over. In addition, due to increased life expectancy, this number is 
predicted to be over 2 million in 2051, with 62% of the incidence predicted 
to be AD related, followed by vascular dementia (17%) and mixed dementia 
(10%) (Prince et al., 2014).  
 
AD was first diagnosed by Alois Alzheimer in 1907, when he noted  the 
occurrence of neuritic plaques and neurofibrillary tangles (NFTs) in the 
cerebral cortex during the autopsy of a 56-year old woman with dementia 
(Carreiras et al., 2013). Subsequently, Perry et al. reported the depletion of 
the neurotransmitter acetylcholine, which is involved in cognition and 
attention, in the brain of AD patients (Perry et al., 1978).  
 
The main hallmark of AD is the abnormal aggregation of harmful proteins, 
with the Aβ (β-amyloid) peptide and tau protein the most common, leading 
to amyloid plaques and NFTs, respectively, which are toxic to the neuronal 
cells (Hurtado-Puerto, Russo and Fregni, 2018; Iaccarino et al., 2018). 
 
The main constituent of the amyloid plaques is the β-amyloid peptide (Aβ); 
However, they may contain other proteins (e.g. acetyl and butyryl 
cholinesterases, superoxide dismutases) and metal ions such as copper and 
zinc (Lovell et al., 1998; Atwood et al., 2002). The latter peptide is a 38-43 
amino acid residues, with the code sequence Asp-Ala-Glu-Phe-Arg-His-Asp-
Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-
Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-Thr. It 
is generated through enzymatic cleavage by β- and - secretase of the 
amyloid precursor protein (APP), a type-1 trans-membrane protein widely 
expressed in the central nervous system (Cheignon et al., 2018). The 
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physiological role of APP is not fully understood, but it is linked to beneficial 
effects on neurons, including promotion of neurite outgrowth, 
synaptogenesis and cell adhesion while also protecting the cells against 
oxygen-glucose deprivation and excitotoxicity through inhibition of calcium 
currents (Chow et al., 2010). The metabolism of APP can follow two 
different pathways, known as amyloidogenic and non-amyloidogenic 
pathways (see figure 5.1).  
 
 
Figure 5.1. APP cleavage in the non-amyloidogenic and amyloidogenic pathways, altered from (Munoz 
and Feldman, 2000; Bachurin, Bovina and Ustyugov, 2017; Cheignon et al., 2018). 
 
In the normal non-amyloidogenic pathway, APP is cleaved by  -secretase 
followed by -secretase, yielding the non-toxic truncated (p3) peptide. In 
the amyloidogenic pathway, APP is cleaved by β-secretase followed by -
secretase, yielding the full length amyloid peptides, mainly Aβ(1-40) and Aβ(1-
42) (Nalivaeva and Turner, 2013). It is worth noting that these two amyloid 
fragments exert different toxicities: the Aβ(1-42) form promotes greater 
fibrillar formation compared to Aβ(1-40), due to the presence of  two extra 
hydrophobic amino acids (isoleucine and valine), hence showing higher 
toxicity (Butterfield, Swomley and Sultana, 2013). The fibrillar formation is 
the result of an aggregation process which involves the sequential 
aggregation of the monomers into oligomers followed by mature fibrils 
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formation (Verma, Vats and Taneja, 2015). Very recently, it has been 
proposed that although amyloid plaques are strictly related to AD, the 
oligomers are the main contributor to the neurotoxicity (Verma, Vats and 
Taneja, 2015). He et al. demonstrated that oligomeric amyloid infused into 
the left ventricles of rat brains displayed significant impairment of learning 
and memory functions whereas no significant effects were observed after 
fibrils infusion (He et al., 2012). The toxicity of oligomers relies on their 
ability to insert themselves in the bilayer of the membrane in neuronal cells 
and the generation of ROS leads to lipid peroxidation (Butterfield, Swomley 
and Sultana, 2013). 
 
The aggregation of tau protein in NFTs is another hallmark of AD. Tau 
protein belongs to the family of microtubule-associated proteins (MAP) 
family, with MAP1 (A and B) and MAP2 the most common, and is mostly 
expressed in neuronal cells where it is involved in the assembly and 
stabilization of microtubules (Buée et al., 2000; Iqbal et al., 2005).  
The binding of tau protein to microtubules is modulated by phosphorylation. 
For optimal activity, tau contains 2-3 mol of phosphate/mol of protein; once 
hyperphosphorylated, it loses its affinity for microtubules, leading to the 
loss of structural integrity in the neurons with consequent impairment of 
normal cellular trafficking and possible neuron death (Iqbal et al., 2005; 
Tramutola et al., 2017).  
A couple of decades ago, Bramblett et al. located the residue, SER-396, as 
the possible site on tau protein where abnormal phosphorylation occurred, 
hence contributing to the loss of affinity for microtubules (Bramblett et al., 
1993).  
In addition, hyperphosphorylated tau protein tends to aggregate as paired 
helical filaments (PHF), leading to the NFTs (Iqbal et al., 2005); however, 
the exact mechanism of aggregation is still under investigation. Tau 
hyperphosphorylation and the subsequent NFT formation can induce 
neurodegeneration in the absence of other brain amyloids, for example in 
other tauopathies such as Pick’s disease and Guadeloupean Parkinsonism. 
This led to the hypothesis that tau plays a role in the final, shared pathway 
leading to neuronal death or dysfunction, which can be triggered by other 
events (Skovronsky, Lee and Trojanowski, 2006; Williams, 2006). 
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Along with abnormal protein aggregation, oxidative stress, disturbed metal 
homeostasis and cholinergic neurons depletion are the main hallmarks of 
AD.  
As described before, oxidative stress is strictly linked with amyloid 
oligomers, which are able to generate ROS in the membrane of neuronal 
cells (Uttara et al., 2009; Butterfield, Swomley and Sultana, 2013). It is 
worth noting that neuronal cells are very susceptible to oxidative stress due 
to low levels of enzymatic and non-enzymatic antioxidants (Ahmed et al., 
2015).  
 
Homeostasis of zinc, copper and iron are significantly altered in the AD 
brain tissue; for example, abnormal levels of the latter metals have been 
found in subcortical regions such as the hippocampus, amygdala, and 
olfactory bulb, as well as the neocortex (Cuajungco et al., 2006). In 
addition, these redox-active metals are known to contribute to the 
misfolding and aggregation of amyloid proteins and are found in high 
concentrations in amyloid plaques of AD patients (Picciano and Vaden, 
2013). 
Moreover, the link between transition metals and oxidative stress, through 
Fenton reaction, has been widely discussed in the first chapter (see 
equations 7 and 11, pages 6-7, chapter 1). 
 
The depletion of cholinergic neurons in the basal forebrain is one of the 
earliest hallmarks of AD observed in post-mortem brains although 
cholinergic transmission was unaffected in other brain regions such as the 
ganglia, cerebellum and thalamus (Parent et al., 2013). Cholinergic neurons 
use the neurotransmitter, acetylcholine (Ach) (see figure 5.2), and contain 
the acetyltransferase enzyme which, along with acetylcholine transporter, is 
found in the presynaptic component of the cholinergic pathway (Mesulam, 
2004).  
 
 
Figure 5.2. Chemical structure of acetylcholine 
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The postsynaptic components in the cholinergic pathway consist in nicotinic 
and muscarinic receptors, which are able to bind acetylcholine molecules. 
Nicotinic channels are a family of ligand-gated ion channels (Gotti and 
Clementi, 2004), whereas muscarinic receptors are G-protein coupled 
receptors involved in the second messenger cascade (Caulfield, 1993). The 
interaction of acetylcholine with the latter receptors is strongly involved in 
memory and learning processes as well as muscle activation (Caulfield, 
1993; Gotti and Clementi, 2004; Hasselmo, 2006). The termination of the 
synaptic action of ACh is achieved through its catalytic hydrolysis by 
cholinesterases enzymes, such as acetylcholinesterase (AChE) and 
butyrylcholinesterase (BChE). The evident depletion of cholinergic neurons 
in AD is thus strongly linked with memory loss and cognitive and 
behavioural impairment (Mesulam, 2004). 
 
5.1.3 Current Therapies for AD 
 
At present, no cures are available for AD; however, several symptomatic 
treatments are available for AD patients.  
 
The application of cholinesterase inhibitors aims to increase the availability 
of acetylcholine in the basal forebrain by inhibiting the hydrolysis of the 
latter neurotransmitter mediated by acetylcholinesterase. Three AChE 
inhibitors are currently used in AD therapy: galantamine ((4aS,6R,8aS)-3-
methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-
benzo[2,3]benzofuro[4,3-cd]azepin-6-ol), rivastigmine ((S)-3-(1-
(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate) and donepezil (2-
((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-
one) (see figure 5.3) (Yiannopoulou and Papageorgiou, 2013). For the 
purpose of this thesis, it is also worth mentioning tacrine, the first AChE 
inhibitor approved for AD treatment and later discontinued due to liver 
toxicity (Crismon, 1994; Watkins et al., 1994; Mehta, Adem and Sabbagh, 
2012). 
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Figure 5.3. Chemical structures of current AChE inhibitors for AD treatment (donepezil, galantamine and 
rivastigmine) and the discontinued tacrine. 
 
The only drug currently used for AD therapy not belonging to AChE 
inhibitors is memantine (3,5-dimethyladamantan-1-amine) (see figure 5.4), 
which is a N-methyl-D-aspartate (NMDA) receptor antagonist (Witt, 
Macdonald and Kirkpatrick, 2004). 
 
 
Figure 5.4. Chemical structure of memantine. 
 
NMDA receptors are neuronal ligand-gated ion channels that bind to 
glutamate, the main excitatory neurotransmitter in the central nervous 
system, and allow the entrance of calcium ions. NMDA receptors are 
involved in learning and memory, but their overactivation due to increased 
glutamate release leads to excessive calcium entry, activating neuronal 
death, a phenomenon known as ‘excitotoxicity’ (Rothman and Olney, 1987; 
Witt, Macdonald and Kirkpatrick, 2004). 
 
5.1.4 AD Drug Development 
 
Therapies for AD are urgently needed due to the large increase in 
individuals suffering from this illness. To date, 112 agents are in clinical 
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trials with 23 agents in 25 trials in phase I, 63 agents in 75 trials in phase II 
and 26 agents in 35 trials in phase III (Cummings et al., 2018). Among the 
agents in phase III trials, 17 are disease-modifying therapies (DMTs) that 
should prevent or delay the onset or slow the progression of AD; one is a 
cognitive enhancer and 8 are targeting behavioural symptoms. 
Interestingly, among the 17 DMTs, 14 address amyloid targets (mainly in 
the form of immunotherapies), whereas only one is targeted at tau-related, 
neuroprotection or metabolic mechanisms (Cummings et al., 2018). The 
cognitive enhancer is a cholinesterase inhibitor (octohydroaminoacridine 
succinate, known as NCT03283059), whereas the 8 agents addressing 
behavioural symptoms target agitation, sleep disorders and apathy 
(Cummings et al., 2018). 
 
5.1.5 The Multi-Target-Directed Ligands Approach to AD 
 
Due to the multiple factors involved in the physiopathology of AD, the drug 
development based on a “one target-one molecule” point of view is no 
longer preferred (Cavalli et al., 2008). Recently, therefore, a multi-targeted 
approach, aimed at different steps of the neurotoxic cascade, has attracted 
much research attention on neurodegenerative diseases, such as AD (Singh 
et al., 2016). In chapter 1 (pages 35-39), examples of multi-target-directed 
ligands (MTDLs) for AD treatment have been described. 
 
The main targets of the multi-targeted-directed AD therapy are: 
cholinesterases (acetyl and butyryl), monoaminoxidases (in particular, 
MAO-B), β-Secretase (BACE), amyloid aggregation, metal chelation (in 
particular, Zn2+ and Cu2+), calcium channels. In addition, due the role of 
oxidative stress in AD, the presence of antioxidant moieties such as 
melatonin and lipoic acid in the MTDLs have been favoured (Cavalli et al., 
2008; Bajda et al., 2011; Singh et al., 2016; Sameem et al., 2017). 
 
For the purpose of this thesis, the antioxidant properties, the cholinesterase 
enzymes and amyloid aggregation process are the targets investigated for 
the potential use of selected vanillin derivatives in the multi-targeted-
directed approach to AD.  
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The antioxidant properties of the vanillin derivatives have been described in 
chapter 3. 
The amyloid aggregation pathway and cholinesterase enzyme have been 
described earlier in this chapter. However, the structural features of the 
AChE need to be described here in order to appreciate the evaluation of the 
molecular modelling results. 
 
5.1.5.1 AChE, a “Gorge-ous Enzyme” 
 
As previously described, the cholinesterases are primarily responsible of the 
hydrolysis of the neurotransmitter acetylcholine into choline and acetic acid 
(Mesulam, 2004).  
Vertebrates possess two cholinesterases: acetylcholinesterase and 
butyrylcholinesterase (also known as psudocholinesterase). These enzymes 
are distinguished on their substrate specificity; AChE degrades the 
acetylcholine faster than other enzymes and it shows low affinity for the 
synthetic butyrylcholine, whereas BChE is able to hydrolyse both the choline 
esters (Massoulié et al., 1993). In addition, AChE is mainly expressed in the 
nervous system and in muscles whereas BChE is mostly located in the liver 
and in the plasma (Massoulié et al., 1993). In healthy brains, 
acetylcholinesterase predominates with BChE playing a minor role in 
regulating AChE levels (Greig, Lahiri and Sambamurti, 2002).  However, it 
has been shown that during progression of AD, the activity of AChE remains 
unchanged or slightly decreases, whereas the activity of BChE significantly 
increases. Thus both the enzymes represent legitimate therapeutic targets 
in AD therapy (Greig, Lahiri and Sambamurti, 2002; Panek et al., 2017). 
 
AChE molecule has an ellipsoidal shape with dimensions approximately 45 Å 
x 60 Å x 65 Å;  the monomer contains 12 stranded central mixed β sheet 
surrounded by 14 α helices (Colovic et al., 2013).  
 
The active site (see figure 5.5) lies at the bottom of a 20 Å deep gorge and 
it is characterized by the presence of the esteratic site, composed by the 
three residues SER-200, GLU-327 and HIS-440, involved in the hydrolysis 
of acetylcholine, and a catalytic anionic site (CAS), characterized by the 
presence of TRP-84, TYR-130, PHE-330 and PHE-331. TRP-84 plays a 
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fundamental role, binding with the acetylcholine molecule through a cation-
 interaction with its positive quaternary nitrogen (Xu et al., 2008; Dvir et 
al., 2010; Bajda et al., 2013).  
 
 
Figure 5.5. Active site of TcAChE (pdb:1EVE) (Kryger, Silman and Sussman, 1999). The residues are 
rendered accordingly to their positions. Esteratic site: purple, CAS: yellow, Acyl Pocket: grey, Oxyanion 
Hole: green and PAS: orange. 
 
The peripheral anionic site (PAS) lies at the top of the gorge, approximately 
20 Å above the active site. The PAS is involved in the sequestration of 
acetylcholine at the first step of the catalytic pathway though cation- 
interaction with TRP-279. It is composed of other residues such as TYR-70, 
ASP-72, TYR-121 and TYR-334 (Johnson and Moore, 2006). In addition, the 
peripheral anionic site is strongly involved in the selectivity of 
cholinesterase inhibitors. In fact, the selectivity of AChE inhibitors such as 
donepezil is due to their ability to bind TRP-279 in the PAS since the latter 
site is not present in BChE; on the other hand, inhibitors such as tacrine 
and eptastigmine, which bind the esteratic site and CAS are not selective for 
AChE (M., 1999). 
 
PHE-288 and PHE-290 comprise the acyl pocket, preventing the access of 
hindered molecule into the active site whereas the oxyanion hole, composed 
by GLY-118, GLY-119 and ALA-201 is involved in the stabilization of the 
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transition complex during the enzymatic reaction (Bajda et al., 2013; 
Colovic et al., 2013) (see figure 5.6). 
 
 
Figure 5.6. Mechanism of acetylcholine hydrolysis catalysed by AChE, altered from (Houghton, Ren and 
Howes, 2006; Colovic et al., 2013).  
 
The 3D structure of AChE is highly conserved, although the sequence can 
vary among species (Wiesner et al., 2007; Colovic et al., 2013).  
 
5.1.5.2 Assays for the Determination of AChE Activity  
 
The inhibitory activity toward AChE is the main feature of many multi-
target-directed ligands for AD treatment (Rosini et al., 2008; Bolognesi et 
al., 2010; Chen et al., 2014; Liu et al., 2015; Mohamed and Rao, 2017; 
Sameem et al., 2017; Yang et al., 2017) and several technologies and 
assays are available for the determination of AChE activity. 
 
The Ellman assay is one of the most employed in vitro assays for this 
purpose. It was developed by George L. Ellman and co-workers in the early 
1960s and it is based on the AChE-catalysed hydrolysis of acetylthiocholine 
into thiocholine, which can be oxidized by 5,5'-dithiobis-(2-nitrobenzoic 
acid) (DTNB) to yield the yellow 5-thio-2-nitrobenzoate. The latter has a 
maximum absorption at 412 nm and can be measured 
spectrophotometrically (Ellman et al., 1961; Worek, Eyer and Thiermann, 
2012). A schematic of the mechanism is depicted in figure 5.7. 
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Figure 5.7. Mechanism of Ellman assay for the determination of AChE inhibition, altered from  (Worek, 
Eyer and Thiermann, 2012; Badawy and El-Aswad, 2014). 
 
In addition to the Ellman assay, fluorescent methods involving different 
probes have been developed.  
 
The Amplex® Red Acetylcholine/Acetylcholinesterase assay kit is a 
fluorescent method for the evaluation of AChE inhibition based on the use of 
10-acetyl-3,7-dihydroxyphenoxazine. In this assay, the choline obtained 
through the AChE-catalysed hydrolysis of acetylcholine chloride is oxidised 
into a betaine with the generation of hydrogen peroxide as a by-product. 
The latter can be quantified by its reaction with 10-acetyl-3,7-
dihydroxyphenoxazine (1:1 stoichiometry) in the presence of a horseradish 
peroxidase to yield the fluorescent resorufin ( Ex: 571 nm,   Em: 585 nm) 
(Molecular Probes Invitrogen detection technologies, 2004). 
 
Recently, continuous fluorometric assays for AChE activity and its inhibition 
involving the use of different polymers as fluorescent probes have been 
developed (Feng et al., 2007; Wang et al., 2009). The main advantage in 
using these organic compounds is the amplified fluorescence signal obtained 
due to the excitation energy transfer of the conjugated polymer  compared 
to the small molecules usually employed in the bioassays (Feng et al., 
2007). However, no kits employing this technology are commercially 
available.  
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5.1.5.3 Measurement of Amyloid Aggregation 
 
A very common feature of MTDLs for AD therapy is the inhibitory activity 
toward amyloid protein aggregation, which drives many of the toxic effects 
exerted in the neurons (Luo et al., 2011; Chao et al., 2012; Li et al., 2014; 
Zha et al., 2016; Panek et al., 2018). 
 
A wide variety of techniques are currently available for the evaluation of 
protein aggregation in the biotechnology industry, such as field flow 
fractionation, analytical ultracentrifugation, size-exclusion chromatography 
and dynamic light scattering (Pease et al., 2008). 
 
A simple method for this purpose involves the use of the amyloid indicator 
thioflavin T (4-(3,6-dimethyl-1,3-benzothiazol-3-ium-2-yl)-N,N-
dimethylaniline chloride) (ThT). The latter (see figure 5.8) is a benzothiol 
dye that is able to bind β-sheet rich proteins generating a fluorescence 
signal ( Ex: 450 nm,  Em: 482 nm) (Wolfe et al., 2010). 
 
 
Figure 5.8. Chemical structure of Thioflavin T. 
 
Despite its predominant use in AD research, the molecular mechanism of 
the ThT binding to aggregated amyloid protein is not fully understood. 
 
Modelling studies led to the hypothesis of stacking interactions between the 
aniline moiety of thioflavin T and the peptide bone and CH– interaction 
between the GLY residue in the model peptide and the benzothiazole 
moiety; the decreased torsional relaxation upon binding is linked to the 
enhanced fluorescence properties (Rodriguez-Rodriguez et al., 2010). 
 
In addition, the crystal structure of amyloid-like protein in complex with the 
latter benzothiol, showed that the intercalation of ThT between β-sheets 
orthogonal to the β-strands, with aromatic interactions to stabilize the 
electronic distribution of fluorophore. Thus, β-sheet conformations prevent 
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the preferred excited state configuration of ThT, hence increasing the 
quantum yield (Wolfe et al., 2010; Wang et al., 2012). 
 
5.1.5.4 Measurement of Drug Blood-brain Barrier (BBB) Permeation 
 
The failure of many drugs targeting neurodegenerative diseases is often 
linked with their inability to cross the blood-brain barrier (BBB) (Pardridge, 
2003). The BBB relates to the microvasculature of the central nervous 
system (CNS) composed of continuous non-fenestrated vessels that allows 
tight regulation of the movement of ions, molecules and cells. This selective 
regulation is mediated by the endothelial cells in the CNS held together by 
tight junctions, which limit the flux of solutes in the brain (Daneman and 
Prat, 2015). 
 
Almost 100% of large molecules drugs (>500 Da) and 98% of small 
molecules (<500 Da) do not cross the BBB. In addition, although small 
molecules can cross the BBB, only a low percentage can penetrate in 
pharmacologically relevant concentrations. Molecules that cross the BBB are 
typically lipid soluble with a threshold mass of 400-500 Da and show the 
ability to establish a low number of hydrogen bonds with water (Pardridge, 
2003). However, several transporters or endocytosis mechanisms are used 
by hydrophilic compounds such as amino acids, monocarboxylic acids, 
organic cations, sugars and peptides to penetrate the BBB. Drugs such as L-
dopa for PD treatment and the opioid, fentanyl, have been reported to 
employ these transporters to cross the BBB (Tamai and Tsuji, 2000). 
 
Recent research has focused on the development of novel CNS drug 
delivery technologies, such as polymeric nanoparticles, BBB selective 
disruption techniques (ultrasound, microbubbles, electromagnetic waves), 
cell mediated delivery and viral vectors (Spencer and Verma, 2007; Pandey, 
Sharma and Gupta, 2016). 
 
When undertaking neurodegenerative research, several in vitro methods 
and computational models are available for the prediction of drug BBB 
permeation such as logP/logD, immobilized artificial membrane, polar 
surface area, membrane permeability across cell culture systems and 
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parallel artificial membrane permeation assay (PAMPA) (Kansy, Senner and 
Gubernator, 1998; Di et al., 2003). 
 
For the purpose of this thesis, an online BBB predictor was employed 
(https://www.cbligand.org/BBB/). The predictor belongs to the domain-
specific chemogenomic knowledgebase AlzPlatform (Liu et al., 2014). The 
latter is a cloud computing server implemented with computational 
algorithms for the studies regarding target identification and pharmacology 
of novel small molecules in AD therapy. The platform is comprehensive of 
928 genes and 320 proteins related to AD, 194 approved or under clinical 
trial drugs for AD therapy and more than 400000 chemicals (Liu et al., 
2014).  
 
5.1.6 Aims and Objectives 
 
The aim of the experimental work described in this chapter was to evaluate 
the potential use of selected vanillin derivatives in the Multi-targeted 
approach for AD treatment. 
 
To achieve the above aim, the following objectives were completed: 
- Determination of inhibitory activity toward AChE of selected vanillin 
derivatives using the Ellman assay. 
 
- Molecular modelling studies for the interpretation of the experimental 
results obtained in the Ellman Assay. 
 
- Determination of inhibitory activity toward amyloid aggregation of 
selected vanillin derivatives through ThT assay. 
 
- Prediction of BBB permeation using the BBB online predictor server 
(https://www.cbligand.org/BBB/). 
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5.2 Materials and Methods 
 
5.2.1 Materials 
 
All reagents were purchased from Sigma Aldrich, unless otherwise stated, 
and were used without any further purification. 
 
β-amyloid peptide (1-42)       Calbiochem 
PBS                  Oxoid 
Thioflavin T             Acros Organics 
 
5.2.2 Instrumentation 
 
Absorbances for Ellman assay were measured using a Bio-Rad iMark 
microplate reader. 
Fluorescence for ThT assay was measured using a Perkin Elmer LS55 
fluorescence spectrophotometer. 
Molecular modelling studies were performed using an ASUS F550L series 
laptop. 
 
5.3 Methods 
 
5.3.1 AChE Inhibition Assay 
 
The inhibitory properties of selected vanillin derivatives toward AChE was 
determined using the Ellman method, with minor changes (Ellman et al., 
1961). An Electrophorus electricus AChE stock solution (22 U/ml) was 
prepared in 20 mM Tris HCl (pH 7.5) and was diluted 1:100 before use. A 
5,5'-dithiobis-(2-nitrobenzoic acid) solution (3 mM) was prepared in 
phosphate/hepes buffer (50 and 90 mM, respectively, pH 7.5). A 15 mM 
acetylthiocholine iodide solution was prepared in deionized water. A series 
dilution of vanillin derivatives was made in methanol in Eppendorf® tubes 
and 25 l of each solution was pipetted in the corresponding well in a 96-
well plate; 25 l of methanol was pipetted in the control wells. DTNB 
solution (125 l) was pipetted in each well along with diluted solution of 
AChE (25 l). The 96-multi wells plate was incubated at 37°C for 10 
minutes before the addition of 25 l of acetylthiocholine iodide solution in 
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each well. The plate was incubated for an additional 10 minutes before 
absorbance measurement (415 nm) using a Bio-Rad iMark microplate 
reader. An example of the 96-well plate settings is shown in figure 5.9. 
 
 
Figure 5.9. 96-well plate settings for Ellman assay. Two compounds can be tested at the same time. The 
control is represented in yellow, the first AChE inhibitor is represented in blue and the second AChE 
inhibitor is represented in orange (different shades represent different concentrations tested). 
 
5.3.2 Molecular Modelling  
 
For the docking procedure, three different pdb structures (2CMF, 1ACJ and 
1EVE) were downloaded from the Protein Data Base (http://www.rcsb.org) 
(Harel et al., 1993; Kryger, Silman and Sussman, 1999; Rydberg et al., 
2006). The original ligands were removed, along with water molecules, from 
the crystal structures by editing the file with notepad app for Windows. The 
structure obtained was loaded into Autodock Vina 1.1.2 (Trott and Olson, 
2010) and optimized. Ligand optimization was performed using Chemdraw 
16.0 (Cambridgesoft, Waltham, MA) and Chem3D Ultra 16 version 
(Cambridgesoft, Waltham, MA) using its MM2 force field energy 
minimization tool. Molecular binding studies were performed using Autodock 
Vina 1.1.2 on an ASUS F550L series laptop and PyMOL (the PyMOL 
Molecular Graphics System, Version 2.0.7 Schrödinger, LLC) was employed 
for the results visualization. 
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5.3.3 Aβ(1-42) Aggregation Inhibition Assay 
 
The inhibitory properties of selected vanillin derivatives toward the self-
mediated aggregation of Aβ(1-42) peptide was determined using ThT 
fluorescence assay, following the method described by Luo and co-workers 
with minor modifications (Luo et al., 2011). A 500 µM stock solution of 
amyloid Aβ(1-42) peptide was prepared by dissolving 0.25 mg of the latter in 
110 µl of DMSO. The stock solution was aliquoted in Eppendorf® tubes and 
stored at -20°C until further use. Stock solutions of curcumin or selected 
vanillin derivatives (500 µM) were prepared in the same solvent. 2 µl of 
amyloid solution was pipetted in 96 µl of 10 mM phosphate/ 10 mM NaCl 
buffer (pH 8) along with 2 µl of inhibitor stock solution or 2 µl of DMSO (for 
the control). The final concentrations of both the amyloid peptide and 
inhibitors were 10 µM. The solutions were then incubated for 24 hours at 
37°C. After incubation, 300 µl of 50 mM glycine/ NaOH buffer (pH 8.5) 
containing 5 µM of ThT were added to all the samples. Each solution was 
finally transferred into a cuvette and the fluorescence was measured using a 
Perkin Elmer LS55 luminescence spectrometer (excitation 446 nm, emission 
490 nm). 
 
5.3.4 Prediction of BBB Permeation 
 
The BBB permeation properties of selected vanillin derivatives were 
analysed by applying the BBB online predictor server 
(https://www.cbligand.org/BBB/).  
The molecules in the analysis were drawn in the website 
(www.cbligand.org/BBB/predictor.php) and the SVM (support vector 
machine) algorithm was selected along with the MAACS fingerprint in order 
to obtain the SVM_MACCSFP BBB Scores (the threshold for BBB permeation 
was 0.02). 
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5.4 Results and Discussion 
 
5.4.1 AChE Inhibition Assay 
 
A selection of vanillin derivatives was made based on their chemical 
structures (preferring compounds bearing lipophilic moieties, since they are 
more likely to cross the BBB) and the antioxidant and cellular protective 
properties described in chapters 3 and 4. The AChE inhibitory properties of 
selected vanillin derivatives 1a, 1b, 1c, 1d, 1e, 1f, 2b, 2f, 4c were 
determined through Ellman assay.  
 
 
Figure 5.10. Vanillin derivatives tested in the Ellman assay. 
 
The latter assay is based in the cholinesterase-catalysed conversion of 
acetylthiocholine into thiocholine, which can react with the Ellman reagent 
yielding a bright yellow colouration with a maximum absorbance at =415 
nm. An example of the 96-well plate is reported in figure 5.11. 
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Figure 5.11. 96-well plate for Ellman assay. Two compounds were tested at once. The wells in the red 
circle represent the control. The wells in the blue and green circles represent two different compounds at 
different concentrations. The loss in yellow colouration compared to the control is proportional to the 
AChE inhibitory activity.  
 
The results, expressed as concentration in M, are reported as their IC50 
values which are defined as the concentration of compound able to inhibit 
the 50% of AChE enzyme. 
The IC50 was determined by plotting in a graph with concentrations (in µM) 
on the x-axis and their corresponding % absorbance values on the y-axis to 
obtain a curve. The linear portion of the curve was considered for the 
determination of the IC50 values using the equation of the line as shown in 
Figure 5.12. 
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Figure 5.12. Example of Ellman assay’s results for derivative 1f. The concentrations of compound were 
plotted in a graph along with the amount of active AChE expressed as percentage. The linear portion of 
the curve was isolated and the IC50 was calculated using the equation of the line. 
 
 
The results are reported in table 5.1. 
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Table 5.1. AChE inhibitory activity of selected vanillin derivatives. 
 
Compound IC50 (µM) 
1a > 250 
1b 128.3 ± 6.1 
1c > 250 
1d 10.1 ± 1.2 
1e 24.3 ± 1.4 
1f 2.1 ± 0.1 
2b > 250 
2f > 250 
4c 26.9 ± 1.3 % a 
Vanillin INACTIVE b 
Tacrine 0.9 ± 0.1 
Results from each experiment are expressed as mean ± SD of three independent experiments. 
a Compound was tested up to 15.5  due to solubility issues.  
b Compounds were tested up to 250   
 
Vanillin was inactive at concentrations up to 250 µM. On the other hand, all 
the tested vanillin derivatives showed moderate activity (IC50 ranging from 
2.1 – 128.3 µM) in this assay except for compounds 1a, 1c, 2b and 2f 
which showed no IC50 up to 250 µM concentrations. Due to solubility issues, 
tetramer 2c was tested at maximum concentration of 15.5 µM, at which it 
showed a 26.9% of acetylcholinesterase inhibition. Although a hydrochloride 
salt could have be prepared in order to increase its aqueous solubility, this 
would have caused a fall in antioxidant activity, since the nucleophilicity of 
the nitrogen atoms in the structure has been shown to be critical 
importance for the latter property (see conlusion section in chapter 3, pages 
86-88). Compounds bearing a naphthalimido moiety showed different 
inhibitory activities towards acetylcholinesterase enzyme. Recently, a series 
of ranitidine derivatives have been reported for their AChE inhibitory 
activities, and the most active compounds (see figure 5.13) bore 
naphthalimido moieties (Gao et al., 2016).  
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Figure 5.13. Derivatives reported by Gao et al. (2016). The naphthalimido moiety is rendered in red. 
 
The imine 1b displayed the weakest activity among all the compounds 
tested, with an IC50 of 128.3 µM whereas its reduced derivative 1d showed 
a 13-fold increase in activity, with an IC50 of 10.1 µM. This may be due to 
the limited flexibility of imine bond in compound 1b which could impede the 
correct fitting in the narrow gorge of acetylcholinesterase. In contrast, 
monomer 1d could fit due to the absence of the rigid imine bond, facilitating 
the interactions with the amino acids in the gorge. It is interesting to note 
that monomer 1e, bears an extra methoxy group turned out to be 2 times 
less active than 1d (24.3 µM). This reduction in activity may be due to 
steric hindrance exhibited by the extra methoxy group at the entrance of 
the gorge. Finally, the tacrine-vanillin derivative 1f showed the highest 
inhibitory activity, with an IC50 of 2.1 µM; however, tacrine itself turned out 
to be 2 times more active than 1f, with an IC50 of 0.9 µM. Luo et. al 
described novel tacrine-multialkoxybenzene derivatives characterized by the 
presence of long alkyl chains as linker between the two moieties. The latter 
displayed enhanced AChE inhibitory activities compared to tacrine (Luo et 
al., 2011). In particular, the two most active compounds (reported in figure 
5.14) turned out to be 20+ times more active than tacrine. 
 
 
Figure 5.14. Multialkoxybenzene derivatives reported by Luo et al. (2011). 
 
The small reduction in activity displayed by monomer 1f could be associated 
with the presence of the rigid linker (the aromatic ring). However, this fall in 
AChE affinity is counterbalanced by the improved antioxidant activity of 1f 
conferred by the presence of the aromatic ring. 
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5.4.2 Molecular Modelling 
 
In order to identify and appreciate the molecular elements that contribute 
to the AChE inhibitory activities of these vanillin derivatives, molecular 
binding studies were performed on the most active compounds (1d and 1f, 
see figure 5.10).  
 
However, before starting the binding studies, the validation of molecular 
modelling protocol needed to be assessed. To do so, the original ligands 
from three different AChE crystal structures (2CMF, 1ACJ and 1EVE) were 
re-docked and their positions were compared with the original structures.  
The choice of these three crystal structures was based on the good 
resolution of the latter and the chemical similarities of the vanillin 
derivatives with the original ligands in the structures.  
The resolutions of 2CMF and 1 EVE structures, which bear a bis-tacrine 
derivative and donepezil as ligands, respectively, were 2.5 Å whereas the 
resolution of 1ACJ structure, which bear tacrine as ligand, was 2.8 Å. To 
compare the position of re-docked ligands with their corresponding original 
positions, the root-mean-squared distance (RMSD) value was measured 
using the following formula (Carugo and Pongor, 2001): 
 
𝑅𝑀𝑆𝐷 =  √
∑ 𝑑2𝑖𝑖
𝑛
 
 
where d is the distance between each of the n pairs of equivalent atoms 
(excluding hydrogens). The lower the RMSD value, the more accurate is the 
binding model. The results are reported, along with the RMSD values, in 
figure 5.15. 
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Figure 5.15. Superimposition of original (yellow) and redocked (red) ligands in their corresponding 
crystal structures and relative RMSD. 
 
The structure bearing donepezil as ligand (1EVE) showed the lowest 
accuracy in the binding model, with a RMSD of 1.235. In particular, the 
oxygen in the indanone moiety of the re-docked ligand (showed as a C=O 
double bond in the figure above) is reversed compared to the original 
ligand. In contrast, both the tacrine dimer (2CMF) and tacrine (1ACJ) 
showed better accuracy with RMSD values of 0.598 and 0.466, respectively. 
It is worth noting that the RMSD calculated for structure pairs with different 
sizes cannot be directly compared since this value strongly depends on the 
number of atoms in the structure alignment (Carugo and Pongor, 2001). For 
this reason, although the 1ACJ model achieved a slight lower RMSD value, 
2CMF model was chosen because of its more complex pattern. The two 
most efficient AChE inhibitors among the novel vanillin derivatives tested in 
the Ellman assay (1d and 1f) were studied for their binding properties 
toward the 2CMF AChE crystal structure.  
 
Again, the original ligand in the structure was removed before the docking 
process. The predicted binding model for both the compounds positioned 
the vanillin derivatives in the position of the original ligand as depicted in 
figure 5.16.   
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Figure 5.16. Superimposed structures of compound 1d (left) and 1f (right) with the original ligand 
(yellow) in 2CMF AChE structure. 
 
It is interesting to note that the planar portions of compounds 1f and 1d, 
i.e. the tacrine and naphthalimido moieties, are located in the same position 
of the tacrine structure from original ligand in the crystal structure. The 
importance of these planar structures can be appreciated by looking at the 
binding studies of the vanillin derivatives in the 2CMF crystal structure (see 
figures 5.17-5.18 in the following page).  
 
 
Figure 5.17. Predicted binding model of 1d in the CAS of 2CMF AChE structure. 
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Figure 5.18. Predicted binding model of 1f in the CAS of 2CMF AChE structure. 
 
The latter planar moieties are stacked between the residues PHE-330 and 
TRP-84 (- stacking) in the CAS. Although the stacking between these two 
residues is common for the tacrine moiety and already reported in several 
works, e.g. (Harel et al., 1993; Luo et al., 2011; Chand et al., 2016), it has 
never been reported for the naphthalimido moiety. 
In fact, molecular modelling studies performed on the ranitidine derivatives 
by Gao et al. reported - stacking between the latter moiety and TRP-286 
of mouse AChE (mAChE), which correspond to TRP-279 of TcAChE in the 
PAS (Colletier et al., 2006; Gao et al., 2016). 
 
In addition, the carbonyl groups in compound 1d are involved in hydrogen 
bonding with the residues ASP-72, TYR-334 and SER-122 (3.2, 1.9 and 2.5 
Å, respectively) whereas the protonated nitrogen in the tacrine moiety of 
compound 1f formed hydrogen bond with the oxygen in the carbonyl group 
of HIS-440 (2.0 Å). 
 
Moreover, two hydrogen bonds are established between the phenolic group 
of the vanillin moiety of derivative 1d and the carbonyl group of ILE-287 
(2.7 Å) and between the nitrogen linked to the vanillin structure and the 
hydroxyl group of TYR-121 (2.1 Å) in the PAS, as depicted in figure 5.19.  
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Figure 5.19. Predicted binding model of 1d in the PAS of 2CMF AChE structure. 
 
In addition, hydrophobic interactions between the vanillin moiety and TRP-
279 occur. 
Similarly, the phenolic group of the vanillin moiety in derivative 1f 
establishes one hydrogen bond with the carbonyl group of ILE-287 (3.9 Å) 
in the PAS (see figure 5.20). However, the same phenolic moiety is involved 
in another hydrogen bond with TYR-334 (3.8 Å) due to a favoured position 
of the hydrogen compared to the same structure in derivative 1d.  
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Figure 5.20. Predicted binding model of 1f in the PAS of 2CMF AChE structure. 
 
Furthermore, the oxygen in the methoxy group of the vanillin structure 
establishes an additional hydrogen bond with TYR-121 (2.2 Å). Two OH- 
interactions are established between the aromatic linker of compound 1f 
and the hydroxy groups of SER-122 and TYR-334. Finally, hydrophobic 
interactions between the vanillin ring and TRP-279 also occur. 
 
The molecular modelling results obtained for the two vanillin derivatives 
within the gorge of AChE (2CMF) can be appreciated in figure 5.21. 
 
 
Figure 5.21. Predicted binding models for compounds 1d and 1f within the active site of TcAChE. 
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When considering the free binding energies, a good correlation was found 
between the calculated docking scores and the inhibitory activity 
determined by Ellman assay.  
The original bis-tacrine ligand in the 2CMF structure gave the lowest score 
(-14.6 Kcal/mol), indicating a good affinity with the AChE structure (the 
more negative the docking score, the stronger the interaction).  
On the other hand, the scores for the derivatives 1f and 1d were -13.3 and 
-12.0 Kcal/mol, respectively, showing lower affinity for the enzyme 
compared to the original ligand with the tacrine-vanillin hybrid displaying 
better affinity compared to the naphthalimido-vanillin derivative and thus 
confirming the results obtained in the Ellman assay. 
 
5.4.3 Aβ(1-42) Aggregation Inhibition Assay 
 
A selection of five vanillin derivatives (1b, 1d, 1e, 1f and 4c, see figure 
5.10), based on the inhibitory activity toward AChE, was tested, along with 
tacrine and curcumin, for their ability to inhibit the self-mediated 
aggregation of Aβ(1-42) peptide.  
 
ThT fluorescence assay was employed for the determination of the 
inhibitory activities of those selected compounds. The ThT fluorescence 
assay is a well-known method based on the enhanced fluorescence of the 
Thioflavin T upon binding to β-sheet rich proteins such as the amyloid 
protein. The concentrations used in this assay were 10 µM for both the 
amyloid protein and the inhibitors. The results are reported in figure 5.22. 
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Figure 5.22. Self-mediated amyloid aggregation inhibitory effects of vanillin derivatives. All the 
compounds were tested at concentration of 10 µM. Values are expressed as the percentage of the control 
and represented as mean ± SD of three independent experiments in each group. ***p < 0.001, *p < 0.05, 
ns = no significantly different compared to the control. 
 
Imine 1b and tacrine did not show significant inhibition toward self-
mediated amyloid aggregation. On the other hand, all the remaining vanillin 
derivatives displayed significant activity in this assay.  
The tetramer 4c reduced the amyloid aggregation by 24% compared to 
control, whereas the vanillin derivative 1d and the syringaldehyde 
derivative 1e showed the same inhibitory activity toward amyloid 
aggregation, reducing the latter by 30.4 and 33.2%, respectively.  
The tacrine derivative 1f turned out to be the most efficient amyloid 
aggregation inhibitor, reducing the latter by 77.1% compared to the control, 
showing similar activity to the positive control curcumin (75.9%).  
The inhibitory activities of these vanillin derivatives could be explained by 
the work of Reinke and Gestwicki, which suggested the importance of two 
aromatic end groups capable of taking part of hydrogen bonding (Reinke 
and Gestwicki, 2007).  
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Figure 5.23. Vanillin derivatives tested in the amyloid aggregation inhibition assay. The aromatic 
moieties are coloured in black whereas the linker is rendered in red. Phenolic moieties are circled in blue. 
 
In fact, each compound tested in this assay bears at least two aromatic 
structures (rendered in black, in figure 5.23), one of which is vanillin, able 
to establish hydrogen bonding due to the phenolic group (circled in blue).  
The inability of compound 1b to prevent amyloid aggregation could be 
explained by the length of the linker, which has been reported to play a 
critical role in amyloid aggregation inhibition. In fact, Reinke and Gestwicki 
reported an optimal length of the linker to range between 8 and 16 Å.  
The length of the linker in compound 1b, calculated using PyMOL software, 
is 6.9 Å compared to compounds 1d, 1e, 1f and positive control curcumin 
(7.3, 7.3, 8.7, and 9.2 Å respectively).  
The shorter length of the linker in compound 1b is due to the presence of 
the imine bond, which is shorter compared to the corresponding amine bond 
in compounds 1d and 1e. On the other hand, the linker in compound 4c 
cannot be directly measured since more than two aromatic moieties are 
present in the structure.  
Finally, the remarkable activities of compound 1f in inhibiting the amyloid 
aggregation could be explained by the presence of the aromatic linker, 
which confers low flexibility important for the aggregation inhibitory activity 
(Reinke and Gestwicki, 2007). 
215 
 
5.4.4 Prediction of BBB Permeation 
 
The ability of drugs to cross the BBB is of critical importance for the 
treatment of neurodegenerative diseases. In fact, satisfactory treatments 
for certain neurological disorders are lacking due to insufficient crossing of 
therapeutic moieties through BBB to the brain (Nagpal, Singh and Mishra, 
2013). 
 
For this reason, the same selection of vanillin derivatives (1b, 1d, 1e, 1f 
and 4c) was tested, along with tacrine, for its ability to cross the BBB using 
an online predictor for BBB permeation (www.cbligand.org/BBB). 
 
The latter method generates a score for each molecule in analysis and 
predicts if those compounds are able to cross (CNS+) or not (CNS-) the 
BBB (see the example in figure 5.24). 
 
 
Figure 5.24. Prediction of BBB permeation for tacrine obtained through the online predictor  
www.cbligand.org/BBB. 
 
The figure shows high predicted BBB permeation molecule’s scores ranging 
approximately from 0.05-0.1, represented by the red curve in the graph. 
Low predicted BBB permeation scores ranges approximately below values of 
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0.01 and above 0.15, represented by the blue colour. The results are 
reported in table 5.2. 
 
Table 5.2. BBB permeation prediction for selected vanillin derivatives 
 
Compound BBB Score BBB Permeation (±) 
1b 0.057 BBB + 
1d 0.006 BBB - 
1e 0.005 BBB - 
1f 0.031 BBB + 
4c - 0.053 BBB - 
Tacrine 0.120 BBB + 
 
Tacrine displayed the highest predicted BBB permeation properties; with a 
score of 0.120, it lies on the top of the red curve where the density of 
molecule in the CNS is maximum. It is worth noting that tacrine is the first 
AChE inhibitor approved for AD treatment and its ability to cross the blood-
brain-barrier is well recognised (Mehta, Adem and Sabbagh, 2012).  
Among the vanillin derivatives, the imine 1b and the tacrine derivative 1f 
displayed high-predicted BBB permeation, with scores of 0.057 and 0.031, 
respectively, whereas the monomers 1d and 1e were predicted not to be 
able to cross the BBB, with scores of 0.006 and 0.005 respectively.  
 
The high predicted BBB permeation of 1b and 1f could depend on the imine 
group of the first (which reduce the polarity of the molecule) and the tacrine 
moiety of the second, which confer lipophilic properties to these two 
molecules.  
However, the tacrine derivative 1f experienced a lower predicted ability to 
cross the blood-brain-barrier compared to the starting compound tacrine 
(0.031 and 0.120, respectively); this could be explained by the increased 
molecular weight and the increased hydrophilic properties of the latter due 
to the presence of the phenolic moiety and the secondary amino groups in 
the molecular structure.  
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On the other hand, the monomers 1d and 1e showed lower lipophilic 
properties compared to 1b due to the presence of a tertiary amino group, 
which confers hydrophilic properties.  
Finally, tetramer 4c showed the lowest predicted ability to cross the BBB 
with a negative score (-0.053).  
This could be due to the presence of two tertiary amino groups and four 
phenolic moieties in the molecule which increase the hydrophilic properties 
of this derivative. 
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5.5 Conclusions 
 
A selection of vanillin derivatives, based on their chemical structures, was 
tested for their potential use in the multi-targeted-directed therapy of AD. 
The latter is a multi-factorial neurodegenerative disease characterized by 
neuronal death, oxidative stress, depleted cholinergic transmission and 
amyloid plaques. Thus, making multi-targeted-directed therapy approach 
amenable to AD. 
 
In previous years, the design and synthesis of novel synthetic compounds 
able to hit the multiple targets involved in AD, usually by combining two or 
more pharmacophores known to target specific biological structures 
involved in the disease, has shown intense interest among the scientific 
community.  
 
In this chapter, nine vanillin derivatives, selected by their chemical 
structures, were tested for their inhibitory activity toward the AChE enzyme, 
using Ellman assay. Only five compounds showed interesting activities; the 
derivatives bearing a naphthalimido moiety (1b, 1d and 1e) or the tacrine 
moiety (1f) showed IC50 ranging from 128.3-2.1 µM whereas the tetramer 
4c (tested at maximum concentration of 15.5 µM due to solubility issues) 
showed to inhibit the 26.9% of the enzyme. 
 
In order to show further light on the molecular elements involved in the 
observed AChE inhibitory activities of compound 1d (IC50: 10.1 µM) and 1f 
(IC50: 2.1 µM), molecular modelling studies were performed on the latter 
derivatives. The results strongly demonstrated the ability of both 
compounds to bind at the catalytic and peripheral anionic sites of the 
enzyme.  
 
The five vanillin derivatives which displayed AChE inhibitory properties (1b, 
1d, 1e, 1f and 4c) were tested for their ability to inhibit amyloid peptide 
aggregation using ThT assay.  
All the compounds displayed significant inhibitory activities except for imine 
1b, with the tacrine derivative 1f the most active, inhibiting the aggregation 
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by 77.1% compared to the amyloid control, showing similar activity to 
positive control curcumin. 
 
Finally, the same vanillin derivatives were tested for their ability to cross 
the BBB using an online predictor (www.cbligand.org/BBB). Only imine 1b 
and the tacrine derivative 1f were predicted to cross the BBB, although they 
showed lower permeation properties compared to tacrine, due to the 
presence of polar moieties such as phenolic groups in the vanillin moieties 
or substituted amino groups. 
 
Compound 1f turned out to be the most efficient AChE and amyloid 
aggregation inhibitor. Furthermore, as described in chapter 3, it showed 
strong antioxidant properties, especially in the ORAC assay, where it was 
found to be 6.4-fold times more active than the synthetic agent Trolox. To 
our knowledge, only the ferulic acid-tacrine-melatonin hybrids reported by 
Benchekroun et al. achieved such high antioxidant activity in ORAC assay in 
the multi-targeted-directed approach to AD (Benchekroun et al., 2016). 
 
In addition, monomer 1f was found to exert neuroprotective effects in 
hydrogen peroxide-based oxidative stress model, displaying significant 
protective effects in SH-SY5Y cells against hydrogen peroxide-induced death 
at concentration as low as 1 µM (see chapter 4, page 162). 
 
Taken together, these results support derivative to be the lead candidate 
compound for the development of novel multi-targeted-directed ligand for 
the treatment of AD. 
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Chapter 6: Conclusion and Future 
Work 
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The link between oxidative stress and neurodegenerative diseases such as 
Parkinson’s and Alzheimer’s diseases has suggested the possible use of 
antioxidants in the prevention or treatment of the latter. However, 
contrasting results have been obtained in the evaluation of the potential use 
of natural and synthetic antioxidants in such diseases (Uttara et al., 2009; 
Jomova et al., 2010; Kelsey, Wilkins and Linseman, 2010; Firuzi et al., 
2011; Kim et al., 2015). 
 
The aim of this project was the synthesis of novel vanillin derivatives with 
enhanced antioxidant properties compared to the starting compound. The 
choice of using vanillin as starting compound was based on previous work 
reporting the protective effects of this natural compound in several 
oxidative stress models, both in vitro and in vivo (Kamat, Ghosh and 
Devasagayam, 2000; Makni et al., 2012; Dhanalakshmi et al., 2015; Lee et 
al., 2016). 
 
In this work the vanillin derivatives were prepared by exploiting the 
reductive amination reaction, which entails the conversion of the carbonyl 
group in vanillin into the corresponding amine via an imine intermediate 
(Baxter and Reitz, 2002). A selection of amines was employed to generate 
derivatives bearing only one vanillin moiety (monomers), two vanillin 
moieties (dimers) or four vanillin moieties (tetramers). 
 
All the derivatives synthesised, were then evaluated for their antioxidant 
properties using different assays: 
 
- DPPH Assay, for the evaluation of the free radical scavenging activity 
of vanillin derivatives toward the stable 2,2-diphenyl-1-picrylhydrazyl 
radical 
 
- FRAP Assay, for the assessment of the reducing ability of vanillin 
derivatives toward the Fe3+ ion.  
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- ORAC Assay, for the evaluation of the hydrogen transfer ability of the 
selected vanillin derivatives in the scavenging of the peroxyl free 
radical generated by AAPH at physiological pH. 
 
- DNA damage protection Assay, for the determination of the protective 
effects of selected vanillin derivatives against oxidative stress-
mediated DNA strand breakage (in the presence of AAPH stressor) 
with supercoiled DNA plasmid.  
 
Almost all the synthesized derivatives showed improved antioxidant 
activities compared to the starting compound vanillin.  
In addition, a structure-activity relationship (SAR) on the antioxidant 
activity of vanillin derivatives have been hypothesised based on the results 
in the four antioxidant assays. The number of vanillin moieties, the 
nucleophilicity of the nitrogen atom(s), the delocalisation of nitrogen’s 
electrons and the phenolic and methoxy moieties in the vanillin structures 
appear to strongly contribute to the antioxidant activity of these derivatives. 
 
The tetramer 4c turned out to be the most active compound in all the 
antioxidant assays, with an IC50 of 5.8 µM in DPPH assay, 5.29 TE in FRAP 
assay, 20.4 TE in ORAC assay and an IC50 of 0.6 µM in DNA protection 
assay. 
Once the antioxidant properties of the vanillin derivatives were established, 
a selection of three compounds was chosen for further studies on cellular 
model. Neuroblastoma SH-SY5Y cell line was chosen for the in vitro studies 
and two different neurodegenerative models, based on hydrogen peroxide 
and rotenone/oligomycin A mixture as stressors, were employed. 
 
Before the evaluation of the protective effects of selected vanillin 
derivatives (1f, 2b and 4c) in oxidative stress models, their toxicities 
toward the SH-SY5Y cell line were determined through the MTT assay, after 
compounds exposure for 24 hours. The dimer 2b was found to be the safest 
compound with an LC50 higher than 1 mM, whereas monomer 1f and 
tetramer 4c showed higher toxicities with LC50s of 43.7 and 45.1 µM, 
respectively. 
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Toxicity test with hydrogen peroxide and the rotenone/oligomycin A mixture 
were carried out to determine their cytotoxic effects toward the same cell 
line and their IC50 were calculated; 400 µM for hydrogen peroxide (after 24 
hours incubation) and 3 and 1 µM for the rotenone/oligomycin A mixture 
(after 48 hours incubation). The latter conditions were chosen for the 
evaluation of the protective effects of the selected vanillin derivatives. 
 
Compounds 1f, 2b and 4c were finally tested for their protective effects 
toward SH-SY5Y against oxidative stress-induced cell death. The cells were 
then pre-treated with the selected vanillin derivatives for 24 hours before 
the addition of the stressors. 
 
All the three vanillin derivatives showed protective effects against hydrogen 
peroxide-induced (400 µM) cell death. It is worth to note that vanillin did 
not show significant protection even at the highest concentration tested 
(800 µM). The monomer 1f exhibited significant cellular protection at 
concentration as low as 1 µM and a maximum protection at 5 µM, with an 
increase of cell viability of 15 and 30%, respectively. The dimer 2b 
displayed the weakest protective effects, with significant protection at 
concentration as low as 5 µM and a maximum effect at 200 µM, by 
increasing the cell viability by 6 and 20%, respectively. Tetramer 4c 
showed significant protective effects at concentration as low as 0.1 µM and 
a maximum protection at 10 µM, by increasing the cell viability of 10 and 
30%, respectively. 
 
However, with rotenone/oligomycin A (3 and 1 µM, respectively) mixture as 
the stress model, only compound 4c had the ability to protect the SH-SY5Y 
cell line from oxidative stress, displaying significant protective effects at 
concentration of 5 and 10 µM with increasing cell viability by 20 and 25%, 
respectively. 
 
Furthermore, vanillin derivatives were studied for their ability to reduce ROS 
production in the same cell line, after treatment with hydrogen peroxide (1 
mM) for 30 minutes. In this experiment, ROS were detected using the 
fluorescent probe 2',7'-dichlorodihydrofluorescein diacetate and measured 
through flow cytometry. 
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Compounds 2b and 4c were tested at their highest concentration employed 
in the previous assays (200 µM and 10 µM, respectively) whereas monomer 
1f was not tested due to instrumental issues. A significant reduction of ROS 
was found in pre-treated cells with tetramer 4c (24 hours) exhibiting a 76% 
ROS reduction when compared to the peroxide control whereas the dimer 
2b showed a reduction in ROS by 40%. 
 
Both 2b and 4c were then tested for their protective effects against 
hydrogen peroxide-induced DNA damage in SH-SY5Y cell line using the DNA 
comet method. The latter is a technique for the evaluation of DNA damage 
based on its single cell electrophoretic separation (Olive and Banáth, 2006). 
The cells were pre-treated for 24 hours with the usual concentrations of 2b 
or 4c before treatment with hydrogen peroxide (300 µM) for 30 minutes. 
However, both the compounds did not show significant protection against 
oxidative stress-induced DNA damage. 
 
However, a direct antioxidant mechanism based on the free radical 
scavenging and reducing properties of the latter compounds can partially 
explain their protective effects. In fact, the increased cell viabilities achieved 
at concentrations as low as 0.1 µM suggest a more complex mechanism. 
 
In order to evaluate a possible mechanism behind the interesting protective 
effects of compound 4c, the latter was evaluated for its ability to trigger the 
Antioxidant Responsive Element (ARE) pathway, which is known to be 
involved in the antioxidant response in eukaryotic cells. In particular, the 
ability of selected vanillin derivative to induce Nrf2 translocation into the 
nucleus, is a known phenomenon to be linked with antioxidant enzymes 
expression, was determined through western blotting methodology 
(Johnson et al., 2008)(Nguyen, Nioi and Pickett, 2009)(Jin et al., 2015). 
Although an increased concentration of a protein was picked up by the Nrf2 
antibody in the nuclear cell extract after pre-treated with compound 4c for 
24 hours in our laboratory, the molecular weight of the latter protein 
suggested a non-specific binding of the antibody used. 
 
225 
 
In addition, similar experiments performed by Professor Galli and co-
workers at University of Perugia confirmed the inability of the latter vanillin 
derivative 4c to induce Nrf2 nuclear translocation.  
 
Finally, a selection of vanillin derivatives was tested for their potential use in 
a multi-targeted-directed approach for Alzheimer disease. The latter 
approach is aimed to target different hallmarks of this neurodegenerative 
disease, such as oxidative stress, acetylcholine depletion and amyloid 
peptide aggregation (Cavalli et al., 2008; Bolognesi, Cavalli and Melchiorre, 
2009; Bolognesi et al., 2011). 
 
For these reasons, the ability of selected vanillin derivatives to inhibit 
acetylcholinesterase and Aβ(1-42) peptide aggregation was evaluated through 
Ellman assay and ThT assay, respectively. In addition, in silico studies were 
performed for the evaluation of AChE inhibition and BBB permeation 
properties of selected vanillin derivatives. 
 
Monomers 1d and 1f turned out to be the most active AChE inhibitors, with 
IC50 of 10.1 and 2.1 µM, respectively with the latter two-fold less active 
than tacrine. In addition, molecular modelling studies highlighted their 
ability to bind both the CAS and the PAS of the AChE enzyme. 
 
Furthermore, monomer 1f turned out to be the most effective amyloid 
aggregation inhibitor in ThT assay, showing comparable activity to positive 
control curcumin. 
 
Finally, in silico studies predicted monomer 1f to cross the blood-brain 
barrier, which is essential for targeting neurodegenerative diseases. 
 
Overall, the novel vanillin derivatives showed promising potential for the 
treatment or the prevention of neurodegenerative diseases. In fact, the 
compounds described in this thesis showed interesting antioxidant 
properties, cellular protective effects in oxidative stress models and 
inhibitory activities toward acetylcholinesterase enzyme and amyloid 
aggregation. In particular, compounds 4c and 1f can be selected as lead 
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compounds for the development of novel vanillin derivatives with enhanced 
biological activities. 
 
 
Figure 6.1. Summary of the properties of most promising vanillin derivatives, monomer 1f and tetramer 
4c. 
 
Future Work 
 
The evaluation of vanillin derivatives’ abilities to inhibit the NFκB activation 
and to activate AP-1 transcription factor could bring more information 
regarding their mechanism of action at the base of the protective effects in 
SH-SY5Y cells against oxidative stress models (see figure 6.2). Western 
blotting analysis could be employed for this purpose. 
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Figure 6.2. Possible mechanisms behind the protective effects of compound 4c in SH-SY5Y cell line. 
Adapted from (Mattson and Camandola, 2001; Palanki, 2002; Ye et al., 2014; Lan et al., 2017) 
 
In vivo experiments (using mammalian models such as rats or mice) are 
necessary for the determination of the toxic effects of the vanillin 
derivatives and the evaluation of their protective effects in oxidative stress 
models. 
 
Should these compounds show low toxicity and positive effects on such 
animal models, they could be further tested in clinical studies as 
neuroprotective agents. In addition, due to the solubility of compound 4c in 
lipophilic solvents such as chloroform, it could be tested as preservative in 
food industry. 
 
Regarding the multi-target-directed approach for AD, the evaluation of the 
inhibitory activity of vanillin derivatives toward the butyrylcholinesterase 
needs to be assessed since this enzyme plays a fundamental role in the 
progression of AD (Greig, Lahiri and Sambamurti, 2002; Panek et al., 
2017). Contrarily to AChE, the latter enzyme prevent amyloid Aβ formation 
hence selectivity toward AChE inhibition is preferred (Saini and Saxena, 
2018). The BChE inhibitory properties of selected vanillin derivatives could 
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be measured through Ellman assay, following the same protocol described 
in chapter 5. 
 
Furthermore, the chelating properties of the compounds toward Cu2+ and 
Zn2+ should be determined, since the homeostasis of the latter ions is 
dysregulated in AD (Cuajungco et al., 2006) and positive results could 
increase the number of targets involved in this neurodegenerative disease. 
A UV-Vis analysis could be carried out for this purpose. 
 
The evaluation of the toxic effects of the tacrine-vanillin hybrid 1f toward 
hepatic cells should be assessed, since the tacrine moiety is known to exert 
toxic effect in liver. For this purpose, a human hepatocellular carcinoma cell 
line (HepG2) could be employed (Dgachi et al., 2017) and the toxicity could 
be measured through MTT assay, following the same protocol described in 
chapter 4. 
 
Structural modification to the lead compound 1f could be made (see figure 
6.1); in particular, the aromatic linker can be replaced by an alkyl chain 
composed of 7 to 9 methylene moieties, which has shown to increase the 
affinity to AChE since it is known to fit in the narrow gorge of AChE (Luo et 
al., 2011; Agatonovic-Kustrin, Kettle and Morton, 2018).  
 
 
Figure 6.3. Synthetic strategy for novel vanillin-tacrine hybrids. 
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On the other hand, this will impact negatively on the antioxidant activity of 
the compound, since the delocalisation of nitrogen’s electrons plays a 
critical role in scavenging and reducing activity of the vanillin derivatives.  
However, substitution in the tacrine moiety could be made in order to 
increase the affinity of compound 1f to AChE enzyme; for example, it is 
known that a electron withdrawing group, such as -NO2 and -Cl, in the 
position 6 of tacrine moiety is linked with an increased affinity to AChE 
enzyme thus improving the inhibitory activity (Recanatini et al., 2000; 
Agatonovic-Kustrin, Kettle and Morton, 2018). 
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I-1 
 
 
Figure A1. 1H NMR spectrum of intermediate I-1. 
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Figure A2. 13C NMR spectrum of intermediate I-1. 
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Figure A3. LRMS spectrum of intermediate I-1. 
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I-2 
 
 
Figure A4. 1H NMR spectrum of intermediate I-2. 
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Figure A5. 13C NMR spectrum of intermediate I-2. 
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Figure A6. LRMS spectrum of intemediate I-2. 
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I-3 
 
 
Figure A7. 1H NMR spectrum of intermediate I-3. 
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Figure A8. 13C NMR spectrum of intermediate I-3. 
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Figure A9. LRMS spectrum of intermediate I-3. 
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1a 
 
 
Figure A10. 1H NMR spectrum of compund 1a. 
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Figure A11. 13C NMR spectrum of compund 1a. 
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Figure A12. HRMS spectrum of compound 1a. 
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1b 
 
 
Figure A13. 1H NMR spectrum of compund 1b. 
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Figure A14. 13C NMR spectrum of compund 1b. 
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Figure A15. HRMS spectrum of compound 1b. 
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1c 
 
 
Figure A16. 1H NMR spectrum of compound 1c. 
 
296 
 
 
Figure A17. 13C NMR spectrum of compound 1c. 
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Figure A18. HRMS spectrum of compound 1c. 
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1d 
 
 
Figure A19. 1H NMR spectrum of compound 1d. 
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Figure A20. 13C NMR spectrum of compound 1d. 
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Figure A21. HRMS spectrum of compound 1d. 
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1e 
 
 
Figure A22. 1H NMR spectrum of compund 1e. 
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Figure A23. 13C NMR spectrum of compund 1e. 
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Figure A24. HRMS spectrum of compound 1e. 
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1f 
 
 
Figure A25. 1H NMR spectrum of compund 1f. 
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Figure A26. 13C NMR spectrum of compund 1f. 
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Figure A27. HRMS spectrum of compound 1f. 
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2a 
 
 
Figure A28. 1H NMR spectrum of compound 2a. 
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Figure A29. 13C NMR spectrum of compound 2a. 
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Figure A30. HRMS spectrum of compound 2a. 
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2b 
 
 
Figure A31. 1H NMR spectrum of compund 2b. 
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Figure A32. 13C NMR spectrum of compund 2b. 
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Figure A33. HRMS spectrum of compound 2b. 
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2c 
 
 
Figure A34. 1H NMR spectrum of compund 2c. 
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Figure A35. 13C NMR spectrum of compund 2c. 
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Figure A36. HRMS spectrum of compound 2c. 
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2d 
 
 
Figure A37. 1H NMR spectrum of compund 2d. 
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Figure A38. 13C NMR spectrum of compund 2d. 
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Figure A39. HRMS spectrum of compound 2d. 
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2e 
 
 
Figure A40. 1H NMR spectrum of compund 2e. 
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Figure A41. 13C NMR spectrum of compund 2e. 
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Figure A42. HRMS spectrum of compound 2e. 
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2f 
 
 
Figure A43. 1H NMR spectrum of compund 2f. 
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Figure A44. 13C NMR spectrum of compund 2f. 
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Figure A45. HRMS spectrum of compound 2f. 
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2g 
 
 
Figure A46. 1H NMR spectrum of compund 2g. 
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Figure A47. 13C NMR spectrum of compund 2g. 
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Figure A48. HRMS spectrum of compound 2g. 
 
 
 
 
 
 
 
 
 
 
 
 
328 
 
2h 
 
 
Figure A49. 1H NMR spectrum of compund 2h. 
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Figure A50. 13C NMR spectrum of compund 2h. 
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Figure A51. HRMS spectrum of compound 2h. 
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2i 
 
 
Figure A52. 1H NMR spectrum of compund 2i. 
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Figure A53. 13C NMR spectrum of compund 2i. 
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Figure A54. HRMS spectrum of compound 2i. 
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4a 
 
 
Figure A55. 1H NMR spectrum of compund 4a. 
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Figure A56. 13C NMR spectrum of compund 4a. 
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Figure A57. HRMS spectrum of compound 4a. 
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4b 
 
 
Figure A58. 1H NMR spectrum of compund 4b. 
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Figure A59. 13C NMR spectrum of compund 4b. 
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Figure A60. HRMS spectrum of compound 4b. 
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4c 
 
 
Figure A61. 1H NMR spectrum of compund 4c. 
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Figure A62. 13C NMR spectrum of compund 4c. 
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Figure A63. HRMS spectrum of compound 4c. 
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4d 
 
 
Figure A64. 1H NMR spectrum of compund 4d. 
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Figure A65. 13C NMR spectrum of compund 4d. 
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Figure A66. HRMS spectrum of compound 4d. 
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4e 
 
 
Figure A67. 1H NMR spectrum of compund 4e. 
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Figure A68. 13C NMR spectrum of compund 4e. 
 
348 
 
 
Figure A69. HRMS spectrum of compound 4e. 
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4f 
 
 
Figure A70. 1H NMR spectrum of compund 4f. 
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Figure A71. 13C NMR spectrum of compund 4f. 
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Figure A71. HRMS spectrum of compound 4f. 
 
